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Abstract 
 
The aim of the present investigation was to develop and assess the potential of various 
proteomic approaches for the characterisation of two major nosocomial pathogens, S. aureus 
and C. difficile and to further investigate the intraspecies diversity of C. difficile using a 
genotypic approach. The surface-associated proteins of S. aureus and intracellular stable 
ribosomal proteins of C. difficile were analysed by MALDI-TOF-MS and the resulting spectra 
interrogated using two databases viz. MMU (Waters®) and SARAMIS™ (AnagnosTec) 
respectively. A total of 134 clinical S. aureus isolates were tested using the MMU database 
and the MicrobeLynx™ software.  All were successfully identified with minor contamination 
errors that corroborated with 16S rRNA sequencing. By contrast, C. difficile isolates were only 
partially identified (to the genus level) using the MMU database and protocol. Changes in the 
matrix solution and use of the new database (SARAMIS™) resulted in the correct 
identification of all C. difficile isolates and, detailed ultra-structural studies indicated that 
intracellular proteins were the new diagnostic biomarkers. The cytosolic/membrane-bound 
proteins of S. aureus and C. difficile were investigated using SELDI-TOF-MS and, potential 
biomarkers for MRSA and MSSA studied using Artificial Neural Networks. Seven key ions 
were detected for predicting MRSA and MSSA correctly. 1D- gel electrophoresis was also 
carried out on both taxa. To detect novel loci to differentiate the different ribotypes (027 and 
001) and other ribotypes of C. difficile a molecular method, ‘VNTR’, was undertaken using 92 
isolates belonging to three ribotype groups. Ten novel loci were detected and could be used to 
differentiate between isolates of different ribotypes belonging to 027 and 001. This is now 
being implemented as an epidemiological tool because of its high reproducibility and 
throughput for genotyping of the invasive ribotype 027 and 001 of C. difficile. 
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1    Introduction 
 
1.1 Microorganisms used in the study 
 
Nosocomial infections are mainly acquired or associated with hospitals and are also referred to 
as hospital-acquired infections or hospital-associated infections (HAI). The importance of 
these infections cannot be overstated, as it poses a major threat all over the world resulting in 
high rates of mortality and morbidity. It is also a major financial burden to the health care 
system due to the increased cost of patient treatment and infection control (Breathnach 2005). 
Most commonly, the microorganisms involved in these infections are Staphylococcus aureus 
and Clostridium difficile both of which arose from the normal flora of man. S. aureus is 
mainly involved with bacteraemia caused by methicillin-resistant S. aureus (MRSA) while C. 
difficile is mainly responsible for causing antibiotic-associated diarrhoea (AAD). Because of 
their significance in disease, these two pathogens are also referred to as “Superbugs” and is the 
focus of this study.  
 
1.1.1 The genus Staphylococcus 
 
The Staphylococcus was among the earliest recognised of the pathogenic bacteria, having been 
characterised in the early 1880s by Rosenbach. He divided the genus in to two species, S. 
aureus and S. albus. Based on cell morphology and type of cell aggregation, the 
Staphylococcus was placed together with the genus Micrococcus. However the results of DNA 
base composition and later on DNA-rRNA hybridisation and comparative oligonucleotide 
cataloguing of 16S rRNA, have indicated that genus Staphylococcus is most closely related to 
the newly described genus Macrococcus (Kloos et al., 1998) and is phylogenetically very 
distantly related to Micrococcus .  
 
The genus Staphylococcus currently comprises of nearly 40 species and includes some of the 
most common nosocomial pathogens (Bergey’s Manual 2009). Staphylococci are responsible 
for a plethora of medical problems including skin and soft-tissue infections, surgical site 
infections, endocarditis and hospital acquired bacteraemia (Casey et al., 2007). Members are 
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gram positive, spherical cells ranging from 0.5-1.5 µm in diameter and occur singly, in pairs, 
short chains and grape-like clusters when viewed through a microscope. On blood agar plates 
they appear as large, round, golden-yellow colonies, often with β-haemolysis. They are non-
motile, non-spore forming, facultative anaerobes that commonly colonise the skin of mammals 
and are widespread in nature. They are usually catalase and coagulase-positive, while most 
other Staphylococcus species are coagulase-negative. Their cell wall contains teichoic acid and 
peptidoglycan, with L-lysine as the diamino acid a unique interpeptide bridge that is 
susceptible to lysis by lysostaphin but relatively resistant to lysis by lysozyme.  
 
 
1.1.2 Clinical significance/ importance of S. aureus 
 
S. aureus is a major component of the microbial flora of primates and is a well known human 
pathogen, which until recent years has been associated with intermittent infections. It 
colonises the skin and the anterior nares of individuals and is carried by significant proportion 
of the population (Gordon and Lowy 2008). Colonisation also allows S. aureus to be 
transmitted among individuals in both health care and community settings. Severe infections 
caused by S. aureus are associated with high rates of mortality and morbidity worldwide with 
significant increases occurring during the 1990s. S. aureus infections are often acute and 
pyogenic and if untreated, may spread to surrounding tissue or via bacteraemia involving other 
organs. Some of the serious infections caused by S. aureus are bacteraemia, pneumonia, 
osteomyelitis, acute endocarditis, scaled skin syndrome (SSSS) and is a major cause of many 
serious hospital and community acquired infections (Shopsin and Kreiswirth 2001).  
 
S. aureus possesses a wide range of virulence factors and can cause infections at many 
anatomical sites.  The presence of S. aureus in food can be a potential public health hazard 
since many isolates of S. aureus produce enterotoxin (Kaplan and Tenenbaum 1982). Foods 
commonly associated with the staphylococcal food poisoning are meat, meat products, salads 
and bakery products. The most common symptoms are vomiting and diarrhoea. Also, 
Staphylococcal Scaled Skin Syndrome is caused by the effect of exfoliative toxins produced 
by S. aureus (Ladhani et al., 1999) which affects neonates and young children. Toxic Shock 
Syndrome (Chesney 1981) a community-acquired disease, is also a result of colonisation with 
S. aureus and is characterised by high fever, hypotension and rash (Dinges et al., 2000). 
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With increased use of antibiotics, the emergence of antibiotic resistance strains of S. aureus 
developed over the years and has emerged as a major global health problem. Reports of 
MRSA infections occurring in community settings along with high rates of deaths have 
heightened the public awareness of MRSA (Corriere and Decker 2008). In United States, 
MRSA is responsible for approximately 25 % of the nosocomial infections and the Press has 
labelled MRSA as the “Superbug,” which killed more people than AIDS in 2005 (Flynn and 
Cohen 2008). Also the cost for prevention of S. aureus infections has a major impact on both 
the patients and healthcare systems (Corriere and Decker 2008). Due to these factors 
controlling MRSA remains a primary focus of most hospital infection control programmes 
(Das and Lambert 2007). 
 
 
 
1.1.3 Virulence factors of S. aureus 
 
S. aureus has a wide range of virulence factors, both structural and secreted products which 
can cause infections at many sites (Figure 1.1); expression of these virulence factors occurs 
only when required by the bacterium. Surface proteins are generally expressed during 
logarithmic phase whereas secreted proteins such as toxins are produced during stationary 
phase (Gordon and Lowy 2008). These virulence factors may have several functions in 
pathogenesis or multiple virulence factors may increase the aggressiveness of strains. 
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Figure 1.1: Pathogenic factors of S. aureus with structural and secreted products both playing roles as 
virulence factors. A- Surface and secreted proteins. B - Cross section of the cell envelope. Synthesis of 
many of these proteins is dependent on the growth phase as shown in the above figure (Adapted from 
Gordon and Lowy 2008). 
 
 
• Surface proteins 
 
S. aureus has various surface proteins called “microbial surface components recognising 
adhesive matrix molecules” that mediate adherence to host tissue (Lowy 1998). These proteins 
bind to molecules such as, collagen and fibrinogen and play an important role in colonisation 
(Patti et al., 1994). Protein A, the prototype of these proteins has an antiphagocytic property, 
binds to the Fc portion of the immunoglobulin and results in the disruption of the 
phagocytosis.  
 
• Microcapsule 
Most staphylococci produce a microcapsule which is located externally to the cell wall. Unlike 
the true capsule of some bacteria, the microcapsule is only visible by electron microscope. S. 
aureus isolates are assigned to 11 capsular serotypes depending on the microcapsular 
polysaccharides, but the majority of clinical isolates express surface polysaccharides of either 
serotype 5 or 8 (Lowy 1998). Most MRSA isolates are type 5.  Although the function of the 
capsule in virulence is not known, it’s thought to interfere with phagocytosis. 
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• Biofilms (slime) 
Slime is a complex extracellular substance produced in varying amounts by many 
staphylococci. Once S. aureus adheres to the host tissue or prosthetic materials, it can grow 
and form bioflims which tends to interfere with host defence mechanisms such as opsonisation 
and phagocytosis (Gordon and Lowy 2008). 
 
• Enzymes 
During infection S. aureus produces numerous enzymes such as proteases, lipases and 
elastases that enable it to invade and destroy the host tissues. These bacterial products may 
facilitate the spread of infection to adjoining tissues (Lowy 1998). Also the enzymes are 
capable of degrading various macromolecules such as nucleic acid, lipids, proteins and 
polysaccharides, thereby providing low molecular weight nutrients for growth. 
 
• Toxins 
Staphylococci produce numerous toxins that are grouped on the basis of their mechanism of 
action. S. aureus produces a group of pyogenic toxins that cause fever and shock in their hosts. 
These toxins, also known as superantigens, include enterotoxin and toxic shock syndrome 
toxin-1 (TSST-1) and are responsible for food poisoning and toxic shock syndrome. Among 
the S. aureus isolates, 20 % are believed to carry the toxin gene tst (Lindsay et al., 1998).  
Another group of toxins called exfoliative toxins are recognised as the cause of SSSS, a 
disease associated with severe blistering of the skin especially in young children. 
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1.1.4 Evolution and Epidemiology of Staphylococcus aureus 
 
Methicillin-resistant S. aureus (MRSA) emerged in 1980s as a major clinical and 
epidemiologic problem in hospitals. Methicillin, a semi-synthetic penicillin was introduced in 
the UK in 1961 and was largely developed to overcome the problem of penicillin resistant S. 
aureus in hospitals, which increased throughout the late 1950s. In 1942, two years after the 
introduction of penicillin for medical use, the first penicillin resistant S. aureus was isolated in 
a hospital (Deurenberg and Stobberingh 2008).The methicillin-resistant S. aureus (MRSA), 
acquired antibiotic resistance as early as 1961, just one year after the launch of methicillin 
(Jevons 1961). Since then MRSA has gradually disseminated and began causing serious 
hospital infections worldwide. S. aureus is a dynamic and adaptable bacterium that has the 
ability to acquire antibiotic resistance quickly. MRSA can be resistance to methicillin alone or 
to one or more antimicrobials used to treat the staphylococcal infections i.e. clindamycine, 
tetracyclines and gentamycin or to multiple antimicrobial classes (Flynn and Cohen 2008). 
 
One of the most remarkable recent events in chemotherapy was the emergence of 
vancomycin- intermediate S. aureus (VISA) in Japan in 1996 (Hiramatsu et al., 1997). The 
first vancomycin resistant S. aureus (VRSA) strain, containing a VanA resistance operon, was 
isolated in 2002 in Detroit, MI, the operon having been acquired from a vancomycin resistance 
enterococcus (Livermore 2000). 
 
S. aureus became methicillin-resistant by acquiring a mecA gene, usually carried on a larger 
segment of DNA called a staphylococcal cassette chromosome SCCmec (Katayama et al., 
2000; Hiramatsu et al., 2001). In S. aureus, the mecA gene, coding for the 78-kDa penicillin-
binding protein (PBP2a), causes resistance to methicillin and all other β- lactam antibiotics. In 
methicillin- sensitive S. aureus (MSSA), the β- lactam antibiotics bind to the native PBPs that 
are present in the cell wall, which results in the disruption of the synthesis of the 
peptidoglycan layer. However in MRSA, because of the presence of the foreign PBP2a, the 
antibiotics cannot bind and the peptidoglycan layer and synthesis is not disrupted, resulting in 
the growth of MRSA (Berger-Bachi and Rohrer 2002). The mecA gene is regulated by the 
repressor MecI and the transmembrene β- lactam- sensing signal-transducer MecR1. MecI 
represses both the transcription of mecA and MecR1-MecI in the absence of a β- lactam 
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antibiotic. In the presence of β- lactam antibiotics, MecR1 becomes active, cleaves MecI, 
binds to the mecA operator region and allows the subsequent production of PBP2a. 
 
The mecA gene which is 2.1 kb in length is located on a mobile genomic island called 
Staphylococcal Cassette Chromosome mec (SCCmec) (Ito et al., 2003). At present seven main 
types of SCCmec are recognized (Deurenberg and Stobberingh 2008). SCCmec type I, IV, VI, 
and VII causes only β- lactam antibiotic resistance while type II and III cause multiple class 
resistance due to the presence of additional resistance genes. The origin of SCCmec is not 
known. A study of Wu et al. (2001) suggested it was derived from Staphylococcus sciuri, a 
taxonomically primitive Staphylococcal species. In the presence of methicilln, it became 
resistant due to the increased rate of transcription of the mecA homologue (Wu et al., 2001). 
Another study by Wielders et al. (2001) isolated a MRSA strain from a neonate, who had not 
been in contact with MRSA previously and found the mecA gene was identical to that from a 
S. epidermidis strain isolated from the neonate. It was suggested that MRSA had originated in 
vivo through horizontal transfer of the mecA gene between the two staphylococcal species 
(Wielders et al., 2001). 
 
Although MRSA has been seen as a hospital-associated infection, community-acquired MRSA 
isolates have appeared in recent years (Ho et al., 2004; Nelson et al., 2006). Traditionally, an 
infection is defined as hospital-acquired (HA-MRSA) if it occurs more than 48 h after 
admission to the hospital, whereas it is community-acquired (CA-MRSA) if it occurs within 
48 h of admission (Bassetti et al., 2009; Flynn and Cohen 2008). HA-MRSA is both 
genotypically and phenotypically distinct from CA-MRSA. In contrast to HA-MRSA, CA-
MRSA isolates are generally susceptible to non ß- lactum antibiotics (Deurenberg et al., 2007; 
Deurenberg and Stobberingh 2008). HA-MRSA isolates normally contains type I, II or III 
Staphylococcal Cassette Chromosome mec (SCCmec) which mediates resistance, where as 
CA-MRSA isolates contain type IV SCCmec. The S. aureus population presents a highly 
clonal structure. The clonality was first discovered by multilocus enzyme electrophoresis 
(MLEE) and was later supported by multilocus sequence typing (MLST) (Enright et al., 2000; 
2002). MLST is a highly discriminatory method of characterising bacterial isolates on the 
basis of DNA base substitution of several (usually seven) house keeping genes (Maiden et al., 
1998). 
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Historically, HA-MRSA infections have been caused by internationally disseminated clones. 
A study carried out by Enright et al., 2002 using an international collection of 912 MRSA and 
MSSA isolates by MLST and SCCmec typing, identified 11 major MRSA clones within 5 
groups of related genotypes (Iberian, Brazilian, Hungarian, New York/Japan and Pediatric). 
An MRSA clone was defined as a group of isolates from more than one country which had an 
identical sequence type (ST) and SCCmec type. Enright et al. further demonstrated that all 
major MRSA clones were associated with clonal complexes (CC) CC5, CC8, CC22, CC30 or 
CC45 and this occurred among isolates with the same MLST type that differ in SCCmec type. 
Also in this study ST8-MSSA, a member of CC8 was observed, as the putative ancestor of the 
first MRSA strain i.e. ST250-MRSA-I (Figure 1.2). ST8-MSSA is a common cause of 
epidemic MSSA disease and acquired SCCmec type I, II and IV (Figure 1.2). Another clone 
closely related to ST250 is ST247-MRSA-I; an Iberian clone was one of the major MRSA 
clones found in European hospitals (Deurenberg et al., 2007). S. aureus phage type 80/81, 
which was responsible for nosocomial and community acquired infections in 1950s is another 
example of a successful clonal type. ST30 contains a Panton-Valentine Leukocidin (PVL) 
gene and is related to a southwest Pacific clone, and contains a SCCmec IV as well as PVL. 
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Figure 1.2: The evolutionary origins of the major MRSA clones and the possible relation between CA-
MRSA and HA-MRSA. The arrows indicate either (1) the acquisition of SCCmec, (2) a change of 
SCCmec, (3) a change of ST, or (4) the acquisition of PVL. The grey coloured circles represent MRSA 
clones from CC30, while the white circles represent MRSA clones from CC8. ST239-MRSA-III from 
CC8 evolved by the transfer of a 557-kb fragment from the chromosome of ST30 into a ST8 
background (Adapted from Deurenburg and Stobberingh 2008).  
 
 
After the appearance of MRSA in 1960s, in the early 1980s gentamycin was used as a better 
infection control against for MRSA (Livermore 2000). But soon gentamycin resistance began 
to emerge in S. aureus and MRSA isolates and became a problem in mid-1980s and a strain 
designated as epidemic MRSA 1 (EMRSA-1) spread widely in the UK. This was followed by 
another epidemic isolate EMRSA -3, which became prominent in late 1980s and by the 1990s 
EMRSA 15 and 16. EMRSA-15 and 16 (EMRSA-16) are the most important and prevalent 
EMRSA isolates found in the UK and have also been found in a number of European countries 
and the USA. EMRSA-16 is the best described epidemiologically and originated in Kettering, 
England in 1992 (Murchan et al., 2004). The full genome sequence of this strain has been 
published (Holden et al., 2004). These two isolates have achieved a major spread and are 
associated with severe infections (Gould 2008). Apart from the resistance to β lactams, 
EMRSA-15 is resistant to erythromycin and often resistant to ciprofloxacin. EMRSA-16 is 
usually resistance to erythromycin, ciprofloxacin and occasionally to gentamicin (Livermore 
2000). 
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CA-MRSA also emerged as a major threat to the community since its prevalence was 
predicted to rise to 25 % (Chambers 2001).  A major outbreak of CA- MRSA was first 
reported in 1980s in Detroit among the intravenous drug users. Since then, CA-MRSA has 
gradually increased even without a history of intravenous drug use (Corriere and Decker 2008) 
where infections frequently occur in young and healthy individuals. With four pediatric deaths 
from CA-MRSA in Minnesota and North Dakota in 1997-1999, the potential of CA-MRSA 
become more evident (Centres for Disease Control and Prevention: 1999) even without any 
risk factors. The strain responsible for these deaths was later termed as MW2 was a ST1 and 
PFGE type USA400 (Gordon and Lowy 2008 and Said-Salim et al., 2003). DNA sequencing 
of the this strain later revealed a unique SCCmec type IV in contrast to SCCmec type I, II and 
III found in nosocomial MRSA (Said-Salim et al., 2003). Subsequently, outbreaks of skin and 
soft-tissue infection caused by CA-MRSA were also reported among prison inmates, soldiers 
and athletes (Tenover and Goering 2009). The strain responsible for these infections was 
identified as ST8 and PFGE type USA300 (McDougal et al., 2003; Tenover and Goering 
2009). Currently this strain was identified as the major cause of hospital infections in USA 
(Gould 2008). Also a number of other CA-MRSA clones were found to be prevalent. These 
included ST80 (France-Switzerland), ST30 (SWP clone) and ST93 (Australia Queensland 
clone) (Vandenesch et al., 2003). A recent outbreak of CA-MRSA appears to be caused by 
isolates that also carry genes for Panton-Valetine leukocidin (PVL), a toxin that is known to 
cause lysis of white blood cells. It has been shown that PVL contributes to severe haemolytic 
and necrotic pneumonia in children (Lina et al., 1999).  
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1.1.5 Identification of Staphylococcus aureus and other staphylococci 
 
With the increasing outbreaks of Staphylococcal and MRSA infections all over the world, 
controlling these infections remains a primary focus of most hospital infection control 
programs. As a result bacterial strain typing or subspeciation has become an important clinical 
tool to investigate suspected outbreaks and to evaluate nosocomial transmission. To date 
numerous techniques have been implemented to differentiate Staphylococcus species and 
specially MRSA. On the basis of a variety of conventional phenotypic characters, such as 
colony size, colony pigment, aerobic or anaerobic growth, clumping factor and oxidase 
production etc. most of the Staphylococcus species can be identified (Kloos 1990). However 
these characters such as biochemical reactions, physiological or morphological reactions, and 
analysis by conventional methods often require three to five days. To overcome these tedious 
procedures in routine laboratories, several manufactures have developed rapid identification 
kits and automated systems requiring only a few hours to one day for completion of tests 
which provides both rapid and accurate results. 
 
Some of the kits include the API Staph-Ident, DMS Staph-Trac kits, MicroScan Pos ID panel 
and the fully automated VITEK system which utilize a gram positive identification card (GPI) 
(Kloos and George 1991). These kits consist of trays or strips with wells containing 
dehydrated substrates, biochemicals or nutrient media, the wells providing a reaction vessel 
for enzyme activity. After inoculation, the trays are incubated for five to 24 h and then 
interpreted. The API Staph-Ident kit (Analytab Products, Plainview, N.Y.) was developed for 
the identification of coagulase-negative-staphylococci. The main advantage of this kit is it 
only requires a five hour incubation period (Overman and Overley 1990).  A study by Kloos 
and Wolfshohl (1982) using API Staph-Ident kit resulted in more than 90 % similarity 
between conventional methods and the kit while a study by Overman and Overley (1990) 
resulted in 75 - 100 % reproducibility between the two versions of the kits.   
 
Another commercial kit, the DMS Staph-Trac kit (DMS Laboratories, Inc., Flemington, N.J.), 
a miniaturized biochemical test system, requires a 24 h incubation period. Using this system, 
Giger and co workers (1984) have demonstrated that up to an 88 % correct identification could 
be achieved using this system. The MicroScan Pos ID and Rapid Pos ID panel systems (Baxter 
Diagnostic Inc., MicroScan Division, West Sacramento, Calif.) uses  18 and 42 tests which 
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could be read after 15-48 h and  two hr of incubation respectively where results could be read 
using a auto Scan WalkAway. Studies by Kloos and George (1991) using this system 
demonstrated that high degree of similarity could be achieved compared to the conventional 
systems while Iorio et al., 2007 demonstrate a lower percentage (79.3 %) of correct 
identification compared to the conventional methods.  
 
The VITEK system is used for identification and susceptibility testing of both gram negative 
and gram-positive organisms. It contains 25 conventional biochemicals, three proprietary 
substrates, and one antibiotic and identification cards which are read on the automated reader 
incubator. The final identification is usually available after 4 to 18 h of incubation (Rhoads et 
al., 1995). For the identification of S. aureus, tests such as the rapid commercial slide test for 
detecting haemagglutination by clumping factor or the latex agglutination tests to detect 
clumping factor or protein A could be used. With these systems, identification of most 
staphylococcal spp. can be made with an accuracy of 70-95 % (Kloos 1990).  
 
To ascertain the correct antimicrobial therapy for treatment of staphylococcal infections, it is 
necessary that methicillin resistance is detected as rapidly as possible. Many different 
phenotyping and genotyping methods have been developed to distinguish S. aureus isolates 
(Sousa and Lencastre 2004). The oxacillin agar screening test has been a mainstay for the 
detection of MRSA in diagnostic laboratories over many years which included oxacillin-
resistant screening agar base with 5.5 % NaCl and 2 mg/L oxacillin (Casey et al., 2007). Other 
techniques such as phage typing, MLEE (Weller 2000), pulsed-field gel electrophoresis 
(PFGE) (Murchan et al., 2003), amplified fragment length polymorphism (AFLP) (Melles et 
al., 2004), MLST (Enright et al., 2000), spa typing and SCCmec typing for detection of the 
presence of mecA gene using PCR (Swenson et al., 2001) are carried by different laboratories. 
All of these techniques enable the sub typing of unrelated isolates with different 
discriminatory power, accuracy and reproducibility (Melles et al., 2007). 
 
PFGE is one of the most discriminatory and frequently used techniques which became the 
gold standard for outbreak investigation of S. aureus (Weller 2000). In PFGE the S. aureus 
chromosomal DNA is digested with restriction enzyme SmaI and the resulting fragments are 
separated in an agarose gel (Tenover et al., 1995). Despite the efforts to harmonize the 
protocol and the nomenclature, comparison of interlaboratory results remains difficult (Melles 
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et al., 2007; Deurenberg and Stobberingh 2008). MLST as described above (section 1.1.4) is 
based on stable seven housekeeping genes and have proven to be an excellent method to study 
the evolution of S. aureus (Enright et al., 2000). However this method is costly, laborious and 
time consuming. AFLP on the other hand is a whole genome typing method that detects 
genetic variation between isolates using rear-cutting restriction endonucleases followed by 
separation of fragments on an agarose gel is more amenable (Melles et al., 2007). Typing of 
isolates using MLEE involves the extraction of enzymes from the bacterial cell, separation by 
electrophoresis and examination by selective staining (Weller 2000). This method has also 
been applied to MRSA typing by Tenover and co workers and achieved good reproducible 
results (Tenover et al., 1994).  
 
As DNA sequencing and PCR based methods became more assessable and showed higher 
resolution. The last decade has witnessed wider applications of these methods (Weller 2000). 
The method developed by Frenay et al. 1996 determines the sequence variation of the 
polymorphic region X of the protein A locus. It’s been shown that spa typing could be used for 
both molecular evolution as well as hospital outbreaks of MRSA (Koreen et al., 2004). Also 
the detection of the structure of SCCmec using PCR has become the most popular method and 
has developed over the years (Deurenberg and Stobberingh 2008). 
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1.1.6 Staphylococci infection control 
 
Due to the high rates of mortality and morbidity associated with MRSA worldwide, in both 
hospital and community, prevention control strategies are becoming more important and 
receiving increased attention. Multiple infection control practices such as eradication, hand 
hygiene, identification and isolation of MRSA carriers, patient decolonisation and 
environmental decontamination are used in combination to prevent nosocomial infections 
(Gleeson 2008). Also antistaphylococcal immunisation is an area of ongoing research. 
 
There is considerable evidence of S. aureus nasal carriage and the link to the staphylococcal 
infection (Gordon and Lowy 2008). When infections reoccur, studies have shown that patients 
are generally infected with the same strain from the original infection (Huang et al., 2008). 
The most commonly used approach to eradicate or decolonise, is the use of topical antibiotics 
such as mupirocin ointment to the anterior nares twice daily along with chlorohexidine baths, 
using either 4 % chlorohexidine gluconate containing soap or 2 % chlorohexidine gluconate 
wipes (Gleeson 2008). Mupirocin, a topical antistaphylococcal agent that inhibits RNA and 
protein synthesis and eliminates the nasal colonisation in carriers (Wenzel and Perl 1995). 
Hand hygiene is likely to be the most important component of prevention and control of 
MRSA in hospitals since HA-MRSA are most commonly transmitted through healthcare 
workers. Also, isolation of MRSA carriers prevents transmission within the hospital. Another 
component of controlling HA-MRSA is environmental decontamination. Reports indicate that, 
53 % of acquisition of MRSA is derived from the hand of individuals following environmental 
contact (Bhalla et al., 2004). 
 
At present, no vaccine is generally available that stimulates active immunity against the 
staphylococcal infections in humans. The most significant antistaphylococal vaccine published 
to date comprises S. aureus type 5 and 8 capsular polysaccharides conjugated to nontoxic 
recombinant Pseudomonas aeruginosa exotoxin A (Robbins et al., 2004). Evaluation by 
randomised trials on haemodialysis patients showed partial immunity against S. aureus 
bacteraemia for approximately 40 weeks, after which the antibody levels decreased. However 
a successful vaccine with long term efficacy is still a distant goal and other methods are likely 
to be used for the foreseeable future. 
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1.2 Clostridium difficile 
 
The genus Clostridium is a large and diverse group of prokaryotes. Members of the genus 
Clostridium, including its pathogenic species are mainly found in soil while some are found as 
a very small component of the bowel flora of humans and animals. To date more than 190 
Clostridium species have been described (Bergey’s Manual 2009).  Because of its diverse and 
heterogeneous nature, Clostridium has become one of the largest bacterial genera clearly in 
need of taxonomic refinement. The genus Clostridium was first proposed by Winslow et al. 
(1920) and C. butyricum was proposed as the type species by Cato et al. 1986. The genus 
Clostridia has a wide range of G+C content of 22-55 while the toxigenic species have a narrow 
G+C content of 24-29 (Hatheway 1990). Based on 16S rRNA gene sequences Collins et al., 
1994 has suggested a major revision of the genus. Hence the Clostridia were divided into 19 
different clusters where medically important species were included in cluster I. 
 
C. difficile is an anaerobic, gram positive and spore-forming bacterium and microscopically 
appears as long drumsticks with a bulge located at their terminal ends. It  has been isolated 
from diverse natural habitats, including soil, hay, sand, dung from various large mammals and 
the faeces of dogs, cats and humans (Lyerly et al., 1988) and is carried asymptomatically as a 
part of the gastrointestinal flora in many of the healthy new born and in elderly people. C. 
difficile was first isolated by Hall and O’Toole in 1935, who found it as part of the normal 
microbial flora of the stools of infants (see Louis et al., 1962). They referred to this organism 
as Bacillus difficilis because of the difficulty they encountered in the isolation of the organism. 
These investigators were also the first to show that the organism is toxigenic. 
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1.2.1 C. difficile infection, epidemiology and risk factors 
 
C. difficile causes a spectrum of nosocomial diseases ranging from Antibiotic-Associated 
Diarrhoea (AAD) to Pseudo Membranous Colitis (PMC), especially in hospitalized patients 
those over 65 years (CDR., 2000) and is classically associated treatment with clindamycin, but 
it may occur after exposure to a wide range of antibiotics such as ampicillin and 
cephalosporin’s because these antibiotics are widely prescribed (Starr 2005; Deneve et al., 
2009). There are number of cases reported suggesting that almost any antibiotic can cause the 
disease (Bouza et al., 2005), and very rarely, the disease can even occur without prior 
exposure to antibiotics.  
 
C. difficile produces two lethal toxins, enterotoxin and cytotoxin (toxin A and B) and are 
thought to be responsible for the diarrhoea and inflammation (Poxton et al., 2001). The normal 
bacterial flora in the gut serves as the major barrier against the colonisation by the pathogen. 
When the flora is disturbed in some manner, the host becomes susceptible to colonisation or 
over growth by this pathogen (Cloud and Kelly 2007). Antibiotics such as clindamycin, which 
is the primary cause of PMC act in this manner by disturbing the normal gut flora of the 
bowel. Typical symptoms of AAD in older patients are represented by frequent loose watery 
or bloody stools which maybe accompanied by abdominal cramps and fever (Borriello 1998).  
 
The hospital environment and hospitalised patients are the major reservoirs of C. difficile 
where nosocomial transmission occurs by the faecal-oral route (Doshi et al., 2009). At present 
epidemic C. difficile isolates are widely distributed in the hospital environment, both as a 
cause and result of nosocomial diarrhoea and it is clear that some isolates are more virulent 
than others (Wilcox 2003). C. difficile is now recognised as the primary cause of hospital-
acquired colitis in patients who receive antibiotics, chemotherapeutics or other drugs that alter 
the normal flora and is also responsible for considerable patient morbidity and cost to the 
health care system (Wilcox et al., 1996, Dawson et al., 2009). An HPA, Press release (2007) 
stated that, more than 15,000 cases of C. difficile infections occurred in over 65 years during 
the first quarter of the year. However in the first quarter of 2009 it has decreased to less than 
7000 cases (http://www.hpa.org.uk/HPA/). Analysis carried out on discharge patients in 
hospitals in the US revealed that, CDAD rates increased rapidly from 2001 and doubled until 
2003 (McDonald et al., 2006) and is the major cause of health care associated diarrhoea in  
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USA (Doshi et al., 2009). Due to the increase in C. difficile infections, it was reported that in 
USA, more than $ 1.1 billion costs per annum was spent on management (Kyne et al., 2002). 
However, C. difficile is responsible for only 20 % or less of the AAD while the aetiology of 
the remaining 80 % is still unknown, although potential suggestions such as S. aureus and C. 
perfingens have been proposed (Wilkins and Lyerly 2003 and Bouza et al., 2005).  
 
When the number of CDAD outbreaks began to rise, resulting in increasing number of deaths, 
the emergence of a hyper virulent epidemic strain was suggested. The earliest report was in 
Pittsburgh, Pennsylvania (Muto et al., 2005), soon followed by Quebec and Montreal 
surrounding hospitals in Canada. Later it was found that an uncommon strain of C. difficile 
was responsible for these multiple outbreaks (Loo et al., 2005). It was also been identified as 
causing outbreaks in UK and in parts of Europe, suggesting, it was a global epidemic strain 
(Kuijper et al., 2006, Dawson et al., 2009) and it was characterised as toxinotype III, North 
American Pulsed Field Type 1 (NAP1), restriction enzyme analysis type “B1” and PCR 
ribotype 027 (Warny et al., 2005). It was found that, in addition to the large clostridial toxins 
A and B, which are the main virulence factors, NAP1/BI/027 possesses an extra toxin known 
as binary toxin (Warny et al., 2005). It was also shown that this strain can produce 16 times 
more toxin A and 23 times more toxin B (McDonald et al., 2005) than any other C. difficile 
strain. In addition, this virulent strain possessed an 18 base pair deletion in gene tcdC, a 
putative regulatory factor of toxin A and B, suggesting that this might be the cause of 
increased toxin production (McDonald et al., 2005). Whether it was a binary toxin or increase 
toxin A and B production or other unidentified virulence factors that were responsible for this 
hyper virulent strain, evidence indicated that this toxinotype III strain was more virulent and 
caused a major shift in epidemiology of C. difficile infection. Apart from the changes in the 
virulence factors, NAP1/BI/027 also exhibited resistance to fluoroquinolones. An infection 
with this strain was specifically linked to fluoroquinolone exposure as this was increasingly 
prescribed (Loo et al., 2005). 
 
It is known that antimicrobial therapy is the most widely recognised risk factor involved in 
CDAD, by disturbing the normal gut flora and produces a niche for C. difficile to multiply. In 
addition to this, increase use of antimicrobial therapy and use of broad spectrum 
antimicrobials also contribute to the occurrence of CDAD (Deneve et al., 2009). Other notable 
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risk factors involved in the infection are the use of stomach suppression medications such as 
proton pump inhibitors, nasogastric tubes and gastrointestinal surgery (Rupnik et al., 2009). 
 
 
 
1.2.2 Virulence factors of C. difficile 
 
Toxin A and B 
 
The best described virulence factors of C. difficile are the toxins A and B, encoded by the 
genes tcdA and tcdB (Warny et al., 2005, Rupnik et al., 2009). Toxin A is an enterotoxin and 
toxin B is cytotoxin. When the toxins are released in to the bowel, they adhere to the receptors 
of the colonic brush border and cause necrosis and shedding of these cells into the lumen 
leaving a shallow ulcer on the mucosal surface (Doshi et al., 2009). 
 
The genes encoding toxin A and B are part of the pathogencity locus (paLoc), harbouring five 
genes (tcdABCDE) (Sebaihia et al., 2006) which is a short chromosomal segment carried by 
pathogenic isolates of C. difficile (McDonald et al., 2005). In addition to this, a separate binary 
toxin has been described in the hyper virulent strain, stated above. The binary toxin is 
expressed by a minority of C. difficile isolates and is encoded in a separate part of the genome 
(Cloud and Kelly 2007). In the epidemic strain NAP1/BI/027, the role of the binary toxin is 
still unknown and since its emergence, the prevalence of isolates producing binary toxin has 
increased (Cloud and Kelly 2007). 
 
 
 
 
 
 
 
 
 
 
 33
1.2.3 Other virulence factors 
 
In addition to the toxins, other factors produced by C. difficile may contribute to the 
colonisation of the gut and its pathology. Adhesion to host cells is known to be important in 
the expression of virulence for many pathogens.  
 
Studies by Borriello (1990) and Borriello and Wilcox (1998) using various strains of C. 
difficile in a hamster model demonstrated the presence of fimbriae at the pole of the cell. 
However their role in colonisation remains unclear (Borriello and Wilcox 1998). Additionally, 
the heat shock protein GroEL in C. difficile has been shown to have a role in cell adherence 
(Hennequin et al., 2001). For many bacteria, the possession of a capsule is an important 
virulence factor and there is evidence that some isolates of C. difficile possess capsule-like 
material in vitro (Borriello 1990). The presence of an antiphagocytic factor in C. difficile was 
reported by Dailey et al. (1987) but the removal of the cell surface carbohydrates showed no 
marked effect on the rate of phagocytosis. The role of hydrolytic enzymes in C. difficile 
infections remains uncertain but it has been shown by Seddon et al. (1990) that virulent strains 
possess a higher level of hyaluronidases.  
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1.2.4 Diagnosis and identification 
 
Diagnosis of C. difficile is mainly done by detection of toxin in stools while the most 
definitive way of diagnosing PMC is by endoscopic detection of pseudomembranes or micro 
abscesses in antibiotic treated patients with diarrhoea (Lyerly et al., 1988). Once C. difficile 
has been identified, efforts to minimise its transmission is required to reduce additional cases 
or outbreaks by isolating the infected patient, followed by disinfection with chemical agents in 
order to minimise further risks (Wilkins and Lyerly 2003). 
 
As an in vitro diagnostic tool for C. difficile detection, many clinical laboratories use 
cycloserine-cefoxitin-fructose agar as a selective medium (George et al., 1979).  Isolates are 
presumptively identified by their colony and cellular morphologies, fluorescence, volatile fatty 
acid profiles and other properties. In general, many clinical laboratories use antibody-based 
tests, because these tests are more cost-effective and have reduced turnaround times (ca. 15 - 
45 min). These tests target the toxin A, a combination of toxin A and B or the common 
antigen; glutamate dehydrogenase (GDH), which is an essential enzyme, produced by all C. 
difficile isolates and could be readily used to detect the presence of this bacterium in faecal 
samples. However, antiserum against C. difficile cross reacts with other anaerobes and newer 
GDH tests avoided this potential pitfall by using antibodies only react with C. difficile 
(Wilkins and Lyerly 2003). 
 
Enzyme linked immunosorbent assay (ELISA) which detects the toxin A and a combination of 
toxin A and B is also used as a diagnostic tool in hospitals (Wilkins and Lyerly 2003). These 
tests are easier, more rapid, less expensive and exhibit a higher sensitivity (> 80 %), although 
it’s less sensitive than the tissue culture assay. ELISAs that detect toxin A and B were 
considered unnecessary, until the recent discovery of a C. difficile isolate CCUG 8864 (Torres 
1991) which is A- B+, and toxin B was found to be more enterotoxic than toxin B from typical 
A+ B+ isolates. 
 
The tissue culture assay has been used extensively for the detection of C. difficile toxin in 
stools specimens. Despite being more time consuming and tedious, the test detects picogram 
levels of C. difficile toxin, making it the most sensitive test available at present and also 
referred to as the “gold standard” (Wilkins and Lyerly 2003). There are possible problems, 
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however, with the assay as it is used currently. The assay is not highly standardised, which 
results in variations in the most appropriate cell line to use and the optimal faecal dilution etc., 
making it difficult to compare the clinical studies (Lyerly et al., 1988). 
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1.2.5 Typing of C. difficile 
 
Although isolation of toxigenic C. difficile from samples is adequate for diagnosis, the typing 
of isolates is essential for epidemiological outbreak investigations. To understand the 
nosocomial epidemiology of C. difficile infection, various typing or fingerprinting methods 
have been applied. 
 
Early methods were mainly based on phenotypic properties such as antibiograms, which was 
studied by Burdon (1982). Although he was able to identify common resistance patterns to 
three antibiotics, the method was rudimentary and soon was suppressed by other methods. 
Several other techniques were applied by Wust et al. (1982) such as, plasmid analysis and 
soluble protein polyacrylamide gel electrophoresis (PAGE). Most of the isolates were 
indistinguishable by these techniques which indicated that cross infection had taken place. Sell 
et al. (1983) used a combination of bacteriocin and bacteriophage typing methods and was 
also unsuccessful. Nakamura et al. (1981) then used serum agglutination as typing method 
which was later improved as a standard serotyping method to compare with other typing 
techniques. All these techniques were developed to understand the epidemiology of C. difficile 
infection at the local level. Since these methods indicated that cross-infection had occurred 
and they were investigated to study the epidemiology in Outbreaks. For this purpose 
comparison between typing schemes were performed and a good correlation between the types 
recognised by plasmid profiling, serotyping and PAGE were found by Mulligan et al. (1988). 
 
Whole cell fingerprinting by pyrolysis mass spectrometry (PMS) was successfully used as a 
means of investigating putative C. difficile outbreaks (Magee et al., 1993). This method has 
the advantage that it can cope with a large throughput of isolates and has a high degree of 
discrimination (Brazier 2001). However apart from its initial cost of the equipment inter 
laboratory reproducibility was poor. 
 
Molecular typing methods are generally regarded as superior to phenotypic methods in terms 
of the stability of expression and greater degrees of typeability, and a number of methods have 
been applied to C. difficile (Brazier 2001). Plasmid profiling proved largely unsuccessful due 
to the sparse distribution of these extra chromosomal genetic elements within the species. 
Kuijper et al. (1987) used whole cell DNA restriction endonuclease analysis (REA) using 
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HindIII for C. difficile chromosomal DNA analysis. REA is highly discriminatory and a 
reproducible method although technically demanding and a labour intensive method. 
Restriction fragment length polymorphisms (RFLP) is an alternative genotypic method that 
involves initial REA digestion followed by gel electrophoresis and southern blotting with 
selected labelled nucleic acid probes to highlight specific restriction site heterogeneity. This 
method was first applied to C. difficile by Bowman et al. (1991). However this method is also 
labour intensive and these methods were surpassed by techniques based on polymerase chain 
reaction (PCR) (Brazier and Borriello 2000).  
 
Arbitrarily primed PCR (AP-PCR) is a genotypic method that permits the detection of 
polymorphism within the target genome without prior knowledge of the target nucleotide 
sequence. This was viewed as a potentially useful method for C. difficile by McMillin and 
Muldrow (1992) and others. But results showed poor reproducibility. PCR ribotyping uses 
specific primers complimentary to sites within the RNA operon and was first applied to C. 
difficile by Gurtler (1993) who targeted the amplification process at the spacer region between 
the 16S and 23S rRNA regions. This part of the genome was shown to be very heterogeneous 
and C. difficile was shown to posses ten copies of the rRNA genes in its genome which varied 
between strains and as well as different copies of the same genome (Brazier 2001). Because of 
its discriminatory power, this method has been used routinely by the UK Anaerobe Reference 
Unit in Cardiff, which has provided a C. difficile typing service for the UK since 1995. A 
library containing 116 distinct ribotypes has been constructed using over 3000 isolates (Stubbs 
et al., 1999). 
 
Another method, pulsed field gel electrophoresis (PFGE) allows the whole genome to be 
analysed after digestion with rare cutting restriction endonucleases, such as SmaI, KspI, SacII 
or NruI. Although analysis and comparison between PFGE gels are simple and discriminatory, 
disadvantages include the cost of the equipment, slowness of the electrophoresis procedure 
and its complexity. A comparison of the three methods PCR ribotyping, AP-PCR and PFGE 
by Bidet et al. (2000) concluded that PCR ribotyping, although marginally less discriminatory 
than PFGE offered the best combinations of advantages and is the method most commonly 
used today. 
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1.2.6 Variable Number Tandem Repeats (VNTR) 
 
The analysis of DNA has been used in a large number of studies in bacterial taxonomy, 
bacterial typing and for further understanding the basic mechanisms of evolution (Gurtler and 
Mayall 2001). A wide range of molecular techniques including PCR ribotyping, Pulsefield Gel 
Electrophoresis (PFGE), Amplified fragment length polymorphism (AFLP), Multi locus 
sequence typing (MLST) and Random Amplified Polymorphic DNA (RAPD) are used as 
typing methods for the characterisation and differentiation of bacterial species down to the 
strain level. Strain differentiation has become an invaluable tool in epidemiological 
investigations and the generated data could be used for comparison between laboratories, 
regions and countries (Kanduma et al., 2003). In addition, strain identification can be useful to 
determine the outbreak strain and distinguishing it from epidemiologically unrelated isolates 
(Ramazanzadeh and McNerney 2007). 
 
Tandemly repeated sequences were first described in eukaryotic genomes many years ago (van 
Belkum et al., 1998) and these were thought to occur in several to thousands of copies, 
dispersed throughout the genome (Jeffreys et al., 1985). These sequenced elements showed 
hypervariability among individual persons and were used to prepare DNA fingerprints that are 
specific to each individual (Jeffreys et al., 1985).  Loci with short sequence repeats (SSRs) of 
one–three bp are generally referred to as microsatellites, whilst loci with 10–100 bp are 
referred to as minisatellites (Haddad et al., 2004). The repeats tend to vary in size, location 
and complexity (Lindstedt 2005). With the sequencing of bacterial genomes, it became evident 
that micro-organisms also contain a high number of these direct repeats. Since many of these 
loci show hypervariability in their repeat numbers in humans and animals, they are also 
referred to as Variable Number Tandem Repeat (VNTR) loci (Ramazanzadeh and McNerney 
2007). Variability observed in VNTRs is thought to be caused by a mechanism called slipped-
strand mispairing (SSM) (Strand et al., 1993), where DNA repeats are inserted or deleted 
during DNA duplication (Figure 1.3). 
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Figure 1.3. Schematic representation of the mechanism of SSM during replication, which results in 
shortening or lengthening of SSRs. Individual repeat units are identified by arrows; bulging is the 
presence of non-base-pair base residues interrupting a regular 2-strand DNA helix. Bulging in the 
nascent strand leads to a larger number of repeat units; bulging in the template strand results in a 
smaller numbers of units. During replication, bulges can occur in both strands, and the effect of 
insertion or deletion can be neutralized by occurrence of the adverse event. The number of repeat units 
can decrease or increase by multiple repeats once multiple bulging in one strand has occurred (Adapted 
from van Belkum et al., 1998). 
 
 
VNTRs have been studied extensively in eukaryotic genomes and have been successfully used 
for identification (van Belkum et al., 1998). The first bacterial species in which they were 
identified was Mycobacterium tuberculosis (Supply et al., 2000) and is described as 
Mycobacterial Interspersed Repeat Units (MIRUs). Recently, a number of studies have used 
VNTRs as a means for identification of bacterial isolates i.e. Bacillus anthracis (Lista et al., 
2006), Yersinia pestis (Klevytska et al., 2001), Haemophilus influenzae (van Belkum et al., 
1997), Vibrio cholerae (Ghosh et al., 2008), S. aureus (Sabat et al., 2003, Hardy et al., 2004) 
and many other bacteria. Although most of the early work on tandem repeats was used for 
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strain identification of bio terror-related micro-organisms, it is now being used for human 
pathogens such as Salmonella serovars (Lindstedt et al., 2003) and E. coli (Noller et al., 
2006). Many studies have named the repetitive DNA structure differently; eg. MLVA, MIRU, 
and SIRU, but in this study they will be referred to as VNTRs. 
 
Due to the rapidly increasing knowledge of genome sequences, the search for faster, less 
labour intensive and low cost methods has lead to DNA-based typing methods. Since VNTR 
assays are based on PCR amplification of specific locus where targets are known, it has 
become a promising tool in strain typing (Lindstedt 2005, van Belkum 2007 and Budowle et 
al., 2005). Also, the ability to use fluorescent dyes allows multiplex assays to be developed, 
giving amplicons different colours and separating it on capillary sequencers, making it a rapid, 
reliable, high-throughput strain identification technique. The typing methodology involves 
PCR amplification of the entire tandem repeat loci using primers positioned in the flanking 
regions of the locus.  
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1.2.7 Treatment and infection control 
 
Antibiotics remain the most frequently used treatment for CDAD while a number of 
nonantibiotic agents are under investigation for treatment. For several years oral vancomycin 
was thought to be the treatment of choice, but later studies revealed that oral metronidazole 
was therapeutically equivalent to oral vancomycin for treatment for CDAD (Teasley et al., 
1983). The main advantages of using metronidazole were, it was less expensive and was less 
likely to promote the spread of vancomycin-resistant enterococci (Cloud and Kelly 2007). It 
was also suggested that the patients with severe symptoms who cannot receive oral treatment, 
a combination of intravenous vancomycine and intravenous metronidazole should be 
considered (Stoddart and Wilcox 2002). 
 
Although metronidazole and vancomycin remains the main treatment for CDAD, several new 
antibiotics such as rifaximin and nitazoxanide are also under investigation and are already 
approved for other gastrointestinal infections (Blossom and McDonald 2007). Also tolevamer, 
a C. difficile toxin-binding resin, monoclonal antibodies directed at toxin A and B and a C. 
difficile vaccine for immunisation are in early stages of development (Wilcox 2003). Since 
perturbation of the bowel flora by antibiotic use, it was thought that probiotics maybe effective 
in prevention of CDAD or in treatment of recurrent CDAD. The most common probiotics 
include Lactobacillus rhamnosus GG, Saccharomyces boulardii and other probiotic mixtures 
including bifidobacteria (Cloud and Kelly 2007). Although a number of studies indicated 
mixed results for probiotic use, it as been shown recently that in a mouse model, intestinal 
immunoglobulin A and antitoxin A secretion is stimulated by S. boulardii indicating its 
possible efficacy (McFarland 2006). 
 
Health care facilities remain the main centre for C. difficile transmission and measures should 
be taken to prevent the infection control i.e. patient to patient transmission. When a patient is 
diagnosed with CDAD, prevention methods such as isolating the patient, patients with CDAD 
should be allowed to use the same bathroom and once the diarrhoea ceases, transferring the 
patients to another room should be taken. Also healthcare workers should always take 
measures such as wearing gloves and gowns for all patient contacts (Blossom and McDonald 
2007). Hand hygiene also plays a major role in infection control. Since C. difficile spores have 
the ability to survive under any environmental conditions, measures should be taken to prevent 
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the spread through spores. It was shown that hand washing by alcohol based sanitizes are 
unable to prevent the spread. Hence, healthcare workers were adviced to wash their hands with 
soap and water after removal of gloves. Also a special attention should be given to 
environmental cleaning of care areas those accommodate patients with CDAD. At present the 
most commonly used sporicidals i.e. household bleach, contains 5000 ppm of sodium 
hypochlorite and fresh solutions should be used to clean the surfaces of hospitals in order to 
prevent the infection spread through spores (Blossom and McDonald 2007). 
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1.3 Genomics to Proteomics 
 
With the completion of the human genome project and the sequencing of many prokaryote and 
eukaryote genomes, interest in studying proteins has risen to determine the identity and 
quantity of expressed proteins (Graves and Haystead 2002). While the genome remains stable 
to a large extent, the proteome of a cell reflects the immediate environment in which it is 
studied. In response to internal or external cues, proteins can be modified by post-translational 
modifications (PTM), undergo translocations within the cell, or be synthesized or degraded 
(Mirza and Olivier 2008). 
 
Although genomics provide a vast amount of information and also DNA/ RNA is relatively 
easy to work with, the information on gene regulation and protein identification cannot be 
obtained from DNA/ RNA analysis. After synthesis on ribosome, simple chemical groups or 
complex molecules may be attached to the proteins and following translation proteins are 
chemically change through PTM, mainly through the addition of carbohydrate or phosphate 
groups. Hence one cell can contain between one and more than 100,000 copies of a single 
protein (Celis and Gromov 1999). Therefore DNA sequence analysis does not predict the 
active form of a protein and RNA quantitation does not always reflect the corresponding 
protein levels. Thus, examination of the proteome of a cell is like taking a “snapshot” of the 
protein environment at any given time. 
 
Considering all the possibilities, it is likely that any given genome can potentially give rise to 
an infinite number of proteomes and is far more complex than the genome (Cho 2007). Hence 
DNA sequence analysis alone cannot provide an accurate profile of protein abundance, 
structure and activity. Also, proteins are directly involved in both normal and disease 
associated biochemical processes, a more complete understanding of the diseases maybe 
gained from looking directly into the proteins. The term “proteomics” was first coined in 1995 
and was defined as the large-scale characterisation of the entire protein complement of a cell 
line, tissue, or organism (Anderson and Anderson 1996; Wilkins et al., 1995 and Tyers and 
Mann 2003).  However the first protein studies that can be referred to as “proteomics” began 
much earlier in 1975 with the introduction of the two-dimensional gel (2-DE) by O’Farrell 
(O’Farrell 1975).  
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Due to the complex nature of the proteome, proteomic analysis has become a challenging 
field. The proteomics field can be divided into two main areas; expression proteomics and 
functional proteomics. The former is the study of differentially expressed proteins in various 
conditions while the latter refers to the study of proteins involved in function such as 
signalling pathways etc. (Graham et al., 2007).  A vital role of proteomics is the discovery of 
disease biology, mechanisms and new drug targets (biomarkers) which will ultimately help 
design products to prevent, diagnose and treat diseases (Mirza and Olivier 2008). Biomarkers 
can be broadly defined as indicators of normal biological or pathological disease states as well 
as pharmacological responses to therapeutic inventions (Elrik et al., 2006). Hence 
identification of earlier and specific biomarkers should provide target molecules to diagnose 
disease and improve in patient treatment. 
 
Earlier proteome analysis mainly relied on gel-based proteomics such as SDS-PAGE and 2-
DE that permits the separation of thousands of proteins based on mass and charge. High 
resolution 2D-PAGE can resolve up to 10,000 protein spots per gel and could be visualised 
using stains such as Coomassie blue, silver, SYPRO Ruby and Deep Purple (Lauber et al., 
2001). The limitations of 2D-PAGE mainly are that it is a time consuming and labour-
intensive process has low dynamic range and inherent gel-to-gel variability. However, with the 
rapid progress in mass spectrometry (MS) in the last decade has made it a key technique for 
the investigation of the proteome and has increasingly become the method of choice for 
analysis of complex protein samples (Aebersold and Mann 2003; Tyers and Mann 2003; 
Kolker et al., 2006 and Domon and Aebersold 2006). Due to the high accuracy of this method, 
which detects peptides up to femtomole to attomole level, it is now possible to detect the 
proteins by using public protein databases such as NCBI (Hirsch et al., 2004) which could be 
easily accessed electronically. 
 
In order to analyse a complex protein sample by MS, involves an initial fragmentation step, a 
separation step for the fragmented complex protein mixture and mass spectral analysis of the 
fragmented particles. The fragmentation is normally done by digesting the protein sample 
using trypsin and separating the fragmented protein mixture using chromatography (LC) and 
analysed using tandem MS (MS/MS) (Kolker et al., 2006). Subsequently, an alternative to 2-
DE, a gel-free approach was developed as multidimensional protein identification technology 
(MUDPIT) to overcome the limitations of 2D-PAGE (Roe and Griffin 2006). Depending on 
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the methodology used to identify certain proteins, two strategies have been introduced (Mirza 
and Olivier 2008 and Graham et al., 2007); top down and bottom up proteomics. The top 
down methodology identifies the proteins/ peptides without the prior proteolytic digestion of 
the sample while bottom up methodology analyse the peptides derived from the digested 
samples (Zhou and Veenstra 2008, Lin et al., 2003).   
 
In addition to protein identification, it is essential to quantify the proteins in order to 
understand its role in the organism (Bantscheff et al., 2007) and several mass spectral 
approaches have been established to quantify proteins. Traditionally, gel-based approaches 
were used in order to quantify the proteins while new methods such as stable isotope labelling 
and label-free approaches have been introduced (Kito and Ito 2008). Differential gel 
electrophoresis (DIGE) has been established to overcome the limitations of 2DE as well as to 
highlight differentially expressed proteins. In DIGE, proteins can be detected with highly 
sensitive fluorescent dyes known as CyDye fluors (Marouga et al., 2005) and up to three 
different samples can be identified on a same gel, each labelled with a different fluorescent 
dye. For the relative quantification of different protein samples, the samples are labelled with 
stable isotopes and analysed by MS e.g. isotope coded affinity tagging (ICAT) and stable 
isotope labelling by amino acids (SILAC)  (Kito and Ito 2008) while for both relative and 
absolute quantification a more advanced MS method such as isobaric tagging (iTRAQ) has 
been used. Recently, label-free methods for protein quantification have been used. But this 
technique also has its limitations (Kito and Ito 2008). 
  
 
 
 
 
 
 
 
 
 
 
 
 46
1.4 Proteomic techniques used in this study 
 
1.4.1 Mass spectrometry 
 
One of the most important developments in protein identification has been the development of 
mass spectrometry technology. The first major technology to emerge for the identification of 
proteins was the sequencing of proteins by Edman degradation (Edman 1949). In contrast to 
Edman sequencing, mass spectrometry is a high sensitivity, high-throughput technique used to 
acquire both molecular weight and sequence information of both proteins and peptides.  
 
Pyrolysis mass spectrometry (PY-MS) was one of the first MS techniques to be used to 
fingerprint and discriminate between bacteria at species and even strain level (Goodfellow 
1995). But one of the major disadvantages of PY-MS is that little structural information is 
obtained as the size and range of masses obtained is small. The rapid progress in mass 
spectrometry in the last decade has made it a key technique for the investigation of the 
proteome, which was initiated by the development of the two ionisation techniques, Matrix 
Assisted Laser Desorption/Ionisation (MALDI) (Karas and Hillenkamp 1988) and Electro 
Spray Ionisation (ESI) (Tanaka et al., 1987) which has led to significant improvements in the 
central step of protein identification. Due to the high accuracy of this method, detection of 
peptides in the femtomole to attomole range with an accuracy of <5 parts per million (ppm) 
(Clauser et al., 1999) is now possible by using “protein databases” such as, National Centre 
for Biotechnology Information (NCBI). 
 
Thomson developed the first mass spectrometer (then called the parabola spectrograph) during 
the first decade of the 20th century. There are many different types of mass spectrometers, but 
the basic principle is universally applicable: the sample is ionised and subsequently the ions 
are separated according to their mass to charge (m:z) ratio and displayed as a mass spectrum. 
Hence a mass spectrometer comprises of two major components which are an ionisation 
source for the production of ions and a mass analyser to detect the masses of produced ions. 
Throughout the 1980s emerging desorption/ionisation techniques such as Plasma Desorption 
(PD), Laser Desorption (LD) and Fast Atom Bombardment (FAB) were evaluated for the 
generation of molecular ions from microorganisms.  But there were drawbacks and limitations 
for these techniques such as ionisation efficiency, mass range of the ionisable compounds and 
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other practical issues. With the rapid development in MS, during the 1980s-1990s, Matrix 
Assisted Laser Desorption/Ionisation (MALDI) and Electro Spray Ionisation (ESI) evolved as 
new methods for the ionisation of biological samples. In both methods, peptides are converted 
to ions by the addition or loss of one or more protons. ESI and MALDI are “soft” ionization 
methods that allow the formation of ions without significant loss of sample integrity. This is 
important because it enables accurate mass information to be obtained for proteins and 
peptides in their native states (Zhou and Veenstra 2008). 
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1.4.2 Matrix Assisted Laser Desorption/Ionisation (MALDI) 
 
Matrix Assisted Laser Desorption/Ionisation (MALDI) is a soft ionisation technique used in 
mass spectrometry, allowing the analysis of biomolecules / biopolymers such as proteins, 
peptides and sugars and large organic molecules which tend to be fragile and fragment when 
ionised by more conventional ionisation methods such as electro spray ionisation (ESI). The 
term Matrix Assisted Laser Desorption/Ionisation was first coined in, 1985 by Franz 
Hillenkamp, Michael Karas and their colleagues (Karas et al., 1985). They found that the 
amino acid alanine could be ionised more easily if it was mixed with the amino acid 
tryptophan and irradiated with a pulsed 266 nm laser. Thus tryptophan regarded as an 
“absorbing matrix” resulting in molecular ion formation of alanine. 
 
Until recent years, desorption of bioorganic compounds in the mass range above 10,000 Da 
could be done only by Plasma Desorption Mass Spectrometry (PDMS). In 1988, Tanaka 
reported the laser desorption of protein molecular ions up to a mass range of 34 000 Da using 
“ultra fine metal plus liquid matrix method” that combined 30 nm cobalt particles in glycerol 
with a 337 nm nitrogen laser for ionisation (Tanaka et al., 1988). However with the discovery 
of MALDI, Karas and Hillenkamp were subsequently able to ionise the protein albumin, up to 
67,000 Da with a 266 nm laser and a solution of nicotinic acid served as the absorbing matrix 
(Karas 1988). 
 
While the exact desorption/ionization mechanism for MALDI is not known, it is generally 
believed that MALDI causes the ionization and transfer of a sample by mixing with solid 
organic chemical, the matrix. In the MALDI process the peptides or proteins which need to be 
identified are placed on a target plate, co-crystallised with a matrix solution usually a UV-
absorbing weak organic acid and air dried (Karas 1988). Irradiation of this analyte-matrix 
mixture by a laser results in the vaporization of the matrix, which carries the analyte with it. 
The matrix plays a key role in this technique. The co-crystallized sample molecules also 
vaporize, but without having to directly absorb energy from the laser. Ions produced by 
MALDI are generally singly-charged ions, but doubly charged ions have also been observed 
e.g. in the case of matrix molecules and other stable molecules (Siuzdak 1994).  
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Once in the gas phase, the desorbed charged molecules are then directed electro statically from 
the MALDI ionization source into the mass analyzer to perform the mass analysis. Time-of-
flight (TOF) mass analyzers are often used to separate the ions according to their mass-to-
charge ratio (m/z). It is calculated from the time taken by the ions to travel through the length 
of the flight tube to the detector (Figure 1.4). 
 
 
             
 
Figure 1.4: Basic components of a Linear-TOF Mass spectrometer. The left side shows the ion source 
where analytes ionised. The narrow flight tube during which charged ions travel to reach the detection; 
the smaller masses arriving first (Modified from The Institute of Food Research and John Innes Centre 
Joint Proteomics Facility). 
 
 
1.4.3 The Matrix 
 
A non-volatile solid material facilitates the desorption and ionization process by absorbing the 
laser radiation. As a result, both the matrix and any sample embedded in the matrix are 
vaporized. The matrix also serves to minimize sample damage from laser radiation by 
absorbing most of the incident energy. 
 
A variety of matrices have been suggested for the use of MALDI. The selection of a 
compound for the use as a MALDI matrix must be soluble in a solution with the analyte; if 
this is not possible the matrix and the analyte must be deposited separately on to the target 
plate. The matrix consists of crystallized molecules, fairly low molecular weight and acidic, 
therefore act as a proton source to encourage ionization of the analyte. A further requirement 
for a matrix is to be chemically inert in terms of reactivity with the analyte (Beavis and Chait 
1989). 
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The three most commonly used matrices are 3, 5-dimethoxy-4-hydroxycinnamic acid 
(sinapinic acid) (Beavis and Chait 1989), α-cyano-4-hydroxycinnamic acid (alpha-cyano or 
alpha-matrix) and 2, 5-dihydroxybenzoic acid (DHB). A solution of one of these molecules is 
made, often in a mixture of highly purified water and an organic solvent normally acetonitrile 
(ACN) or ethanol. Trifluoroacetic acid (TFA) may also be added.  
 
Matrix Assisted Laser Desorption/Ionisation Time-of-flight mass spectrometry (MALDI-TOF-
MS) has a number of advantages over other methods of mass spectrometry when analysing 
biological material. Crude proteins can be analysed without the need for extensive separation 
(Hillenkamp et al., 1991) and the insensitivity to impurities can eliminate sample purification 
steps, reducing the time needed for analysis (Easterling et al., 1998). A variety of studies have 
shown that MALDI-TOF-MS may be used for the rapid analysis of biological components of 
bacterial cells (Dai et al., 1999; Chong et al., 1997; Liang et al., 1996). Another great 
advantage of MALDI-TOF-MS is that intact cells can be taken directly from a colony and 
analysed within minutes, reducing the sample preparation time (Holland et al., 1996; Claydon 
et al., 1996; Krishnamurthy and Ross 1996; Welham et al., 1998, Fenselau and Demirev 
2001). Intact cell MALDI-TOF-MS, also known as ICM-MS generally detects the surface 
components which have not been studied systematically up to now. Since many of the 
interesting properties associated with microbial physiology, virulence and pathogenicity are 
associated with the surface components of the cell, MALDI-TOF-MS offers the large scale 
comparative analysis of such molecules and provides the means to study their diversity among 
the microorganisms. 
 
 
 
 
 
 
 
 
 
 
 
 51
1.4.4 Waters® (MMU) database 
 
With the aim of establishing a high throughput system for the characterisation of microbes, 
based on intact cell MALDI-MS (ICM-MS), a database was created by a consortium 
comprising Waters Inc, Manchester Metropolitan University (MMU) and Health Protection 
Agency, Centre for Infections (HPA, CFI). It comprised nearly 5000 MALDI spectra of Type 
and reference stains (Keys et al., 2004) obtained from the National Collection of Type 
Cultures (NCTC), HPA. The parameters which are likely to affect the reproducibility of the 
mass spectrum were studied extensively prior to assembling the database. Some of these were, 
sample preparation, growth phase, culture conditions, sample storage, mass range of ions, 
reproducibility between instruments and the methodology prior to database entry (Shah et al., 
2002). For database entry twelve replicates per sample were analysed on 96-well target plates 
containing central wells for peptide standards to correct against mass drift during analysis. The 
quality of the data was assessed statistically prior to database addition using root mean squared 
values of <3.0 as the criterion for rejection. 
 
To date, MALDI-MS has shown that type and laboratory reference isolates often differ from 
clinical isolates (Rajakaruna et al., 2009). Therefore it is uncertain how the database will 
perform when challenged with clinical isolates. A major aim of this study was therefore to 
collect field isolates from a hospital, give them minimal time to adapt to the laboratory 
conditions, to ascertain their purity and attempt to identify isolates by comparative analysis of 
their MALDI profile to an existing profile in the database described above.  
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1.4.5 Spectral ARchive And Microbial Identifications System (SARAMIS™) database 
(AnangnosTec, Germany) 
  
During the course of the above study, another database referred to as SARAMIS™ was 
initiated by AnagnosTec in Germany (Kallow et al., 2006). The SARAMIS™ software and 
database of human and veterinary pathogens, food pathogens, environmental and natural 
product producing microorganism began development using MALDI-TOF-MS. The database 
consisted of, reference spectra and software that allowed the comparison of the mass 
fingerprint of an unknown sample to the reference spectra 
(http://www.anagnostec.eu/home.html). Due to the soft ionisation of MALDI, mass signals 
from 2000- 20,000 Da were collected to assemble the database. It was subsequently found that 
most of the signals were mainly from stable ribosomal proteins (bacteria) and surface proteins 
(fungi) (Ryzhov and Fenselau 2001 and Pineda et al., 2003). This was confirmed when the E. 
coli K12 whole cell extracts were analysed and the mass signals obtained superimposed with 
the E. coli K12 ribosomal proteins (Figure 1.5). 
 
 
           
                
Figure 1.5: Example of E. coli K12 when analysed using SARAMIS™ and most of the peaks detected 
were of stable ribosomal proteins (Taken from Mass Spectrometry for Microbial Proteomics 2010: 
Wiley). 
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1.4.6 Quality control, sample preparation and different matrix:  
 
In order to ensure the quality of microorganism identification with SARAMIS™, different 
procedures and control mechanisms have been used.  The SuperSpectra™ have been generated 
from replicate mass spectra of multiple isolates of a single species or sub-species. To generate 
the SuperSpectra™, high quality mass spectra of a species of interest were collected from 
multiple isolates, grown under varying conditions and in different laboratories. Beside the 
fingerprint spectra, the identity of every isolate was also determined by different methods, e.g. 
biochemical methods and 16S RNA-sequencing identification procedures. The result of the 
identification by SARAMIS™ SuperSpectra™ was then compared with the other methods. In 
addition, the SARAMIS™ microorganism identification database is routinely evaluated by 
inter laboratory comparisons.  
 
To obtain a successful MALDI-TOF-MS analysis, good sample preparation is a crucial step. 
AnagnosTec has developed several sample preparation methods using different matrix 
solutions, which could be used to yield high quality spectra (Table 1.1 and Figure 1.6). 
 
 
(a). Sample preparation 1 (alpha-cyano-4-hydroxy cinnamic acid) 
 
This sample preparation is recommended when rapid species identification is desired. It 
requires a lower number of laser shots, thus saving time and maintenance costs. However, in 
the resulting spectra lower numbers of peaks are recorded compared to the other sample 
preparation methods (Table 1.1 and Figure 1.6). 
 
(b). Sample preparation 2-(2, 5-Dihydroxybenzoic acid/ DHB) 
 
In addition to identification if strain typing is desired, this method is recommended. It requires 
a higher number of laser shots and as a result, the spectra contain higher number of peaks 
(Table 1.1 and Figure 1.6). 
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(c). Sample preparation 3 
 
If the spectra obtained from above mentioned procedures are not satisfactory for identification, 
as an additional step, the sample is pre-extracted using 25 % formic acid. Formic acid 
increases the permeability of the cell wall and protein extraction efficiency. 
 
    
Matrix Species identification Strain typing 
DHB 1 min / 1,500 laser shots 1-2 min / 2,000 laser 
shots 
alpha-cyano-4-hydroxy 
cinnamic acid 
30 s /  400 laser shots Not suitable 
 
    Table 1.1: Overview of the sample preparation procedures using different matrix solutions. 
 
                                   
                                  (a) 
                                     
                                  (b) 
Figure 1.6: (a) Samples prepared with Alphacyano matrix. Small spherical crystals are homogeneously 
distributed on the spots. (b) Samples prepared with DHB matrix. Large, needle shaped crystals are 
found at the outer border of the spots. 
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1.4.7 Review of MALDI-TOF-MS used for bacterial identification and characterisation 
 
The first attempts to utilise MALDI-TOF-MS for the characterisation of intact bacterial cells 
were reported in 1996 by several workers. Holland and co workers (1996) who demonstrated 
the ability to differentiate isolates representing genus Pseudomonas by using characteristic 
mass ions while Krishnamurthy and Ross (1996) reported species-specific biomarkers for 
Bacillus sp., Yersinia pestis and Francisella tularensis. Claydon et al. (1996) further 
confirmed the potential of the approach for the rapid identification of gram negative and gram 
positive bacteria representing different genera and species. In 1998, an improved sample 
preparation method was introduced by Welham et al. (1998), which enabled the identification 
of species-specific markers in a wider mass range compared to other studies of gram negative 
bacteria. Anaerobic bacterial species such as Porphyromonas, Bacteroides and Prevotella 
were also delineated using MALDI using a simple sample preparation method (Shah et al., 
2002).   
 
A study by Shah et al. (2000) on gram positives and gram negative bacteria, suggested the 
potential of a database of archived mass listings of profiles to be utilised in order to compare 
an unknown to a given spectrum for rapid identification. More recently, Carbonelle et al. 
(2007) reported the separation of coagulase-negative staphylococci from other closely related 
taxa using an archived spectral database. Rapid discrimination of 24 bacterial species 
associated with food contaminants were carried out by Mazzeo et al. (2006). This work 
resulted in the development of a database for public access to identify food contaminant 
microorganisms that cause human diseases. A subsequent study by Barbuddhe et al. (2008) 
developed and expanded MALDI-TOF-MS methods for analysing multiple Listeria species.  
 
The above studies were mainly based on identifying biomarkers in lower mass range for 
differentiation at genus or species level. In 1999, Dai et al., used solvent extracts of E. coli, 
fractionated using HPLC followed by MALDI analysis in order to identify low mass proteins 
and peptide biomarkers (Dai et al., 1999). Arnold and Reilly (1998) focused on the HPLC 
separation of ribosomal proteins and identified around 55 distinct components. The ability to 
differentiate minor differences between phylogenically similar bacteria by MALDI analysis 
was demonstrated by Lynn et al. (1999), who reported family-specific biomarkers within the 
Enterobacteriaceae. 
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The thrust of MALDI-MS application has been clinical. For example, a method has been 
described for rapid discrimination of MRSA and MSSA using ICM-MS (Edwards-Jones et al., 
2000). The clarity of discrimination between MRSA and MSSA strain spectra and the speed of 
the method suggests a potential role for ICM-MS in the diagnostic laboratory, which could 
lead to major improvements in the treatment strategy for infected patients. However, another 
study by Bernardo et al. (2002), who used cell extracts of MRSA and MSSA was unable to 
discriminate between the two using MALDI but concluded that MALDI could be used for 
discrimination of clonal isolates of MRSA, which might be useful to track epidemic outbreaks 
of both community and hospital isolates. 
 
A study by Haag et al. (1998) reported the identification and speciation of pathogenic 
Haemophilus isolates. H. ducreyi was shown to be distinct from other genera and species and 
strain differences were also found. Strain specific biomarkers were detected for H. pylori 
(Nilsson 1999) based on MALDI.  Reference and environmental isolates of E. coli, Salmonella 
and Acinetobacter, isolated from sewage sludge were successfully identified using MALDI by 
Ruelle et al. (2004).  
 
The above examples serve to demonstrate the growing interest of MALDI-TOF-MS in the 
identification of pathogenic bacteria. This is mainly due to its speed of analysis, minimal 
sample preparation and biomass required. MALDI provides characteristic mass spectral 
fingerprints of bacterial species and provides unique insights into bacterial biology and 
chemistry based on the detection of specific chemicals or chemical changes in response to 
environmental or other external influences (Lay 2001).  
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1.5 SDS-PAGE 
 
Taxonomic relationships between organisms can be estimated using variety of characteristics. 
The majority of bacterial classifications have, in the past, been based on phenotypic or 
observable characters. But it suffered major drawbacks and limitations such as, reproducibility 
and was time consuming.  In the last two decades, the use of molecular methods for bacterial 
identification has been employed with considerable success. The composition and order of 
amino acids which makes up proteins, is determined by the sequence of nucleotides encoded 
on the DNA of an organism. Thus, the protein pattern reflects the genome of a particular 
strain. Electrophoresis of a bacterial protein sample under standardised and reproducible 
conditions therefore produce a protein banding pattern that is characteristic “fingerprint” of a 
particular strain (Costas 1995). 
 
Polyacrylamide Gel Electrophoresis (PAGE) of proteins has been used increasingly during the 
past few decades in bacterial classification and identification (Cato et al., 1982). Sodium 
Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) is a technique which can 
be used for separation of whole-cell proteins according to their molecular weight and appears 
to detect broader taxonomic relationships especially at the species and subspecies level. 
(Vandamme et al., 1998). Sodium dodecyl sulphate (SDS) is an anionic detergent which 
denatures proteins by "wrapping around" the polypeptide backbone and SDS binds to proteins 
fairly specifically in a mass ratio of 1.4:1. In so doing, SDS confers a negative charge to the 
polypeptide chain and disrupts all noncovalent protein bonds causing the macromolecules to 
unfold (Garfin 1990). By treatment with disulphide-reducing agents such as, 2- 
mercaptoethanol or dithiothreitol further denatures the proteins. There are two types of buffer 
systems in electrophoresis, continuous and discontinuous (Laemmli 1970). A continuous 
system has only a single separating gel and uses the same buffer in the tanks and the gel. In a 
discontinuous system, a non-restrictive large pore gel, called a stacking gel, is layered on top 
of a separating gel called a resolving gel. Each gel is made with a different buffer, and the tank 
buffers are different from the gel buffers. The resolution obtained in a discontinuous system is 
much greater than that obtained with a continuous system. SDS-PAGE offers the combination 
of high resolution and good reproducibility and has clear advantages over the earlier used non-
denaturing systems (Costas 1995).  
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SDS-PAGE has been successfully applied for the identification of several bacterial groups. 
Differentiation and identification of thermophilic campylobacter’s (Vandamme et al., 1997), 
Campylobacter lari (Duim et al., 2003) and identification of bacterial isolates in activated 
sludge were shown by Hantula et al. (1991). A recent study by Santos and co workers 
demonstrated the reliability of the technique by identifying species and subspecies of 
Staphylococci by SDS-PAGE (Santos et al., 2009). Costas examined the protein patterns of 50 
isolates of Staphylococcus, 41 of which were MRSA and showed that the technique could be 
used to study the epidemiology and the evolution MRSA isolates (Costas et al., 1989). A study 
by Calderon used the technique to asses the similarities between the Burkholderia cepacia 
complex isolates and to identify common protein bands that could be associated with 
resistance to certain antimicrobial agents (Calderon et al., 2008). Some other studies included 
the identification of bacterial groups such as Bacteroides ureolyticus (Taylor et al., 1987) and 
Providencia rettgeri (Costas et al., 1989). 
 
 
1.5.1 NuPAGE® electrophoresis system 
 
The NuPAGE® Bis-Tris [Bis (2-hydroxyethyl) imino-tris (hydroxymethyl) methane-HCL] 
electrophoresis system is a neutral pH and discontinuous SDS-PAGE medium. It uses pre-cast 
polyacrylamide mini-gels with ready-made buffers, which provide a better band resolution 
(NuPAGE® Technical guide) and is compatible with subsequent MS analysis. Although the 
Laemmli system (Laemmli 1970) is the most widely used SDS-PAGE system, the highly 
alkaline operating pH causes, band distortion, loss of resolution, or artefact bands. The 
NuPAGE® Gels have overcome this problem and results in sharper band resolution (1-200 
kDa) and accurate results (Moos et al., 1998).  
 
In this study a new system, NuPAGE® (Invitrogen™) 1D precast gels were used to compare 
the whole cell protein profiles of the bacteria and to assess the reproducibility and resolution 
of the system against MALDI-TOF-MS. The rational for this is that a large number of isolates 
can be compared relatively easily. NuPAGE® gels are compatible with mass spectrometry 
analysis, therefore the proteins can be cut out from gels trypsin digested and identified using 
MS techniques.  
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1.6 Surface- Enhanced-Laser-Desorption/Ionisation (SELDI) 
 
The advents of ESI and MALDI have extended the application of mass spectrometry to the 
study of proteins from complex biological systems. However, complex biological material 
such as blood, sera, plasma, lymph, whole cells, cell lysates, urine and cellular secretion 
products typically contain thousands of biological molecules as well as organic and inorganic 
salts which can interfere with direct MS analysis. Thus, significant sample preparation and 
purification steps are necessary prior to MS investigation. Classical methods of sample 
purification such as liquid chromatography, electrophoresis, centrifugation and membrane 
dialysis are often labour intensive and need higher sample volumes. Furthermore, samples 
may be lost due to precipitation, dilution effects or non-specific binding. 
 
Towards the end of 1993, Hutchens and Yip introduced the concept of Surface Enhanced 
Laser Desorption/Ionisation (SELDI) which is essentially MALDI-TOF-MS combined with 
the use of ProteinChip® arrays as a MALDI target plate (Hutchens and Yip 1993). This 
combined concepts from different technologies: Surface-Enhanced Affinity Capture (SEAC), 
Surface-Enhanced Neat Desorption (SEND) and Surface-Enhanced Photo Labile Attachment 
and Release (SEPAR) (Merchant and Weinberger 2000). 
 
SEND is a process by which analytes, even those of large molecular weight, may be desorbed 
and ionised without the need for addition of the matrix while SEPAR is a hybrid of SEAC and 
SEND, where the affinity capture device also functions as an energy absorbing molecule 
promoting analyte desorption and ionisation. To date, SEAC application show a more similar 
approach to the SELDI technology. In SEAC, the probe surface plays an active role in the 
extraction, presentation structural modification or amplification of the sample (Merchant and 
Weinberger 2000). 
 
Surface Enhanced Laser Desorption/Ionisation (SELDI) ProteinChip® technology has the 
ability to provide a rapid protein expression profile from a variety of biological samples, 
which will allow for the rapid characterisation of the microbes in order to assess the 
heterogeneity in their expression patterns (Schmid et al., 2005). However, unlike the MALDI 
target surfaces, the SELDI protein chip surfaces are uniquely designed to retain proteins of 
interest from complex mixtures according to their specific properties. A few µl of a sample of 
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interest is placed on the chromatographic surface, incubated and washed with appropriate 
buffer. The proteins of interest are captured on the chromatographic surface and co-
crystallised with a matrix solution and analysed by a TOF-MS. The result is a mass spectrum 
which comprises the mass to charge (m/z) values and the intensities of bound proteins/peptides 
(Issaq et al., 2002 and Graham et al., 2007). 
 
The commercial version of SELDI is the, ProteinChip® array system (Ciphergen Bio systems/ 
Bio-rad, USA). The current platform consists of linear mode Time-of-Flight mass 
spectrometer and ProteinChip® arrays with a variety of affinity surfaces and analysis software 
packages. The protein arrays can be categorised by the nature of their affinity surfaces (Figure 
1.7). Currently, there are two types of surfaces available which are chromatographic and 
biological surfaces (Fung et al., 2001). The chromatographic surfaces include hydrophobic, 
hydrophilic, weak cation exchange, strong anion exchange and an immobilised metal affinity 
surface. These surfaces were developed to selectively capture proteins via charge, 
hydrophobic or metal chelate interactions. The biological surfaces are designed to covalently 
bind to biomolecules and enable specific protein-protein or DNA-protein interactions such as 
antibody-antigen, receptor-ligand or nucleic acid-binding protein interactions. The system is 
most effective at profiling low molecular weight proteins that are < 20 kDa. However, SELDI-
TOF-MS is more sensitive and requires smaller amounts of sample compared to 2-D-PAGE 
(Issaq et al., 2002). 
 
The ProteinChip® platform has been shown as potential screening tool for lung cancer (Yang 
et al., 2005). It has also proven to be useful in the discovery of potential diagnostic markers 
for prostate, bladder (Vlahou et al., 2001), breast (Wulfkuhle et al., 2001), ovarian cancers, 
renal carcinoma (Xu et al., 2009) Alzheimer’s disease (Austen et al., 2000), Human tumors 
(Ball et al., 2002) and profiling of urinary proteins to assess renal function (Hampel et al., 
2001). ProteinChip® Arrays have also been used to characterise protein-protein interactions 
(Stoica et al., 2001) and to detect virulance factors of Yersinia pestis (Thulasiraman et al., 
2001).  
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Figure 1.7: Diagrammatic representation of different types of ProteinChips®. (Modified from 
Ciphergen Bio systems).  
 
 
1.6.1 Different ProteinChip® arrays generally used to study microorganisms 
 
 a) Weak Cation Exchange ProteinChip® array (WCX/CM10) 
 
This surface contains carboxylate groups that interact with positively charged amino acids 
such as lysine, arginine or histidine at a given pH, on the surface of the analyte. 
 
 b) Strong Anionic Exchange ProteinChip® array (SAX2/ Q10) 
 
The active surface of the array contains positively charged, quaternary ammonium groups that 
interact with negative charges on the surface of target proteins e.g. aspartic acid or glutamic 
acid. 
 
c) Hydrophobic ProteinChip® array (H50) 
 
The active surface of this array contains 16 methylene groups that bind proteins through 
reverse phase chemistry. The binding is performed to proteins rich in alanine, valine, leaking, 
isoleucine, phenylalanine, tryptophan and tyrosine. 
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1.7 Analysis of MS data 
 
Due to the high sensitivity, accuracy, detection limits, speed and diversity of applications, MS 
has become an important tool in proteomics (Aebersold and Mann 2003). To date, one of the 
main applications of MS is for biomarker discovery; hence the quality of mass spectra is a key 
factor before the detection of biomarkers. One of the major problems involved in MS data 
mining is the complex nature of the data produced i.e. noisy and fuzzy data (Lancashire et al., 
2009). In order to overcome these problems, robust computational algorithms have been 
developed to help the data analysis i.e. cluster analysis, decision trees, principle component 
analysis (PCA) and machine learning algorithms such as support vector machines (SVM), 
Artificial neural networks (ANN) (Ball et al., 2002; MS Book chapter 17; 2010; Wiley in 
press). These algorithms may be divided into two types i.e. supervised and unsupervised 
learning. Supervised learning is more powerful and based on prior knowledge whereas 
unsupervised learning needs no extra knowledge about the samples (Mendes 2002). 
 
The fist step in MS data analysis is to minimise the complexity of the datasets produced to 
improve the quality of the output. This could be obtained at the beginning of sample 
processing by reducing the contaminants. The next step involves the pre-processing of the 
samples by the removal of noisy, fuzzy data from the MS which could appear due chemical 
contaminants present in the samples and the electrical noise which could occur during the 
processing of the samples in the mass spectrometer. Once the MS are obtained, baseline 
correction and normalisation of the peaks is carried out in order to subtract the low frequencies 
from the spectra and to correct experimental variations from the spectra respectively. These 
steps involve the use of various statistical analytical methods (MS Book 2010: chapter 17: 
Wiley and Hilario et al., 2004).    
 
Once the peaks have been detected in the mass spectrometer and the mass spectra produced, 
the next step is to identify the peptides by matching the experimental spectra with the 
theoretical spectra using database search algorithms. To generate highly sensitive and specific 
classification models, selection of the features that are able to discriminate between correct 
and incorrect peptides with high accuracy are necessary. If this is not considered 
appropriately, the data can lead to false representation of samples, false detection of 
biomarkers or determination of biomarkers that actually represent noise in the sample.                            
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• Clustering 
 
Clustering techniques are an example of an unsupervised learning.  One very common method 
is known as Hierarchical clustering. It functions by arranging the profiles of samples into a 
tree-like structure so that the most similar profiles lie close together and profiles very different 
to one-another lie farther apart, allowing for the rapid visual assessment of patterns within the 
data. The methodology is based on the construction of a distance matrix which enables the two 
samples with the most similar profiles to be determined.  These are then placed together in the 
tree to form a cluster, and the distance between this newly defined cluster and the remaining 
sample is calculated.  A new cluster is then determined and this process is repeated until all of 
the samples have been placed into a dendogram. One common use of hierarchical clustering is 
to create phylogenetic trees or identify structures in populations i.e. Lancashire et al. (2005) 
and Seibold et al. (2007) used both hierarchical clustering and PCA to differentiate Neisseria 
meningitides and Francisella tularensis. 
 
• Decision trees 
 
Decision trees are essentially an extension of clustering approaches where rules are applied to 
the clustering dendrogram to try and separate individuals in the population into meaningful 
classes. Adam et al. (2001) attempted to identify biomarkers for prostate cancer discovery.  
They used proteins derived from ProteinChip® surfaces using laser desorption/ionization 
(SELDI) mass spectrometry and decision trees to discriminate prostate cancer proteins and 
benign prostate hyperplasia/healthy men.   
 
• PCA 
 
One of the common methods used for visualisation and dimensionality reduction in mass 
spectrometry datasets is Principal components analysis (PCA) (Harrington et al., 2005).  This 
technique appears widely as a software tool for mass spectrometry and provides a useful 
approach for the visualisation of structures within a population of mass spectrometry runs and 
can be used to identify the main component ions associated with that structure. PCA 
transforms the input space into a new space described by what are known as principal 
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components, which are expressed as linear combinations of the original variables, essentially 
drawing a line through the data that explains most variation. 
 
• Support Vector Machines 
 
Support Vector Machines (SVMs) are a relatively powerful supervised learning algorithm that 
has been widely implemented in mass spectrometry. It’s a binary classification algorithm that 
separates the positive and negative examples by constructing a straight line or hyper plane that 
is rotated in multi-dimensional space. 
 
• Artificial Neural Networks (ANNs)  
 
Artificial Neural Networks (ANNs) are a form of Artificial Intelligence (AI) capable of 
modelling for complex systems and fast emerging as one of the most popular tools for 
complex data analysis. It is a mathematical/computational model based on biological neural 
networks that organises and process information (Lancashire et al., 2005). ANNs gathers 
knowledge by detecting patterns and relationships in data and learn through experience, not 
from programming. The most important aspect of the ANN function is that it is built from a 
potentially large number of interconnected processing elements, also known as nodes, which 
work together in a network. Once trained, ANNs can be used to predict the class of an 
unknown sample of interest. ANNs were first proposed for use in the identification of 
biomarkers from SELDI- MS data by Ball et al. (2002). 
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1.8 Aims and objectives of this study 
 
The emergence of microbes with low genomic diversity but increasing pathogencity or 
antimicrobial resistance necessitates the development of high-resolution protein- based 
techniques capable of exploring minute variation between related isolates. Today, as a result 
of the rapid and relentless improvements in the analytical capabilities of the technologies, 
proteomics has changed the way in which many research investigations including 
physiological function, pathogenesis and diagnostics are approached. In general most 
proteomic studies commence with gel-based approaches and use MS-based techniques to 
identify unique biomarker molecules. This study focused on the two major nosocomial 
pathogens that have been reported to be very diverse species. Here the aim was to develop and 
assess the potential of various proteomic approaches for the characterisation of these bacteria 
at the species level and further investigate the intraspecies diversity of one pathogen.  
 
In summary these are: 
 
1). To develop novel protein expression-based methods for the characterisation of various 
isolates, including both type and clinical isolates of Staphylococcus aureus and Clostridium 
difficile using Matrix Assisted Laser Desorption/Ionisation Time of Flight Mass Spectrometry 
(MALDI-TOF-MS). 
 
2). To characterise MRSA, MSSA and C. difficile by their unique intracellular protein 
biomarkers using Surface Enhanced Laser Desorption/Ionisation (SELDI) ProteinChip® 
technology and SDS-PAGE. 
 
3). To detect novel loci to differentiate different ribotypes i.e. 027, 001 and other ribotypes of 
C. difficile by using Variable Number Tandem Repeats (VNTR).  
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Chapter 2 
 
Materials and Methods 
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2. Materials and Methods 
 
2.1 S. aureus Sample Collection - London Hospital isolates for MALDI-TOF-MS study 
 
Samples were collected from the Microbiology Department of the London Hospital following 
5 visits made during September and October 2005.  Isolates were provided by the Laboratory 
Manager at each visit, that were representative of the work going through the department at 
the time. 
 
Each isolate was identified by standard methods used at the London Hospital. The London 
Hospital reference, culture conditions, Gram stain, and the morphology were recorded for each 
isolate together with the identification. The cultures were assigned an HPA number and sub 
cultured to Blood agar slopes for transport to HPA where they were incubated for 24 h at 37 
°C. Isolates were plated for purity onto Columbia Blood agar, incubated for 24 h at 37 °C and 
stored by the Micro bank preservation system (Pro-Lab Diagnostics, UK) at -80 °C. A total of 
107 (n = 107) S. aureus isolates were collected. Reference isolates/ Type isolates were 
obtained from the department of National Collection of Type Cultures (NCTC), HPA, London 
(Table 2.1). 
 
 
2.1.1 Staphylococcal Reference Laboratory isolates for MALDI-TOF-MS study 
 
Thirty nine isolates were provided by the HPA’s Staphylococcal Reference Unit and included 
cultures that were sent to the laboratory from geographically diverse centres throughout 
England and Wales for identification and characterisation. All except two were MRSA 
isolates, isolated during 2007 and included sub-types of current epidemic MRSA isolates 
(EMRSA-15, -16 and -17) in addition to representatives of three pandemic Community-
Associated MRSA lineages (so-called USA300, South West pacific and European clones). 
The isolates were subcultured on to Columbia blood agar plates for analysis on MALDI-TOF-
MS (Table 2.1). 
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HPA No. Hospital ID. HPA No. Hospital ID. HPA Sample ID Source 
HPA 26 MRSA HPA 294 S. aureus H072660527 Clinical isolate 
HPA 30 MRSA HPA 299 S. aureus H072580475 Clinical isolate 
HPA 39 MRSA HPA 318 S. aureus H071920422 Clinical isolate 
HPA 40 MRSA HPA 319 S. aureus H071200363 Clinical isolate 
HPA 41 MRSA HPA 322 S. aureus H072940574 Clinical isolate 
HPA 75 MRSA HPA 323 S. aureus H073020460 Clinical isolate 
HPA 76 MRSA HPA 324 S. aureus H072660333 Clinical isolate 
HPA 77 MRSA HPA 334 S. aureus H072800374 Clinical isolate 
HPA 78 MRSA HPA 339 S. aureus H072340414 Clinical isolate 
HPA 79 MRSA HPA 344 S. aureus H072640555 Clinical isolate 
HPA 80 MRSA HPA 345 S. aureus H072500404 Clinical isolate 
HPA 81 MRSA HPA 346 MRSA H072240800 Clinical isolate 
HPA 82 MRSA HPA 347 MRSA H072900348 Clinical isolate 
HPA 83 MRSA HPA 348 S. aureus H072580470 Clinical isolate 
HPA 84 MRSA HPA 353 MRSA H064560442 Clinical isolate 
HPA 85 MRSA HPA 356 S. aureus H072860414 Clinical isolate 
HPA 86 MRSA HPA 358 S. aureus H041940150 Clinical isolate 
HPA 133 MRSA HPA 389 S. aureus H072680434 Clinical isolate 
HPA 134 MRSA HPA 401 MRSA H072640554 Clinical isolate 
HPA 139 MRSA HPA 404 S. aureus H072280533 Clinical isolate 
HPA 140 MRSA HPA 405 S. aureus H072820462 Clinical isolate 
HPA 144 MRSA HPA 408 MRSA H072860467 Clinical isolate 
HPA 160 MRSA HPA 409 S. aureus H072580469 Clinical isolate 
HPA 222 MRSA HPA 410 S. aureus H072820481 Clinical isolate 
HPA 229 MRSA HPA 412 MRSA H072740472 Clinical isolate 
HPA 230 MRSA HPA 441 S. aureus H072240582 Clinical isolate 
HPA 233 S. aureus HPA 442 S. aureus H072820446 Clinical isolate 
HPA 239 S. aureus HPA 443 S. aureus H072720523 Clinical isolate 
HPA 242 MRSA HPA 444 MRSA H072680446 Clinical isolate 
HPA 247 MRSA HPA 489 S. aureus H072660541 Clinical isolate 
HPA 248 S. aureus HPA 496 S. aureus H072860465 Clinical isolate 
HPA 249 S. aureus HPA 497 S. aureus H072720526 Clinical isolate 
HPA 250 S. aureus HPA 499 S. aureus H072820480 Clinical isolate 
HPA 256 S. aureus HPA 500 S. aureus RH070000211 Clinical isolate 
HPA 257 S. aureus HPA 501 S. aureus RH070000253 Clinical isolate 
HPA 258 MRSA HPA 523 MRSA H072920482 Clinical isolate 
HPA 259 S. aureus HPA 524 MRSA H072660333 Clinical isolate 
HPA 260 S. aureus HPA 545 MRSA H072820464 Clinical isolate 
HPA 261 MRSA HPA 546 S. aureus H071380629 Clinical isolate 
HPA 262 MRSA HPA 547 S. aureus   
HPA 273 S. aureus HPA 549 S. aureus   
HPA 279 S. aureus HPA 550 S. aureus   
HPA 280 S. aureus HPA 556 S. aureus   
HPA 281 S. aureus HPA 563 S. aureus   
HPA 284 S. aureus HPA 569 S. aureus   
HPA 285 S. aureus HPA 571 S. aureus   
HPA 287 S. aureus HPA 573 MRSA   
HPA 293 S. aureus     
 
Table 2.1: S. aureus isolates used for MALDI-TOF-MS study. All ‘HPA’ isolates (95) were collected from 
Royal London Hospital and the remaining 39 isolates were provided by the Staphylococcal Reference Laboratory 
at HPA, London. 
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2.1.2 MRSA and MSSA sample collection for ANN analysis 
 
Most of the isolates used in this part of the study were from a past PhD student (Ines 2008). 
Out of the 99 isolates, six isolates were from Saunders et al. (2004) study and 45 isolates were 
from the Glasgow collection at HPA, London. Another 48 isolates were obtained from the 
Staphylococcal Reference Laboratory HPA, London (Table 2.2a and b). 
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Strain Date of Isolation Methicillin susceptibility Epidemiology
Sanger 476 MSSA High virulance community acquired
NCTC 8325 1960 MSSA Laboratory strain
01.1974 W MSSA Glasgow collection
00.9302 B MSSA Glasgow collection
00.9839 V MSSA Glasgow collection
00.11053 Y MSSA Glasgow collection
01.1652 H MSSA Glasgow collection
01.2463 W MSSA Glasgow collection
H355 MSSA Clinical Isolate
H493 MSSA Clinical Isolate
H494 MSSA Clinical Isolate
H495 MSSA Clinical Isolate
H454 MSSA Clinical Isolate
H499 MSSA Clinical Isolate
H512 MSSA Clinical Isolate
H514 MSSA Clinical Isolate
H456 MSSA Clinical Isolate
H440 MSSA Clinical Isolate
H187 MSSA Clinical Isolate
H479 MSSA Clinical Isolate
H108 MSSA Clinical Isolate
H178 MSSA Clinical Isolate
H419 MSSA Clinical Isolate
H450 MSSA Clinical Isolate
H354 MSSA Clinical Isolate
H349 MSSA Clinical Isolate
H420 MSSA Clinical Isolate
H057 MSSA Clinical Isolate
H175 MSSA Clinical Isolate
H278 MSSA Clinical Isolate
H279 MSSA Clinical Isolate
H280 MSSA Clinical Isolate
H281 MSSA Clinical Isolate
H282 MSSA Clinical Isolate
H472 MSSA Clinical Isolate
H248 MSSA Clinical Isolate
H249 MSSA Clinical Isolate
H461 MSSA Clinical Isolate
H096 MSSA Clinical Isolate
H344 MSSA Clinical Isolate
H339 MSSA Clinical Isolate
H328 MSSA Clinical Isolate
H318 MSSA Clinical Isolate
H409 MSSA Clinical Isolate
H595 MSSA Clinical Isolate
H460 MSSA Clinical Isolate
H423 MSSA Clinical Isolate
H401 MSSA Clinical Isolate
H305 MSSA Clinical Isolate
H571 MSSA Clinical Isolate  
 
Table 2.2a: MSSA (50) isolates used for the SELDI-TOF-MS and ANNs analysis. All the isolates 
were from a previous study (Ines 2008), which was from Saunders et al., 2004 and Glasgow collection. 
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 Strain Date of Isolation Methicillin susceptibility Epidemiology
 Sanger 252 MRSA Hospital acquired
MU 50 1996 VISA* Hospital acquired
MW 2 1998 MRSA High virulance community acquired
COL MRSA
97.1636 A MRSA-E15 Glasgow collection
97.1866 D MRSA-E15 Glasgow collection
98.1859 B MRSA-E15 Glasgow collection
01.5323 F MRSA-E15 Glasgow collection
00.9521 M MRSA-E15 Glasgow collection
98.2028 X MRSA-E16 Glasgow collection
97.1128 Y MRSA-E16 Glasgow collection
97.1396 J MRSA-E16 Glasgow collection
97.2637 D MRSA-E16 Glasgow collection
00.9523 R MRSA-E16 Glasgow collection
01.5366 R MRSA-E16 Glasgow collection
97.2935 K MRSA Glasgow collection
00.7895 V MRSA Glasgow collection
00.5472 R MRSA Glasgow collection
98.1695 K MRSA Glasgow collection
01.4964 S MRSA Glasgow collection
00.6545 X MRSA Glasgow collection
99.3249 A MRSA Glasgow collection
03.3200 J MRSA Glasgow collection
99.3700 W MRSA Glasgow collection
01.6742 M MRSA Glasgow collection
01.7633 M-1 MRSA Glasgow collection
01.1119 S MRSA Glasgow collection
01.2426 C MRSA Glasgow collection
02.6225 E MRSA Glasgow collection
00.10399 P MRSA Glasgow collection
00.1924 K MRSA Glasgow collection
99.3248 W MRSA Glasgow collection
97.1948 S MRSA Glasgow collection
99.1133 M MRSA Glasgow collection
97.1000 K MRSA Glasgow collection
02.3022 X MRSA Glasgow collection
01.9694 M MRSA Glasgow collection
02.5856 E MRSA Glasgow collection
97.3130 D MRSA Glasgow collection
02.5099 D MRSA Glasgow collection
03.1475 D MRSA Glasgow collection
03.1036 Z MRSA Glasgow collection
03.7230 R MRSA Glasgow collection
H516 MRSA Clinical Isolate
H527 MRSA Clinical Isolate
H528 MRSA Clinical Isolate
H532 MRSA Clinical Isolate
H610 MRSA Clinical Isolate
H497 MRSA Clinical Isolate
* MRSA displaying intermediate resistance to vancomycin  
 
Table 2.2b: MRSA (49) isolates used for the SELDI-TOF-MS and ANNs analysis. All the isolates 
were from a previous study (Ines 2008), which was from Saunders et al., 2004 and Glasgow collection. 
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2.1.3 C. difficile sample collection for MALDI-TOF-MS, SELDI-TOF-MS and SDS-
PAGE analysis 
 
One hundred and fifty isolates of C. difficile, which span over a 30 year period (1970s- 2007) 
collected from infected patients, were provided by Dr. I. Poxton at the Microbial Pathogenicity 
Research Laboratory, MPRL, University of Edinburgh, on ampoules. Isolates were plated for 
purity on to Columbia Blood agar (CBA) or Fastidious Anaerobic agar (FAA) plates, 
incubated for 48 h at 37 °C in anaerobic conditions and stored by the Micro bank preservation 
system at -80 °C. Reference isolates and Type isolates, Clostridium beijerinckii (NCTC 
13035), Clostridium chauvoei (NCTC 8361), Clostridium bifermentans (NCTC 6800), 
Clostridium difficile (NCTC 11209), Clostridium difficile (NCTC 11207), Clostridium tertium 
(NCTC 2917), Clostridium septicum (NCTC 549), Clostridium butyricum (NCTC 6084), 
Clostridium paraperfringens (NCTC 10986), Clostridium perfringes (NCTC 13112), 
Clostridium histolyticum (NCTC 7124), Clostridium tetanomorphum (NCTC 543), 
Clostridium sporogenes (NCTC 275) and Clostridium putrificum (NCTC 4718) were obtained 
from the NCTC, HPA, London and stored by the Micro bank preservation system at -80 °C. 
The outbreak isolates, B1 (1970s) and T (1980s) were kindly supplied by Professor S. P. 
Borriello’s personal collection. Also the highly virulent strain isolated from the Stoke-
Mandeville outbreak in 2006, ribotype 027 (L) were used in the study as well. Another set of 
isolates were obtained from a hospital outbreak strain collection (Table 2.3).  
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ID Original No. Ribotype Isolated year 
NCTC 13287=R7404   17 -  
NCTC 13307=630   12 - 
NCTC 13366=R20291   27 - 
NCTC 13404  106 - 
MPRL 4847 XE123850H 106 - 
MPRL 4848 XE123008E 23 - 
MPRL 4849 XE118229R 14 - 
MPRL 4850 XE117617C 42 - 
MPRL 4851 XE118399 1 - 
MPRL 4852 XE117124E 1 - 
MPRL 4853 121311 2 - 
MPRL 4854 120953J 70 - 
MPRL 279  Not known 1980 
MPRL 296  70 1980 
MPRL 307  103 1981 
MPRL 369  12 1982 
MPRL 402  Not known 1982 
MPRL 560  2 1983 
MPRL 588  32 1983 
MPRL 591  171 1983 
MPRL 613  120 1983 
MPRL 616  106 1983 
MPRL 1037  Not known 1972 
MPRL 2783  2 1991 
MPRL 808  2 - 
B1  5 1970s 
L  27 2006 
T  1 1980s 
MPRL 050  179 1980 
MPRL 219  Not known 1980 
MPRL 309  12 1981 
MPRL 347  Not known 1981 
MPRL 368  Not known 1982 
MPRL 371  Not known 1982 
MPRL 380  5 1982 
MPRL 408  Not known 1982 
MPRL 558  171 1983 
MPRL 589  104 1983 
MPRL 604  Not known 1983 
MPRL 678  Not known 1984 
MPRL 4856  Not known - 
MPRL 4857  Not known - 
MPRL 4858  106 - 
MPRL 4859  42 - 
N 4(2)  Not known - 
MPRL 407  Not known -  
MPRL 4846 XE123899W Not known - 
MPRL 002  Not known 1979 
MPRL 223  104 1980 
MPRL 282  69 1980 
MPRL 370  Not known 1982 
MPRL 372  12 1982 
MPRL 379  12 1982 
MPRL 406  Not known 1982 
MPRL 665  Not known 1984 
MPRL 687  12 1984 
MPRL 712  Not known 1984 
MPRL 2282   171 1989 
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 ID Original No. Ribotype Isolated year 
27 MPRL 13366   -  
Not known MPRL 199   1980 
Not known MPRL 202   1980 
Table 2.3: C. difficile isolates used for MALDI, SELDI and SDS-PAGE. 
Not known MPRL 381   1982 
MPRL 215   Not known 1980 
MPRL 248 153   1980 
2 MPRL 250   1980 
173 MPRL 255   1980 
173 MPRL 291   1980 
2 MPRL 844   - 
Not known - MPRL 326 
Not known - MPRL 059   
23 - MPRL 339   
125 - MPRL 349   
1 - MPRL 554   
33 - MPRL 382   
2 - MPRL 556   
  23 - MPRL 396 
  Not known - MPRL 397 
  Not known - MPRL 398 
  Not known - MPRL 405 
  Not known - MPRL 418 
  12 - MPRL 421 
  140 - MPRL 845 
  12 - MPRL 422 
  189 - MPRL 548 
  1 - MPRL 549 
  Not known - MPRL 602 
  Not known - MPRL 555 
  13 - MPRL 615 
  2 - MPRL 557 
  12 - MPRL 559 
  23 - MPRL 585 
  1 - MPRL 586 
  Not known - MPRL 587 
  165 - MPRL 590 
  Not known - MPRL 592 
  Not known - MPRL 595 
  176 - MPRL 597 
  Not known - MPRL 1039 
  Not known - MPRL 842 
  Not known - MPRL 617 
  Not known - MPRL 629 
  Not known - MPRL 688 
  Not known - MPRL 689 
  Not known - MPRL 841 
  23 1981 MPRL 308 
  2 1981 MPRL 319 
  1 - MPRL Outbreak strain 
MPRL Outbreak strain   1 - 
MPRL Outbreak strain   1 - 
MPRL Outbreak strain   1 - 
MPRL Outbreak strain   1 - 
MPRL Outbreak strain   1 - 
MPRL Outbreak strain   1 - 
MPRL Outbreak strain   1 - 
MPRL Outbreak strain   1 - 
MPRL Outbreak strain   1 - 
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2.2 MALDI-TOF-MS analysis of S. aureus using Waters® (MMU) database 
 
2.2.1 Selection of a suitable growth medium and incubation time for S. aureus 
 
In order to find a suitable growth medium and incubation time required for yielding the 
maximum high density mass spectrum of S. aureus, a randomly selected isolate (HPA 30), 
was maintained on Columbia Blood agar (CBA), Nutrient agar (NA), Chocolate agar (CHOC) 
and Manitol Salt agar (MSA). The isolate was incubated for different time periods: 24 h, 48 h 
and 72 h in aerobic conditions at 37 °C. All isolates were subcultured on three successive 
culture plates prior to MALDI-TOF-MS analysis. 
 
2.2.2 S. aureus analysis; Target plate preparation 
 
All reagents were from Sigma UK, unless otherwise stated. 
 
Bacterial cultures were maintained on CBA (Media Department, HPA, London) for 24 h at 37 
°C. Chemically cleaned target plates (Waters Corporation, UK) were wiped with methanol 
(BDH, Poole, UK) and allowed to air-dry prior to use. A small amount of growth was 
removed from the culture plate using a 1 µl loop and transferred to the target plate. One µl 
matrix solution containing acetonitrile, water and methanol (BDH, Poole, UK) in a ratio of 
1:1:1 (v/v), 0.01M 18-crown-6 ether, 0.1 % formic acid (v/v), saturated with 5-chloro-2-
mercaptobenzothiazole (CMBT) at a concentration of 3.0 mg/ml was added to the plate for 
gram positive organisms. Each plate was calibrated using a peptide mix (Table 2.4), which 
was prepared by mixing it with alpha-cyano-4-hydroxy-cinnamic acid (α- cyano) at a 
concentration of 14.0 mg/ml. Matrix solution was sonicated in a sonic bath (Ultrawave, UK) 
for 10 min prior to use. Micrococcus lylae (NCTC 13377), EMRSA (NCTC 13134), MRSA 
(NCTC 11940), S. aureus (NCTC 7727), S. epidermidis (NCTC 11047) and S. epidermidis 
(NCTC 11407) were included as ‘blind’ controls. Twelve replicates were analysed for each 
sample.  
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Peptides Volume (µl) Final Con. MW of peptides 
Bradykinin 2 1 pmol/µl 1060.2 
Angiotensin I 2.6 1 pmol/µl 1296.5 
Glu-fibrinogen 3.14 1 pmol/µl 1570.6 
Renin 3.52 1 pmol/µl 1759.0 
ACTH 4.94 1 pmol/µl 2465.7 
Insulin (bovine) 22.93 2 pmol/µl 5733.5 
Ubiquitin (bovine) 171.2 10 pmol/µl 8564.9 
 
Table 2.4: List of peptides used to prepare the peptide mix used for calibration with final 
concentrations and molecular weights. 
 
 
 
2.2.3 Data acquisition and processing 
 
Data acquisition was done using a MALDI-TOF Mass Spectrometer (Waters®/ Micromass 
Ltd. UK) and data processing was performed using MicrobeLynxTM software as described 
previously (Keys et al., 2004). The instrument was fitted with a 337 nm nitrogen laser. Fifteen 
spectra per sample well and 10 spectra per lock mass well were collected for each strain in the 
mass range of 500-10,000 Da. Individual spectral profiles were lock mass corrected with the 
exact mass of the rennin peak, which is 1759 Da and then the 15 spectral profiles were 
combined in order to improve the mass accuracy and to produce a reproducible bacterial 
spectrum for each replicate. 
 
The spectra obtained for the clinical isolates of S. aureus were searched against the existing 
database (MicrobeLynxTM 2005) and the search was based upon an estimation of the 
probability of the mass spectral peaks in the test spectrum to be comparable with the database 
spectrum. A list of top eight matches was provided together with Root Mean Square (RMS) 
value. A high relative and absolute probability and low RMS value indicates a good match 
(Figure 2.1). 
 
 
 
 
 
 77
2.2.4 Identification of S. aureus by comparative 16S ribosomal RNA sequence analysis 
  
Isolates were grown on CBA (Media Department, HPA) for 24 h at 37 °C. DNA was extracted 
by resuspending the cells in 60 ml of Prepman Ultra (Applied Biosystems, UK) and heating 
the suspension for 10 min at 99 °C followed by incubation at 4 °C. The sample was 
centrifuged at 2500 × g for 10 min and 1 ml was used for PCR. The primers (MWG) used 
were ANT1F, 5’-AGA GTT TGA TCC TGG CTC AG-3’, and 1392R, 5’-ACG GGC GGT 
GTG TAC AAG-3’giving a product size of 1300 bp. PCR cycle conditions using PCR Ready 
Mix (Sigma, UK) were as follows: initial denaturation 95 °C for 2 min, followed by 35 cycles 
of 95 °C for 45 s, 56 °C for 45 s and 72 °C for 60 s. Final extension was carried out at 75 °C 
for 5 min. Products were cleaned using AMPure PCR Purification Magnetic Beads Kit 
(Beckman Coulter, UK), following the manufacturer’s instructions. The sequencing primers 
used was 357F, 5’-CTC CTA CGG GAG GCA GCA G-3’, and 3R, 5’-GTT GCG CTC GTT 
GCG GGA CT-3’. DNA sequencing was carried out using Beckman Capillary sequencer 
(CEQ 8000). The bacteria detected by 16S rDNA PCR were identified by sequence 
comparison to the GenBank database using BLAST (http://www.ncbi.nlm.nih.gov). 
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2.2.5 C. difficile analysis using the Waters® (MMU) database 
 
Bacterial cultures were maintained on both CBA and Fastidious Anaerobic Agar (FAA) 
(Media Department, HPA, London) for 24 h and 48 h at 37 °C in anaerobic conditions. In 
addition, bacterial cultures were grown on Fastidious Anaerobic broth (FAB) for 48 h at 37 °C 
and re-subcultured on to FAA plates and incubated for 24 h at 37 °C. Target plates were 
prepared as described above (2.2.2) and the matrix was added prior to analysis. Data 
acquisition and processing was done as described as above (2.2.3). 
 
 
 
 
 
Figure 2.1: MicrobeLynxTM search results window showing the top 8 matches for the unknown isolate 
against the database. The green spectrum shows the composite profile for all the 12 replicates of the 
unknown isolate applied to row B. Different colours of the wells on the target plate indicate the 
probability value: Green- > 80 % relative probability and Blue- up to 80 % relative probability. 
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2.3 MALDI-TOF-MS analysis of C. difficile using the SARAMIS™ database 
 
 
2.3.1 Optimisation and Sample preparation - C. difficile 
 
 
In order to find the optimal incubation time and a suitable growth medium which gives a high 
density mass ion spectral profile for C. difficile, bacterial cultures were maintained on CBA, 
Nutrient agar (NA) and Fastidious Anaerobic agar (FAA) plates (Media department, HPA, 
London) for 24 h and 48 h at 37 °C in anaerobic conditions (AnaeroGen, Oxoid). Forty two 
isolates (n = 42) on CBA for 24 h, 43 (n = 43) on CBA for 48 h, 10 (n = 10) isolates on FAA 
for 48 h and 9 (n = 9) isolates on NA for 48 h were subcultured on the first phase.  
 
For the second phase of the study, 22 C. difficile isolates (n = 22) on CBA for 24 h, 25 isolates 
(n = 25) on CBA for 72 h and 16 (n = 16) on CBA for 48 h were analysed including the 
reference strains of C. difficile NCTC 13404, NCTC 13366, NCTC 13307, NCTC 13287 and 
ATCC 630. 
 
Fresh cells from individual colonies were transferred to a cleaned stainless steel 48 well target 
plate (Shimadzu Corporation, UK) using a sterile blunt pipette tip in duplicates. Once on the 
plate, the cells were immediately mixed with 0.5 µl of matrix solution. The matrix solution 
contained 10 mg/ml of 2, 5-dihydroxybenzoic acid in acetonitrile: ethanol: water (1:1:1) with 
0.3 % trifluoro acetic acid (AnagnosTec, Golm, Germany). The plate was left to air dry at 
room temperature for a few mins. E. coli (DSM 1576, CCUG 10979, and ATCC 8739) were 
used as the positive control and the calibrant (Figure 2.2 and 2.3). 
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2.3.2 Data acquisition 
 
Mass spectrometric measurements were performed on an AXIMA CFR Plus (Shimadzu 
Corporation, UK) instrument. Mass spectra were acquired in a positive linear mode with a 
nitrogen laser of 337 nm. The data acquisition range were from m/z = 2,000 Da to 20,000 Da. 
All spectra were processed using the accompanying Shimadzu Biotech software and the peak 
lists were exported to the SARAMIS™ software (AnagnosTec, Golm, Germany). The 
software was used to match the pattern with comparison function to identify unknown isolates. 
 
 
2.3.3 Analysis of closely related different Clostridium spp. using SARAMIS™ database 
 
 
Reference and Type isolates closely related to C. difficile were obtained from NCTC, HPA, 
London. These were: Clostridium difficile (NCTC 11207), Clostridium difficile (NCTC 
11209), Clostridium beijerinckii (NCTC 13035), Clostridium chauvoei (NCTC 8361), 
Clostridium bifermentans (NCTC 6800), Clostridium tertium (NCTC 2917), Clostridium 
septicum (NCTC 549), Clostridium butyricum (NCTC 6084), Clostridium paraperfringens 
(NCTC 10986), Clostridium perfringes (NCTC 13112), Clostridium histolyticum (NCTC 
7124), Clostridium tetanomorphum (NCTC 543), Clostridium sporogenes (NCTC 275) and 
Clostridium putrificum (NCTC 4718). The isolates were subcultured on CBA for 24 h at 37 
°C.  
 
The target plates were prepared as described above (2.3.1) and MS profiles were analysed by 
SARAMIS™ software (2.3.2). Further, these isolates were confirmed by 16S ribosomal 
sequencing to ensure their authenticity (2.2.4). 
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                   Figure 2.2: Workflow for SARAMIS MALDI-TOF MS Analysis 
 
           
24 h Growth time on CBA 
48 h Growth time on CBA 
48 h Growth time on FAA 
48 h Growth time on NA 
 
 
  Figure 2.3: Sample preparation overview of the different growth times and conditions.
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2.3.4 Electron Microscopy of C. difficile cells; effect of drying time before MALDI 
analysis 
 
In order to assess the effect of the matrix on intact cells following addition of the matrix 
solution, cells taken at different time intervals were processed and observed under electron 
microscopy. 
 
The electron microscopy was carried out by Dr. Hazel Appleton at HPA, London. 
 
 
Sample preparation-Batch 1 
 
C. difficile NCTC 13366 was cultured for 16 h on CBA. Cells were collected with a sterile 
loop and re- suspended in 10 ml of distilled water and the optical density was measured 
(OD600 0.744). The cell suspension and the matrix solution (AnagnosTec, Germany) were 
mixed at 1:1, (680µl of the cell suspension and 680 µl of matrix solution) and from this 
solution 170 µl were mixed with 30 µl of 10 % formaldehyde, to obtain a final concentration 
of 1.5 % of formaldehyde (Table 2.5). A total of seven samples were prepared at 30S time 
intervals to cover the drying times used in the standard protocol. Formaldehyde was used as a 
fixing solution to prevent further reaction of matrix with the cells and prepare grids for 
Electron Microscopy (EM).  
 
     
Sample No: Time 
Intervals (S) 
Cell Vol: (µl) Formaldehyde 
Vol:(µl) 1.5 % 
Total Vol: (µl) 
1 0 170 30 200 
2 30 170 30 200 
3 60 170 30 200 
4 90 170 30 200 
5 120 170 30 200 
6 150 170 30 200 
7 180 170 30 200 
 
 
Table 2.5: The number of samples prepared with different time intervals and the volume of cell 
suspension and formaldehyde used for each sample. 
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Sample preparation-Batch 2 
 
CBA plate cultures of 16 h, 24 h and 72 h, C. difficile NCTC 13366 isolates were re-
suspended in 2 ml of distilled water and optical density measured (OD600 1.022, 1.078 and 
1.061 respectively). The cell suspension and the matrix solution were mixed at 1:1, (340µl of 
the cell suspension and 340 µl of matrix solution) and from this solution, 170 µl were mixed 
with 30 µl of 10 % formaldehyde, to reach a final concentration of 1.5 % of formaldehyde. A 
total of four samples per culture were prepared at different time intervals (Table 2.6). 
 
Sample No: Time 
Intervals (m) 
Cell Vol: (µl) Formaldehyde 
Vol:(µl) 1.5 % 
Total Vol: 
(µl) 
0 170 30 200 
5 170 30 200 
10 170 30 200 
 
 
16 h Culture 
 15 170 30 200 
0 170 30 200 
3 170 30 200 
6 170 30 200 
 
 
24 h Culture 
10 170 30 200 
0 170 30 200 
3 170 30 200 
6 170 30 200 
 
 
  72 h Culture 
10 170 30 200 
 
 
Table 2.6:  The number of samples prepared for different timed interval using cultures,  
different incubation times, volume of cell suspensions and formaldehyde used for each  
sample. 
 
Sample preparation-Batch 3 
 
 
CBA plate cultures of 16 h, 24 h and 48 h C. difficile LHI-644 strain was re-suspended in 1 ml 
of  PBS (Phosphate Buffered Saline) (Media department, HPA, London) and the optical 
density was measured (OD600  2.217, 2.006 and 2.400 respectively). The cell suspension was 
centrifuged at 21000 × g for 2 min and the supernatant removed. The pellet was re-suspended 
in 1 ml of the matrix solution. From this solution, 170 µl were mixed with 30 µl of 10 % 
formaldehyde, to reach a final concentration of 1.5 % of formaldehyde. Five samples per 
culture were prepared at different time intervals. A control was prepared for all the cultures by 
suspending the cells in PBS and without the matrix solution (Table 2.7). 
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Sample No: Time 
Intervals (m) 
Cell Vol: (µl) Formaldehyde 
Vol:(µl) 1.5 % 
Total Vol: (µl) 
0 170 30 200 
1 170 30 200 
2 170 30 200 
5 170 30 200 
 
 
16 h Culture 
 
10 170 30 200 
0 170 30 200 
1 170 30 200 
2 170 30 200 
5 170 30 200 
 
 
24 h Culture 
10 170 30 200 
0 170 30 200 
1 170 30 200 
2 170 30 200 
5 170 30 200 
 
 
  48 h 
Culture 
10 170 30 200 
 
 Table 2.7:  The number of samples prepared at different timed intervals using cultures at  
 different incubation times, volume of cell suspensions and formaldehyde used for each  
 sample. 
 
 
2.3.5 Scanning Electron Microscopy of C. difficile cells; images before and after MALDI 
analysis 
 
 
In order to view the effect of the matrix solution in cell preparations directly on the target plate 
prior and post mass spectral analysis, 3 target plates were carefully cut into sections, each 
containing four wells per section. Each section was mounted on to an SEM specimen stub 
using carbon based electrically conductive double-sided adhesive discs (Agar Scientific). The 
steel slides were then conductive coated with gold using an Atom Tech Ultra Fine Grain 
Coating Module (800 series) ion beam coater. The coated slides were examined with an 
Philips XL30 FEG SEM. 
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2.4 SELDI-TOF-MS 
 
In the last few years several protocols were developed for protein extractions and analysis of 
various bacterial pathogens for SELDI-TOF-MS (e.g. Encheva 2005 and Ines 2008). However 
it is evident that up to the present time universally standardized protocol is not available and 
prior to any new study, it is necessary to develop an optimum protein extraction procedure. 
Here several approaches were under taken to obtain a reproducible method for SELDI-TOF-
MS analysis of MRSA and MSSA strains of S. aureus and to study the microevolution of C. 
difficile. 
 
 
2.4.1 Different protein extraction methods 
 
1). French Press 
 
The growth from four S. aureus plates were suspended in 500 µl of lysis solution and forced 
through a French Press mini cell (Thermo Fisher, UK) for five times to determine the 
maximum number of passages required to obtain maximum protein release from cells. During 
processing, aliquots were taken and protein concentrations estimated using Bradford protein 
assay (Bradford, 1976). A graph was plotted of concentration against number of passages 
(Figure 2.4) and demonstrated that the amount of protein extracted reached maximum after 
three passages and were standardised thereafter.  
 
The same protocol was repeated by re-suspending the cells in distilled water and the protein 
yield was compared between lysis solution and distilled water. 
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Figure 2.4: The effect of the number of passages through the French Press on protein yield. The results 
demonstrated that after four passages the protein concentration reaches a maximum.   
 
 
 
2) Mickle beating combined with freeze/thawing and different concentrations of 
Lysostaphin 
 
Growth from four plates of S. aureus was harvested and re-suspended in 500 µl of standard 
lysis solution (8 M urea, 2 % CHAPS (Melfords, UK), 40 mM Tris base, 25 mM PMSF). The 
samples were tested in duplicate with addition of 15 µl and 30 µl of lysostaphin (Sigma, UK). 
The cells were mechanically disrupted using the Mickle Cell Disintegrator (Mickle Laboratory 
Eng.Co Ltd, UK), in the presence of 0.3 g of glass beads, grade 13 (< 105 µm) (Sigma, UK), 
frozen for 15 min and defrosted for 5 min. This step was repeated twice. The cell debris and 
the beads were separated from the resulting crude cell extract by centrifugation at 21000 × g 
for 30 min at 4 °C. The resulting supernatant was collected and the protein content measured 
using the Bradford protein assay (Bradford, 1976) using serial dilutions of Bovine Serum 
Albumin (BSA, Sigma UK) as a standard. The same protocol was repeated using distilled 
water and the protein yield was compared. 
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2.4.2 Protein extraction for MRSA and MSSA 
 
 
Protein extraction was carried out as described above by Mickle beating combined with 
freeze/thawing (2.4.1 (2)) using lysis solution and 30 µl of lysostaphin on each sample. 
 
 
2.4.3 Different ProteinChip® arrays used for MRSA and MSSA 
 
Three types of ProteinChip® surfaces were tested. 
  
• Weak cationic exchange (CM10) 
• Hydrophobic (H50) 
• Strong Anionic Exchange (SAX). 
 
 
2.4.4 Preparation of CM10 array for S. aureus 
 
The CM10 array was prewashed twice in 50 % methanol (BDH, Poole, UK), followed by 5 
min incubation with 250 µl of 50 mM sodium phosphate (pH = 7) (Sigma, UK) buffer. This 
step was repeated twice. The buffer was removed from the wells and a total of 150 mg/ml 
protein of each sample added to separate wells and incubated for 30 min with vigorous 
shaking. Samples were removed from the wells and 250 µl of 50 mM sodium phosphate buffer 
(pH = 7) added and left for 5 min and this step was repeated once more. Buffer was removed 
and each spot was briefly washed with 250 µl of de-ionised water. The array was air dried for 
a few minutes. One microlitre of the matrix solution containing 14 mg of sinapinic acid 
(Fluka, UK), 50 % acetonitrile (Sigma, UK) and 0.05 % TFA (BDH, Poole, UK) was added to 
each spot and analysed using a MALDI-TOF-MS (ProteinChip reader, PBS II, Ciphergen 
Biosystems). External calibration was performed using the All-in-1 Protein Standard 
(Ciphergen Biosystems). 
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2.4.5 Preparation of SAX/Q10 array for S. aureus 
 
The SAX/Q10 ProteinChip® array was pre-washed by adding 350 µl binding buffer (50 mM 
Tris Base pH = 7.8 (Sigma, UK), 2 % Triton X-100 [Sigma, UK]) to each spot and incubating 
with constant shaking for 15 min. The binding buffer was removed and samples were diluted 
to 300 mg/ml of protein concentration and 350 µl were added to the wells. The array was 
incubated for 1 h with constant shaking at room temperature. After incubation, the samples 
were removed and each spot was washed twice with 350 µl of binding buffer for 5 min. The 
whole array was washed once in HPLC grade water (Sigma, UK) and left to air dry. One µl of 
matrix (14 mg of sinapinic acid (Fluka, UK), 50 % acetonitrile (Sigma, UK) and 0.05 % TFA 
(BDH, Poole, UK)) was added to each spot and analysed using PBS II MALDI-TOF-MS. 
External calibration was performed using the All-in-1 Protein Standard (Ciphergen 
Biosystems).  
 
 
2.4.6 Preparation of H50 array for S. aureus 
 
The H50 ProteinChip® array was tested using two different buffers (10 % acetonitrile with 0.1 
% TFA (BDH, Poole, UK) and 50 % acetonitrile with 1 % TFA). From each buffer, 250 µl 
was added to each spot and incubated for 5 min at RT with vigorous shaking. The step was 
repeated. The binding buffer was removed and 120 µl of sample containing 300 mg/ml 
proteins were immediately added to each spot. Incubated with vigorous shaking for 30 min. 
Samples removed from the wells and washed by adding 250 µl of binding buffer for 5 min 
with agitation. This step was repeated twice. The buffer was removed and washed with 250 µl 
of HPLC grade water. This step was repeated once. The array was air dried for 30 min and one 
µl of matrix (14 mg of sinapinic acid (Fluka, UK), 50 % acetonitrile (Sigma, UK) and 0.05 % 
TFA (BDH, Poole, UK)) was added to each spot and analysed using the PBS II MS (2.4.5). 
External calibration was performed using the All-in-1 Protein Standard (Ciphergen 
Biosystems). 
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2.4.7 Effect of different pHs on CM10 array  
 
Effect of pH for SELDI analysis was tested for CM10 array using two different buffers: 50 
mM sodium phosphate (pH = 7 and 8) and 50 mM ammonium acetate (pH = 4 and 6). The 
ProteinChip® arrays were tested as described above.  
 
 
 
2.4.8 Data acquisition parameters 
 
The captured proteins on the surface of the arrays were analysed using a MALDI-TOF- Mass 
Spectrometer, PBS II (Ciphergen Biosystems. The instrument was equipped with a holder for 
the ProteinChip® array and used a nitrogen laser (wavelength 337 nm). The instrument was 
operated in positive ion mode and spectral profiles were collected in the mass range 3000 – 
30000 Da. Laser energy used was 200 eV, the plate detector voltage was set at 1900 V, pulse 
voltage at 3000 V and the source voltage at 20 000 V. Five shots per sample well were 
acquired and a total of 65 shots were collected from each well.  The resulting data were further 
analysed using Artificial Neural Network (ANNs).  
 
 
2.5 ANN model parameters 
 
This study utilised a three layer Multi Layer Perception (MLP) ANN model together with the 
back propagation algorithm. The raw data obtained from the SELDI-TOF-MS consisted of 
individual m:z values with their corresponding relative abundance values between 3,000 Da – 
30,000 Da. It is these relative abundance values for each m: z values that were used as inputs 
in the input layer. The network utilised a constrained approach to maximise the efficiency of 
the analysis whereby two hidden nodes were used in the hidden layer. Two hidden nodes were 
used in order to amplify the importance of key ions within the mass spectrometry data, while 
producing accurate predictions and maintaining model generalisation. This approach has been 
adopted with success on earlier mass spectrometry data (Ball et al., 2002). The output layer 
consisted of a single node encoded with Boolean representation where MRSA was represented 
by 1 and MSSA represented by 0. 
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Prior to analysis and model development, m/z values below 1,000 Da were removed as values 
below this mass value was deemed to be noisy and unimportant. Also due to the limitations in 
accurate mass resolution beyond 30,000 Da, everything above this mass value was also 
removed as reported previously by Ball (Ball et al., 2002). It is also important to select the 
right combination of learning rate and momentum factor values when creating an ANN model 
which will control the over training of the model. For this study, a learning rate of 0.1 with a 
momentum value of 0.5 was used as these values had previously produced encouraging results 
(Lancashire et al., 2005).  
 
Here, a stepwise approach was taken where the ranking of the important ions were considered. 
The data set containing 50 isolates of MSSA and 49 MRSA isolates were mixed and fed in to 
the model which was considered as the inputs. Each ion/data point was passed through 50 sub-
models and ions were ranked based on the ability to predict as MRSA or MSSA. After 
selecting the first representative ion from the first run, the process was repeated by adding 
other single ions to find the best pair of ions and repeated again until the best sub-set of ions 
was achieved which had the ability to predict the isolates as MRSA and MSSA. When 
developing the model, an error threshold value of 0.5 was assigned where the isolates 
predicted above the value of 0.5 were assigned as MRSA and the rest were as MSSA. 
 
The ANNs analysis was carried out by Dr. Graham Ball at NTU. 
 
 
2.6 Protein extraction for C. difficile 
 
Protein extraction was carried out using the same protocol used for S. aureus as described 
above in section (2.4.1 (2)) using lysis solution. But without lysostaphin. 
 
 
2.6.1 Effect of lysozyme on SELDI profiles 
 
C. difficile is a gram positive organism that is very resistant to cellular disruption. To aid the 
process of lysis, cell suspensions were incubated with lysozyme and protein extractions were 
carried out as described above in section 2.4.1 (2) with the addition of 50 mg/ml of lysozyme 
per sample. 
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2.6.2 Different ProteinChip® arrays tested 
 
The ProteinChips®, SAX/Q10, CM10 and H50 were tested using the prepared protein 
extracts. Based on the preliminary MS analysis, the SAX/Q10 ProteinChip® was chosen for 
further studies and prepared and analysed as described above (2.4.5). 
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2.7 SDS-PAGE 
 
2.7.1 Protein extraction methods tested for S. aureus 
 
a) Boiling method with sample extraction buffer containing SDS for SDS-PAGE 
 
The growth from four S. aureus plates was suspended in sample extraction buffer (0.5 M Tris-
HCl, 0.4 % SDS [Sigma UK]) and boiled for 10 min. Samples were left to cool, and 
centrifuged for 30 min. at 15000 × g. The supernatant was removed and protein concentrations 
estimated using the by Bradford protein assay.  
 
 
 
(b) Protein extraction using lysostaphin and SDS 
 
The growth from five plates of S. aureus was collected in 1 ml of deionised water and 
vortexed for 1 min. Samples were centrifuged for 10 min at 5000 × g and the supernatant 
removed. A buffer containing 970 µl of 10 mM sodium phosphate (Sigma, UK) and 30 µl of 
lysostaphin (2 µg/µl) (Sigma, UK) was prepared and 0.5 ml of this solution added to the 
remaining pellet and incubated at 37 °C for 30 min. Following the incubation 0.5 ml of buffer 
containing 4 % SDS, 20 % glycerol, 2 % 2- β mercaptoethanol, Tris-HCl pH 6.8 (Sigma, UK) 
was added and vortexed for 1 min. The samples were incubated in a heating block for 10 min 
at 100 °C followed by the addition of 0.5 ml of deionised water and incubation for a further 10 
min at 100 °C. Samples were left to cool and centrifuged for 30 min at 4 °C, at 15000 × g. 
Supernatants were collected and protein concentrations estimated using the Bradford assay. 
SDS-PAGE was carried out on precast NuPAGE® ready-to-run gels (Invitrogen, UK).  
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2.7.2 C. difficile 
 
The same protein samples prepared for SELDI analysis (2.4.2) were used for electrophoresis. 
 
 
2.7.3 Running the Samples on NuPAGE® ready-to-run gels 
 
The protein samples were denatured in the presence of NuPAGE® LDS sample buffer (106 
mM Tris HCl, 141 mM Tris base, 2 % LDS, 10 % glycerol, 0.51 mM EDTA, 0.22 mM 
SERVA® Blue G250, 0.175 mM Phenol Red pH = 8.5 [Invitrogen UK]) and reduced using 
500 mM dithiothreitol (DTT)(Invitrogen UK). The samples were heated in a water bath for 10 
min at 70 °C and run on 10 % and 12 % NuPAGE® ready-to-run gels for 40 min with a 
voltage set at 200 V. A total of 10 µg of the sample was loaded to each well. Rainbow marker 
and See blue markers were used as the protein standards. NuPAGE® MES SDS (50 mM MES, 
50 mM Tris base, 0.1 % SDS, 1 mM EDTA, pH = 7.3 [Invitrogen UK]) was used as running 
buffer. 
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2.8 Studies on the intraspecific diversity of C. difficile using Variable Number Tandem 
Repeat (VNTR) analysis 
 
Ninety two isolates including the recently sequenced strain NCTC 13366 (027) strain from 
Stoke-Mandeville outbreak were used in this part of the study. C. difficile isolates were kindly 
provided by Prof. I. Poxton, MPRL (Microbial Pathogencity Research Laboratory), University 
of Edinburgh. Another 43 strains were used from a collection from an outbreak in a hospital. 
This included a recent outbreak strain; ribotype 027 from the Stoke-Mandeville outbreak in 
2006 (Table 2.8). The ribotypes of most of the isolates were known prior to VNTR analysis, 
which was done according to the traditional ribotyping technique (Stubbs et al., 1999).  Out of 
the 92 isolates, 45 belonged to the ribotype 027, 25 were ribotype 001 and the remaining 22 
were assigned to different ribotypes. 
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Strain ID Source Ribotype 
NCTC 13366 NCTC Ribotype 027 
MPRL 597 MPRL Ribotype 027 
R12087 CD196-Paris Ribotype 027 
R16760 Birmingham Ribotype 027 
R12628 Preston Ribotype 027 
A027 Stoke-Mandeville outbreak Ribotype 027 
G1 Outbreak strain Ribotype 027 
G2 Outbreak strain Ribotype 027 
G3 Outbreak strain Ribotype 027 
G4 Outbreak strain Ribotype 027 
G5 Outbreak strain Ribotype 027 
G6 Outbreak strain Ribotype 027 
G8 Outbreak strain Ribotype 027 
G9 Outbreak strain Ribotype 027 
G10 Outbreak strain Ribotype 027 
G11 Outbreak strain Ribotype 027 
G12 Outbreak strain Ribotype 027 
G13 Outbreak strain Ribotype 027 
G16 Outbreak strain Ribotype 027 
G19 Outbreak strain Ribotype 027 
G20 Outbreak strain Ribotype 027 
G21 Outbreak strain Ribotype 027 
G31 Outbreak strain Ribotype 027 
G32 Outbreak strain Ribotype 027 
G34 Outbreak strain Ribotype 027 
G35 Outbreak strain Ribotype 027 
G37 Outbreak strain Ribotype 027 
G41 Outbreak strain Ribotype 027 
G43 Outbreak strain Ribotype 027 
G45 Outbreak strain Ribotype 027 
G46 Outbreak strain Ribotype 027 
G47 Outbreak strain Ribotype 027 
G49 Outbreak strain Ribotype 027 
G50 Outbreak strain Ribotype 027 
G52 Outbreak strain Ribotype 027 
G54 Outbreak strain Ribotype 027 
G57 Outbreak strain Ribotype 027 
G58 Outbreak strain Ribotype 027 
H 518-G59 Outbreak strain Ribotype 027 
H 521-G62 Outbreak strain Ribotype 027 
H 523-G64 Outbreak strain Ribotype 027 
H 524-G65 Outbreak strain Ribotype 027 
H 526-G67 Outbreak strain Ribotype 027 
H 530-G71 Outbreak strain Ribotype 027 
H 536-G77 Outbreak strain Ribotype 027 
MPRL 3224 MPRL Ribotype 001 
MPRL 3417 MPRL Ribotype 001 
MPRL 3465 MPRL Ribotype 001 
MPRL 3468 MPRL Ribotype 001 
MPRL 3542 MPRL Ribotype 001 
MPRL 3667 MPRL Ribotype 001 
MPRL 3668 MPRL Ribotype 001 
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MPRL 3706 MPRL Ribotype 001 
MPRL 3739 MPRL Ribotype 001 
MPRL 3767 MPRL Ribotype 001 
MPRL 3782 MPRL Ribotype 001 
MPRL 4143 MPRL Ribotype 001 
MPRL 684 MPRL Ribotype 001 
MPRL 4147 MPRL Ribotype 001 
MPRL 4178 MPRL Ribotype 001 
MPRL 4340 MPRL Ribotype 001 
MPRL 4342 MPRL Ribotype 001 
MPRL 4702 MPRL Ribotype 001 
MPRL 4773 MPRL Ribotype 001 
MPRL 4778 MPRL Ribotype 001 
G18 Outbreak strain Ribotype 001 
G28 Outbreak strain Ribotype 001 
MPRL 587 MPRL Ribotype 001 
MPRL 549 MPRL Ribotype 001 
MPRL 554 MPRL Ribotype 001 
MPRL 255 MPRL Ribotype 173 
MPRL 585 MPRL Ribotype 23 
MPRL 339 MPRL Ribotype 23 
MPRL 615 MPRL Ribotype 013 
MPRL 845 MPRL Ribotype 140 
MPRL 349 MPRL Ribotype 125 
MPRL 319 MPRL Ribotype 002 
MPRL 557 MPRL Ribotype 002 
MPRL 590 MPRL Ribotype 165 
G23 Outbreak strain Ribotype 081 
MPRL 842 MPRL Ribotype 005 
MPRL 421 MPRL Ribotype 012 
MPRL 688 MPRL Ribotype 012 
MPRL 617 MPRL Not known 
MPRL 602 MPRL Not known 
MPRL 397 MPRL Not known 
MPRL 398 MPRL Not known 
MPRL 841 MPRL Not known 
MPRL 202 MPRL Not known 
MPRL 595 MPRL Not known 
MPRL 381 MPRL Not known 
MPRL 592 MPRL Not known 
 
       Table 2.8: C. difficile isolates used for VNTR analysis obtained from MPRL, Edinburgh  
       and outbreak strains from a hospital. 
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2.8.1 DNA extraction of C. difficile isolates using MagNa Pure LC 
 
DNA extraction was carried out on the MagNa Pure LC Robot using the MagNa Pure LC 
DNA Isolation Kit III (Bacteria, Fungi) (Roche, UK) due to its fast and automated nucleic acid 
purification. The MagNa Pure LC Robot system with the use of MagNa Pure LC DNA 
Isolation Kit III (Bacteria, Fungi) helps to isolate high-quality pure DNA. The kit contains 
three wash buffers which help to remove PCR inhibitors, salts and proteins, a lysis/binding 
buffer for cell lysis and binding of DNA, proteinase K for protein digestion, magnetic glass 
particles for binding of DNA and an elution buffer for elution of pure DNA.  The bacterial 
cells were lysed prior to loading the MagNa Pure Robot (Roche, UK) by using a loopful of C. 
difficile cells grown on CBA for 24 h, suspended in 100 µl of PBS (Media Department, HPA, 
London). To this 130 µl of Bacterial Lysis Buffer and 20 µl of Proteinase K solution were 
added. The samples were mixed and incubated at 65 °C for 30 minutes followed by incubation 
at 95 °C for 10 mins to inactivate the cells. Lysates were transferred to the sample cartridge, 
loaded onto the MagNa Pure machine and DNA was eluted in 100 µl volume of elution buffer 
according to the manufactures instructions. 
 
 
2.8.2 VNTR of C. difficile: primer design and Tandem Repeat Finder 
 
The Tandem Repeat Finder was used to locate and display tandem repeats in the DNA 
sequence. Tandem Repeat Database (http://tandem.bu.edu/TRDB.html) is a public repository 
of information on tandem repeats in genomic DNA and contains a variety of tools for their 
analysis. In addition, TRDB serves as a centralised research workbench. It provides storage 
space for results of analysis and permits collaborators to privately share their data analysis 
(http://cagt.bu.edu/page/TRDB_about). In this study, the genome sequence of strain C. 
difficile NCTC 13307 (630) (GenBank with the accession number AM180355) was used to 
find the variable regions.  
 
For this study, a total number of 47 loci were tested for tandem repeats, including 10 loci 
(Table 2.10) which were already published. The remaining 37 loci were identified from C. 
difficile 630 genome. When selecting the loci, a few parameters were considered in order to 
reduce the complexity. These were copy number, the size of the repeats (pattern size) which 
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was selected to be 2-45 bp and only loci with percent consensus sequence match of ≥ 95 % 
were considered for this study (Table 2.9). Each of the selected loci were designated CD1- 
CD47 with the published loci depicted as CD1-CD10. 
 
 
 
Indices 
Pattern 
Size 
Copy 
Number 
   
%Matches 
  
  167124--167172 | [browser]  7   7.000000   100  
  400403--400585 | [browser]  99   1.800000   97  
  400436--400528 | [browser]  45   2.100000   95  
  400905--401171 | [browser]  45   5.900000   96  
  566910--566950 | [browser]  19   2.200000   97  
 
Table 2.9: Output from the Tandem Repeat finder: ‘Indices’ represents the position of the repeats on 
the genome of C. difficile 630. The ‘Pattern size’ is the number of bases present in each repeat while 
the ‘copy number’ is number of repeats. The percentage matches indicates the percent sequence 
similarity between repeats. 
 
 
2.8.3 Primer designing using Primer3 (http://frodo.wi.mit.edu/) 
 
 
Primer3 is a web-based computer program used for designing PCR primers required for 
amplification (Appendix IV). When designing and optimising primers, important factors 
including melting temperature (Tm), primer length, GC content, 3’ stability and likelihood of 
annealing to or amplifying undesirable sequences were considered. When selecting the 
primers for this study using Primer3, a product size of up to 700 base pairs was considered in 
order to yield a high quality PCR product from the ABI sequencer due to the resolution. 
Melting temperatures between 57 °C – 62 °C were chosen in order to use in multiplex PCR as 
higher melting temperatures avoids non specific annealing of primers (Figure 2.5).  
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OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER        287   24   61.90   33.33  4.00  2.00 
TTCATTTGGAGCTATGGAAATTGA 
RIGHT PRIMER       499   21   62.76   52.38  5.00  3.00 
CCTTCTCCTGGACTTGCCAAT 
SEQUENCE SIZE: 749 
INCLUDED REGION SIZE: 749 
 
 
 
 
 
 
    
Figure 2.5: Example of output from Primer3 for a specific locus. The left primer consists of 24 bases 
while right primer contains 21 bases. The total product size including the repeat region will be 749 
bases. 
 
 
2.8.4 Polymerase Chain Reaction (PCR) for VNTR 
 
 
To increase the throughput of PCR typing and reduce reagent costs, multiple sets of primers 
can be included in a single reaction tube. Hence, a multiplex PCR was optimised in order to 
amplify several loci simultaneously (see Appendix V). The forward primers were labelled at 
the 5’ end with a single fluorescent dye [e.g. 5’-carboxyfluorescein (FAM-blue), 4-N,N-
Dimethylaminoethylene amino-N-allyl-1,8-naphthalimide (PET-red), 2’–chloro-7’-phenyl-1,4-
dichloro-6-carboxyfluorescein (VIC-green) or 2’ –chloro-5’-fluoro-7’,8’-fused phenyl-1,4-
dichloro-6-carboxyfluorescein (NED-yellow)] for all the 47 loci (table 2.6). PCR reactions for 
all the primer pairs were performed in 12 µl reaction volumes containing 0.5 µl of the diluted 
DNA (1: 10), 0.03 µl of 1M Betaine (Sigma, UK), 0.5 µl of each of the forward and reverse 
primers at 5 µM, 4.72 µl of sterile RNAse free water and 6.25 µl of HotStar Taq DNA 
polymerase (Qiagen LTD, UK). The volume of the RNAse free water and the primer 
concentrations were changed depending on the number of loci amplified in the multiplex PCR 
(Table 2.10). When the samples were repeated, a single-plex PCR reaction was carried out for 
each sample.  
 
VNTR analysis was evaluated for its potential to reproducibly amplify, and to precisely size the 
amplified fragments. The same DNA preparation was used in duplicate VNTR reactions, and 
analysed on the same gel, and also on different gels. The sizing precision was also tested for 
single-plex reactions and mulitples reactions. Under all these experimental conditions, the 
characteristic amplified fragment was reproducibly detected, and all fragment sizes did not vary 
in any instance by more than ±0.5 bp.  
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 DNA_1:10 0.5 0.5 
Master mix-(µl) 12 12 
 Multiplex Single-plex 
  
Distilled water 2.82 4.72 
2 X HotStar master mix (1 
×) 6.25 6.25 
1M Betaine 0.03 0.03 
5 mM Labelled P1_F 0.5 0.5 
5 mM-P1_R 0.5 0.5 
5 mM Labelled P2_F 0.5 - 
5 mM-P2_R 0.5 - 
5 mM Labelled P3_F 0.5 - 
5 mM-P3_R 0.5 - 
Final reaction volume 12.5 - 
 
Table 2.10: Template for preparation of master mix for a single-plex PCR reaction and multiplex PCR 
reactions. The total reaction volume for each reaction was 12.5 µl. 
 
 
 
PCR amplifications were performed on a GeneAMP PCR system 9700 (Applied Biosystems, 
UK) using the following cycling conditions:  
 
                     Initial denaturation         94 °C for 15 min – one cycle 
                     Denaturation           94 °C for 30 sec 
                     Primer annealing            57 °C for 30 sec            35 cycles 
                     Extension                       72 °C for 30 sec 
                     Final extension               72 °C for 7 min – one cycle 
                     Hold                                4 °C  
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2.8.5 Capillary gel electrophoresis on automated DNA sequencer 
 
PCR products were separated by capillary electrophoresis on an ABI 3130xl genetic analyser 
(Applied Biosystems, UK) using GeneScan™ LIZ600® (Applied Biosystems, UK) as an 
internal standard for each lane (Figure 2.6). The use of an internal lane size standard enabled 
automated data analysis and assisted in achieving high run-to-run precision in sizing DNA 
fragments. The standard was designed for sizing DNA fragments in the 20-600 bp range and 
provided 36 single-stranded labelled fragments.  
 
For electrophoresis on the genetic analyser, the samples were prepared by adding one µl of the 
diluted product (1:20 dilution) to 0.4 µl of GeneScan™ LIZ600® size standard and 10 µl of 
Hi-Di formamide (Applied Biosystems, UK). These were denatured by heating at 95 °C for 5 
min followed by cooling to 4 °C. Electrophoresis run conditions were 1.5 kV at 60 °C for 45 
min using POP7 polymer as the medium, with a 50 cm capillary array. The GeneMapper 
software v4.0 (Applied Biosystems, UK) was used to analyse the resulting fragment data. 
 
                                   
  
                 
 Figure 2.6: Electropherogram of the GeneScan™ LIZ600® size standard (Applied Biosystems, UK). 
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2.8.6 GeneMapper®  software v4.0 analysis 
 
The GeneMapper® Software v4.0 (Applied Biosystems, UK) allows reproducible and highly 
automated sample analysis, which saves time by facilitating quick data review.  Hence, to 
determine the pattern and size of the fragments obtained from PCR amplification, the 
Genemapper® software v4.0 was used in this study.  
 
Sample files generated from ABI 3130xl, were transferred to the Genemapper® software as 
.fsa files for analysis. Analysis parameters that determine the peak detection, sizing and 
genotyping algorithms were used in the Genemapper® software to analyse the sample files. 
Sizing of the fragments was done using the GeneScan™ LIZ600® size standard and the 
‘basic’ peak detection algorithm was used. Analysed samples were displayed as 
electropherograms and visually inspected for the presence and size fragment. Up to eight 
electropherograms could be viewed at once and the software generates the fragment 
information for each detected peak in a sizing table with peak size, height, peak area and data 
point (Figure 2.7). This table can be imported into Microsoft Excel spreadsheet or other 
software for further analysis. 
 . 
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Figure 2.7: Analysis of multiplex samples using Genemapper® software. Analysed samples were 
displayed as electropherograms and fluorescently labelled amplified fragments could be seen in red, 
green and black, marked with arrows. Fragment information is displayed at the bottom in a table which 
could be imported into an Excel spreadsheet. 
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Locus Genome position Repeat sequence Repeat size 
CD1 755721-755950 AAGAGC 6 
CD 2 3688632-3688751 ATCTTCT 7 
CD 3 3239736-3239835 TATTGC 6 
CD 4 167124-167172 ATAGATT 7 
CD 5 1954913-1954939 TAT 3 
CD 6 664660-664705 TAAAAGAG 8 
CD 7 4116072-4116109 TCTTCTTCC 9 
CD 8 692929-693015 TATATTGG 8 
CD 9 771338-771422 TAAGTATAGAT 11 
CD 10 677132-677386 GTAAATAGGATGTAAAA 17 
CD 11 2168250-2168268 AAAAAATATA 9 
CD 12 804519-804537 CTTCAATAA 9 
CD 13 301056-301074 GCT 3 
CD 14 788448-788465 TAAATCAGA 9 
CD 15 800026-800043 ATAAAGATA 9 
CD 16 484804-484820 GAAAAG 6 
CD 17 3254341-3254357 TGCTTC 6 
CD 18 3014724-3014741 AAACCTTAT 9 
CD 19 2167938-2167955 GAACGAATT 9 
CD 20 2169070-2169086 AAAGTAT 7 
CD 21 2169418-2169435 GATGGCTTA 9 
CD 22 804623-804645 TTC 3 
CD 23 804652-804699 TTCTTCAGCCTTTTTAGC 18 
CD 24 478055-478070 AAAAATG 7 
CD 25 543601-543619 TTGCTCATA 9 
CD 26 3245854-3245874 TCTTGTATA 9 
CD 27 3246180-3246195 AGAATT 6 
CD 28 3246752-3246770 TAGATGCAT 9 
CD 29 789540-789558 ACTTAA 6 
CD 30 794475-794493 ATTAGTG 7 
CD 31 3253605-3253625 AATCTTTTA 9 
CD 32 252622-252644 AGCAGT 6 
CD 33 800719-800741 AT 2 
CD 34 799700-799717 TAATAT 6 
CD 35 797131-797146 TTCATGA 7 
CD 36 881618-881637 AAGAAGAAAA 10 
CD 37 881702-881718 GCTATGAA 8 
CD 38 883903-883918 AGAAAT 6 
CD 39 884179-884194 AAAAAG 6 
CD 40 884601-884612 TAG 3 
CD 41 886202-886220 AATAAGAGA 9 
CD 42 923152-923190 AGTATATTAGTAGTTCTGTA 20 
CD 43 623650-623691 TATATGGATAATATCAATTTA 21 
CD 44 771250-771319 TAAATATAATCTAA 14 
CD 45 3319803-3320164 TTTTATATTAACTATTTTTTT 
ATTACTTCTATATTATTGTATCA 
45 
CD 46 3753183-3753574 TTCTTTAGATTAATTTTCTATA 
CCTAAATTAGTTTATTATAC 
45 
CD 47 1099662-1099714 AATAAC 6 
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Table 2.11: All the 47 loci tested for VNTR analysis. CD-1-10 marked in red are 
already published (van den Berg et al., 2007 and Marsh et al., 2006) and the rest of the 
loci were identified using Tandem repeat finder and primers were designed using the 
web-based programme: Primer3. 
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3. Results 
 
3.1 MALDI-TOF-MS analysis of S. aureus 
  
Spectral profiles of strain HPA 30 grown on different culture media showed striking 
differences except between CBA and CHOC media. Cells cultured on CBA and CHOC 
possessed mass ions in the m/z range of 500-3250 Da (Figure 3.1). Several high intensity 
peaks were characteristic of the microorganisms grown in CBA in the lower mass range (563, 
618, 787, 796 and 825 Da) while a 3012 Da peak had the highest intensity on CHOC grown 
cells. 
 
Mass ions of cells grown on NA were suppressed especially in the lower mass range and were 
particularly prominent in the mass range ~ 2000- 3000 Da where only high intensity peaks 
were 2327, 3009 and 3047 Da. The mass spectral patterns obtained from cells grown on MSA 
contained the largest number of peaks and spanned the m/z range 500-3000 Da. 
 
 
 
 
 
 
 107
       
Figure 3.1: Mass spectral profiles of S. aureus (clinical isolate HPA 30), when grown on four different 
types of media viz. mannitol salt agar (MSA), nutrient agar (NA), chocolate agar (CHOC) and 
Columbia blood agar (CBA). The greatest peak density of mass ions in the m/z 500 to m/z 4000 range 
was detected when S. aureus was grown on MSA and included a number of mass ions with m/z above 
3000 Da. CBA and CHOC profiles also contained a broad range of ions in the m/z range of 500–3200 
Da. Expanded portions of both spectra (not shown) show consistent spectral features. The least number 
of m/z peaks were detected from cells grown on NA and concentrated within a narrow section of the 
spectrum (m/z: between 2239, 2638 and 3047). 
 
 
Although the MSA gave the largest number of peaks compared to the other growth media, on 
CBA the mass ion density was still significant. Since the database was developed using CBA 
medium due to the mass ion density, this was retained as the culture medium for this study. 
 
The MS profiles of strain HPA 30 when grown on CBA showed the largest density of peaks 
after 24h incubation. With the increasing incubation time, the overall quality of the mass 
spectral traces deteriorated (Figure 3.2). Therefore, for the rest of the study cultures were 
grown for 24h at 37 °C. 
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Figure 3.2: Mass spectral profiles of S. aureus (clinical isolate HPA 30), obtained after 24, 48 or 72 h 
of growth on CBA. The greatest number of mass ions was detected on cells grown for 24 h. Consistent 
mass spectral profiles were obtained after 48 h growth but there was a reduction in mass intensity for 
some of the characteristic mass ions such as m/z 3046 and 2649. Only a few detectable ions were 
observed after 72 h emphasising the need to analyse cells within the early to late exponential phase of 
growth (ca. 24–48 h) to obtain high quality MALDI-TOF-MS profiles. 
 
 
 
In the first phase of the study, 95 clinical isolates tested. All except three were correctly 
identified up to the genus and species levels by MALDI-MS using the 2005 database. The 
three aberrant isolates (HPA 80, HPA 547 and HPA 549) were identified as Streptococcus 
pyogenes, S. haemolyticus and S. epidermidis respectively (Figure 3.3). 
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Figure 3.3: Comparison of the profiles of four clinical isolates (573, 571, 569 and 443) which were 
correctly identified as S. aureus and isolates (549, 547 and 80) which was incorrectly identified as S. 
epidermidis, S. haemolyticus and S. pyogenus. All the profiles were visibly similar, shared common 
peaks except the three isolates, which were incorrectly identified by the software (blue arrows). 
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To validate the methodology and assess the inter-laboratory reproducibility, a parallel study 
was performed in collaboration with Manchester Metropolitan University (MMU). All isolates 
were re-analysed on a different instrument using the same protocol except the data were 
searched on MicrobeLynxTM 2006 database which contained a further 700 isolates. 
 
Four of the isolates did not correlate and were different to that reported using the 2005 
database. These isolates were contaminated upon arrival in Manchester (Table 3.1). However, 
when incorrectly identified isolates at MMU were re-analysed using the MALDI instrument at 
the HPA, they were correctly identified as S. aureus. All the isolates incorrectly identified 
using the MALDI-TOF-MS 2005 database were further characterised using sequence analysis 
of the 16S ribosomal gene. The latter confirmed their identity as S. aureus and indicated that 
the MALDI-TOF-MS 2005 database matches for these strains were incorrect (Appendix I). 
 
 
 
ID MALDI-ID 
(HPA) 
MMU-ID 
(1st sub culture) 
MMU-ID 
(2nd sub culture) 
HPA 248 S. aureus Proteus mirabilis Proteus mirabilis 
HPA 260 S. aureus S. warneri S. warneri 
HPA 299 S. aureus Mixed Results Mixed Results 
HPA 356 S. aureus Mixed Results S. aureus 
HPA 410 S. aureus Mixed Results S. aureus 
HPA 563 S. aureus Micrococcus luteus S. aureus 
HPA 569 S. aureus Mixed results Pseudomonas aeruginosa 
Table 3.1: Comparison of the search results of clinical isolates which matched incorrectly with the 
2006 database at Manchester Metropolitan University (MMU) after two subcultures. Results marked in 
red indicate the samples may have been contaminated during transfer while the blue colour indicates an 
incorrect match even after two sub cultures. 
 
 
In the second phase of the study, 35 isolates out of the 39 provided by the Staphylococcal 
Reference Unit were correctly identified to the species level at the first on the MALDI 
(Appendix II). The remaining four isolates were incorrectly identified as S. epidermidis but 
were correctly identified as S. aureus after the re-analysis by MALDI-MS (Table 3.2). 
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 No. 
Isolates 
Staphylococcal 
Reference Unit 
identification 
2006 MALDI 
Database 
identification 
2nd MALDI Run for 
incorrect samples 
      35        S. aureus         S. aureus                - 
        4       S. aureus        S. epidermidis         S. aureus 
 
 
Table 3.2: Key features of the clinical isolates obtained from the Staphylococcal Reference Unit, HPA, 
London and their corresponding identifications obtained by MALDI analysis. A total of 39 isolates 
were analysed using 2006 MS database. Thirty five isolates were correctly identified at the first run 
while four misidentified as S. epidermidis using the MicrobeLynx™ software. These four isolates were 
re-run and correctly assigned to the species S. aureus. 
 
 
 
 
Comparison of the spectral profiles of the clinical isolates against the type isolates, distinct 
peaks could be seen in the mass range ~ 800 - 3500 Da, which are characteristic of the genus 
Staphylococcus which is similar to what was reported by Edward-Jones et al. (2000), Du et al. 
(2002) and Bernardo et al. (2002). Few of the clinical isolates had additional peaks (~ 3200) 
which maybe specific to those isolates that have m/z values in the mass range of ~ 3000- 4000 
Da. The three isolates that showed lower probability scores and mixed matches against the 
database search, shared similar profiles to S. aureus but with less intense peaks in the same 
mass range and possessed additional mass ions (Figure 3.4). 
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Figure 3.4: Comparison of the MS profiles of clinical isolates against the database of Reference/Type 
strains. Characteristic peaks were present in all the isolates within the mass range of 500-3500 Da, 
which are specific to the genus Staphylococcus. Common peaks were observed in the m/z range of 500 
- 1000 Da and 2000 – 3000 Da for both the type strain of S. aureus and clinical isolates. Black arrows 
indicate the peaks which are specific to the genus Staphylococcus and the green arrow shows additional 
peaks in MS spectrum of a clinical isolate. 
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3.2 MALDI-TOF-MS analysis of C. difficile 
 
 
Isolates that date back to 1970s and more recent outbreak isolates were analysed by MALDI-
TOF-MS. Among these were three representative isolates designated B1 (1979), T (1985) and 
L (2006 = ribotype 027). A database search of the spectra was performed against the 
MicrobeLynxTM 2006 version of the database.  
 
Using this database spectral profiles obtained from different culture media and different 
incubation times were unable to delineate C. difficile. However, when the growth medium was 
changed from Colombia blood agar (standard media used to compile database) to Fastidious 
Anaerobe Agar (FAA), identification reached to genus level in a few cases (Table 3.3). 
Although the database predicted results were mixed against the three isolates, they showed 
similar profiles and similar mass ions/ peaks (~ 1400 and 2600 Da) when compared to the 
reference strain of C. difficile, suggesting a close relationship. However, because of the poor 
resolution of this species mix up using this protocol (CMBT) (Figure 3.5), in this following 
section a new approach was applied (SARAMIS™).  
 
 
     
B1 CBA 48 hr Actinomyces howellii
L CBA 48 hr Rhodococcus erythropolis
T CBA 48 hr Sarcina ventriculi
B1 FAA 48 hr Clostridium scatologenes
L FAA 48 hr Clostridium scatologenes
B1 CBA 24 hr Lactobacillus rhamnosus
L CBA 24 hr Sarcina ventriculi
T CBA 24 hr Rhodococcus erythropolis
B1 FAA 24 hr Clostridium scatologenes
L FAA 24 hr Clostridium scatologenes
B1 FAB/ FAA 48 hr/ 24 hr Clostridium scatologenes
L FAB/ FAA 48 hr/ 24 hr Clostridium scatologenes
Strain Name Growth Medium Incubation Time Predicted ID
 
 
Table 3.3: MALDI-TOF-MS predicted results for C. difficile using CBA, FAA and FAB as growth 
media and different incubation times. 
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Sarcina ventriculai 
  (L-CBA-24hr) 
        
Clostridium scatologenes 
        (L-FAA-24hr) 
        
Rhodococcus erithropolis 
       (L-CBA-48hr) 
        
Clostridium scatologenes 
        (L-FAA-48hr) 
        
Lactobacillus rhamnosus 
     (B1-CBA-24hr) 
        
Clostridium scatologenes 
        (B1-FAA-24hr) 
        
Actinomyces howellii  
    (B1-CBA-48hr) 
        
Clostridium scatologenes 
        (B1-FAA-48hr) 
         
Clostridium difficile (Reference) 
                 (FAA-48hr) 
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Figure 3.5: Mass spectral profiles of C. difficile strains L and B1 against an authentic reference 
strain. These strains were cultured on CBA and FAA media. The profiles show a large number of 
common mass ions (black arrows). But the MirobeLynx database matches do not correspond. 
 
3.3 C. difficile analysis using SARAMIS™ database 
 
In attempt to improve the level of differentiation of this taxon, a new protocol involving the 
use of DHB, TFA and ACN (see methods 2.3.1) was applied. 
 
 
3.3.1 Preliminary results using SARAMIS™ database 
 
In a preliminary study, cells were cultured in three different media; CBA as before and in 
addition on NA and FAA between 24 - 48 hrs. A striking improvement was obtained both in 
quality of the MS profiles and the reproducibility. Thus in spite of the variation in the 
composition of the medium, there was a high degree of compatibility between the spectra was 
observed (Figure 3.6).   
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Figure 3.6: Mass spectra of C. difficile (MPRL 1037) using the SARAMIS method.  Spectra from 
different culture media showed similar profiles even though the cultures were grown on different 
media (CBA, FAA and NA) and different incubation times (24 h and 48 h). 
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3.3.2 Electron Microscopic analysis of C. difficile; effect of drying time of the matrix on 
cells 
 
The previous Waters® system used two different matrices CMBT and CHCA for both gram 
positive and negative bacterial analysis respectively. However with the new SARAMIS 
protocol, improvement in data using the ‘new’ matrix solution, (2, 5-dihydroxybenzoic acid in 
acetonitrile: ethanol: water (1:1:1) with 0.3 % trifluoro acetic acid) was observed. Hence, the 
interaction of DHB with the cell was examined using transmission and scanning electron 
microscopy (EM). The following were images obtained from three sample preparations at 
different timed intervals (Figure 3.7 and 3.8). The samples prepared using PBS gave clear 
images compared to the samples prepared with water (Figure 3.7 c). 
 
In the controls of 16 h, 24 h and 48 h cultures prepared using PBS, before the addition of 
matrix, clear intact viable cells could be seen with its capsule around the cell wall and flagella 
(Figure 3.7 a, b and c). At 48 h culture samples revealed a mixture of intact viable cells and 
non viable cells (Figure 3.8 c). The results of the cells’ reaction to the matrix, with different 
drying times revealed that the drying time had no major effect on the cell as they remained 
intact even after five minutes of the addition of the matrix solution. The only effect observed 
was the disruption of the capsule around the cells (Figure 3.9). This maybe due to the higher 
polarity of the solvents used in the matrix solution i.e. ACN, ethanol and TFA. In Waters® 
system, the matrix solutions used were only able to ionise the surface molecules and detected 
peaks were mainly from the surface molecules of the intact cells (Keys et al., 2004). But this 
result indicates that the ‘new’ matrix, DHB is able to disrupt the surface layer i.e. capsule and 
the observed peaks in the MS are mainly from the intracellular proteins. 
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                                (c) 
 
Figure 3.7: The 16 h untreated samples of C. difficile (without matrix) for the three sample 
preparations (a, b and c). Cell suspension prepared using PBS (c) showed a clear image of the intact 
cells. 
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   I                  I 
       500 nm
16 h 
                                (a) 
                                  
   I                 I 
       500 nm 
24 h 
                                 (b) 
                                 
 
   I                  I 
         2 µm 
48 h 
                                 (c) 
Figure 3.8:  The C. difficile untreated samples of 16 h, 24 h and 48 h cultures prepared using PBS (a, 
b, and c) respectively . Clear intact cells could be seen for all three incubation times before adding the 
matrix. However the 48 h culture sample revealed a mixture of non viable and viable cells.   
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                                            (a)                                
                                              
  I                 I 
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       2 µm 
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Figure 3.9: Electron micrographs of different sample preparations of C. difficile after adding the 
matrix: (a) 16 h cells after 150s of matrix addition, (b) 24 h cells prepared by PBS at time 0 and (c) 48 
h cells prepared by PBS after five min. of matrix addition. Cells remain intact even after the addition of 
matrix although damage to the outer polymeric layers was evident. 
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3.3.3 Scanning Electron Microscopy of C. difficile on MALDI target plates: before and 
after MALDI analysis 
 
The scanning electron micrographs were taken on the MALDI target plates, before and after 
the MALDI analysis, in order to observe the cells’ reaction to the matrix solution as well as 
the MALDI analysis. Before the MALDI analysis and after the addition of the matrix solution, 
the intact cells were observed. However, instead of a uniform layer of cells across the target 
well, cells clumped, so that areas of well, showed no cells (Figure 3.10 a). Closer inspection of 
these densely placed areas (Figure 3.10 b) showed cells that were mostly in parallel. Following 
the MALDI analysis, the cells appeared less uniform and showed a metallic sheen indicative 
of disruption of the surface polymers (Figure 3.10 c). 
 
This highly polar solvent (CAN and TFA) would be expected to completely disrupt the cells, 
but it may have rapidly crystallised with evaporation and held the cells in a ‘frozen’ state. 
Consequently, mass spectra of cells were remarkably stable and revealed many intracellular 
proteins such as ribosomal proteins. 
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                                   (a) 
                                    
                                    (b) 
                                   
                                   (c)  
Figure 3.10: Scanning electron micrographs of cells on a MALDI target plate well: (a) A single well 
after MALDI analysis, (b) Target plate well with C. difficile culture on it before the analysis and (c) C. 
difficile cells on the target plate after MALDI analysis. 
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3.4 Mass spectral analysis of C. difficile isolates using SARAMIS™ database 
 
In the first phase of this part of the study, 54 isolates were cultured under anaerobic conditions 
on CBA for 24 h and analysed by MALDI-MS and database searches performed using 
SARAMIS™. Except for two isolates, the rest were correctly identified as C. difficile (Figure 
3.11 and 3.12). The two isolates incorrectly identified as S. warnerai and Propionibacterium 
acnes were due to the presence of mixed cultures (Figure 3.14). Compared to the isolates 
grown on FAA and NA at 24 h and 48 h, the isolates grown on CBA for 24 h produced better 
mass spectra.  
 
In the second phase of the study, a total of 63 isolates including the reference strains were 
analysed by MALDI-MS in duplicates. All the isolates were correctly identified as C. difficile 
and a cluster analysis was performed against the available C. difficile data in the database. All 
isolates showed high affinity and were conserved in a single cluster.  
 
The isolates correctly identified by the software were given as an automatic confidence level 
in percentage. For C. difficile, most of the isolates were identified with a confidence level of 
80 - 99 % when analysed in duplicates (Appendix III) where most of the significant peaks 
were seen at the mass range of 2000- 8000 Da (Figure 3.11 and 3.12). 
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Figure 3.11: Example of a correctly identified isolate (MISU 104) as C. difficile grown on CBA for 24 
h by the SARAMIS™ database. 
 
 
 
Figure 3.12: Mass spectra of different C. difficile isolates.  Significant speaks could be seen for all C. 
difficile isolates at ~ 4200 - 4300 Da and at ~ 5400 Da (red and blue arrows). 
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Further analysis of the spectra of C. difficile isolates revealed characteristic peaks among 
isolates at ~ 4200 Da, ~ 4300 Da,  ~ 5400 Da (Figure 3.12) and ~ 6300 Da, ~ 6640 Da and ~ 
6720 (Figure 3.13). Also the presence of similar peaks with a single mass shift could be 
observed, which may be due to the resolution of the instrument (Figure 3.13).  
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Figure 3.13: Mass spectral profiles of C. difficile isolates: Blue lines indicate the peaks which are 
common to all the isolates. The green and yellow lines indicate peaks that are displaced perhaps due to 
the resolution of the instrument.  
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     (a) 
      
    (b) 
Figure 3.14: MALDI-TOF-MS, SARAMIS™ mass spectral profiles of incorrectly identified isolates: 
MISU 135 (a) and MISU 104 (b) as S. warnerai and P. acnes respectively.  
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3.4.1 Differentiation of C. difficile from other closely related Clostridial species 
 
Fourteen Clostridial species that are closely related to C. difficile were analysed using the 
SARAMIS™ database. Before MALDI analysis, the identity of species was verified by 16S 
rRNA sequencing. All the fourteen species were correctly identified by the SARAMIS™ 
software with a confidence value of more than 65 % (Figure 3.15). Few common peaks could 
be observed among the different species. 
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Figure 3.15: Mass spectral profiles of different species, closely related to C. difficile. Few common 
peaks could be seen among the species (red arrows). 
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3.4.2 Cluster analysis of the C. difficile isolates and closely related Clostridium species 
 
All mass spectra obtained from the 24 h culture (duplicate spectra) were compared using the 
SARAMIS cluster analysis programme which is based on the percentage matching identical 
masses. All replicate spectra of individual isolates clustered closely. The incorrectly identified 
isolate MPRL 4857, clustered separately from the rest of the isolates. This was due to the 
contamination of the sample and poor spectra obtained from the MS analysis (Figure 3.16). 
 
Cluster analysis was performed against different Clostridium sp. and clinical isolates of C. 
difficile formed separate clusters distant from the C. difficile isolates (Figure 3.17). Also, the 
duplicate mass spectra of different Clostridial species identified by the SARAMIS™ clustered 
together and each species formed a separate cluster (Figure 3.18). 
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Figure 3.16: Cluster analysis of mass spectra in the mass range of 2,000 – 20,000 Da on cultures 
grown on CBA for 24 h. The clustering is based on mass signals detected in multiple samples. The   
last two spectra are from the isolate MPRL 4857 (red), identified as S. warneri. 
 
 
                               
 
 
Figure 3.17: Cluster analysis of mass spectra in the mass range of 2000- 20000 Da. Differentiation of 
clinical isolates of C. difficile from other Clostridium species. The latter showed < 30 % similarity of 
mass ions. The Type strain of C. difficile is shown in *.
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Figure 3.18: Cluster analysis of the MS profiles of different species of Clostridia analysed in 
duplicates. 
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3.5 SELDI-TOF-MS analysis 
 
3.5.1 Optimisation of a protein extraction for S. aureus 
 
In order to obtain sufficient protein for SELDI analysis, different protein extraction 
methods were attempted. Since S. aureus is a robust gram-positive organism, lysostaphin, 
an enzyme which helps to dissociate the cell wall components was used in the protocol. 
Protein extractions were carried out using a French press and Mickle beating combined 
with freeze thawing using a standard lysis solution and water resulted in high protein 
concentrations. When the samples were run on SELDI and NuPAGE® gels, both the 
methods showed similar results. 
 
Spectral profiles of the samples prepared by using French press using distilled water 
showed a higher number of peaks than the samples prepared using lysis solution. The 
samples prepared using Mickle beating in the presence of lysis solution also showed a 
greater number of peaks with a higher intensity when compared to the other spectra (Figure 
3.19). Comparison of the samples on NuPAGE® gels revealed that samples prepared using 
the French press had a higher number of protein bands. However, the sample prepared 
using Mickel beating in the presence of lysis solution also showed a similar result (Figure 
3.20).  
 
Comparison of the protein concentrations of the samples prepared using different 
concentrations of lysostaphin revealed the samples prepared using 30 µg of lysostaphin 
gave a higher protein yield. Hence for the rest of the study, protein extractions were carried 
out using the Mickle beating with lysostaphin in the presence of 30 µg of lysostaphin. 
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Figure 3.19: Comparison of the SELDI-TOF-MS profiles of MRSA 252 using the French Pressure 
cell and Mickle beating cell extracts with a protein concentration of 300 mg/ml. Extraction was 
performed both in distilled water and a standard lysis solution. The profiles obtained were very 
similar with the larger number of peaks present in the Mickle beating extract prepared in lysis 
solution.  
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Figure 3.20: Comparison between the protein extractions using the French Press and Mickle 
beating. Each done by using a standard lysis solution and water. RM= Rainbow Marker, FPW= 
French Press using Water, MIW= Mickle beating using Water, FPL= French Press with Lysis 
solution, MIL= Mickle beating using Lysis solution, SM= See blue Marker. Total protein 
concentration was 1 µg/µl and 10 µl was loaded on each well. 
 
 
 
3.5.2 Different ProteinChip® arrays tested for MRSA and MSSA 
 
From the three surfaces investigated, there were 20 peaks detected in the Hydrophobic 
(H50) surface profiles, 34 in the Strong Anionic Exchange (SAX) profile and 42 in the 
weak cation exchange (CM10). The CM10 array also showed high intensity spectra with 
lower background noise and a several high-molecular weight peaks (20-30 kDa). The H50 
profile contained mainly low intensity peaks while the SAX array displayed high level of 
background noise (Figure 3.21). Overall the CM10 chip produced more resolved peaks 
with less noise and was chosen for further analysis.  
 
Using the CM10 ProteinChip® array, preliminary work carried out on MRSA and MSSA 
isolates showed that they both shared similar and reproducible profiles (Figure 3.22).  
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       Figure 3.21: Comparison of H50, SAX and CM10 ProteinChips® for Staphylococus aureus          
(NCTC8325) on SELDI-TOF-MS with a protein concentration of 150 mg/ml on each spot. The 
CM10 array showed more resolved peaks with less noise compared to the other two surfaces. 
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Figure 3.22: Comparison of MRSA (COL) and MSSA (NCTC 8325) on SELDI-TOF-MS using 
CM10 with a protein concentration of 150 mg/ml on each spot, intensity of 200. The gel view 
representation of the profile clearly shows the common peaks present in both MRSA and MSSA. 
 
 
 
 
3.5.3 Effect of pH on CM10 ProteinChip® arrays for MRSA and MSSA 
 
 
Comparing the spectra from pH = 4, 6, 7 and 8, all four spectral profiles gave similar 
patterns. But the spectral profile of   the pH = 7, gave a slightly more stable profile 
compared to the other pHs with high intensity peaks (Figure 3.23). For the rest of the study 
pH = 7 was used when preparing the buffer. 
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                Figure 3.23:  Effect of pH on CM10 array tested using S. aureus NCTC 8325. Compared 
to pH = 4, 6 and 8, pH = 7 spectral profile showed a higher number of peaks and had a 
more stable profile. 
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3.6 Artificial Neural Networks (ANN) analysis of MRSA and MSSA 
 
SELDI-TOF-MS profiles were obtained from a total of 99 S. aureus isolates where 49 (n = 
49) of which were MRSA and the rest were (n = 50) MSSA. However, the complex nature 
of the SELDI data and the large number of spectra accumulated made the analysis difficult 
to perform using comparative gel view images and heat maps. It was evident that a single 
ion could not be used to distinguish between MRSA and MSSA and a combination of 
several of biomarkers was required. 
 
Ion mass intensity profiles generated from SELDI analysis were analysed in a stepwise 
approach in order to rank the ions based on the ability to predict MRSA and MSSA. From 
the first step, one key ion (3,081 Da) which was able to predict MRSA compared to the 
other ions, was chosen for the next stepwise analysis. This kind of model parameterisation 
steps ensued with the aim of identifying which ions are the most important within the 
dataset, allowing the model complexity to be reduced and the predictive capabilities to be 
increased. The chosen ion 3,081 Da was then run through 50 sub-models including the rest 
of the ions to determine the most significant sub-set of ions, capable of predicting MRSA 
and MSSA. 
 
After training the model with all the ions including the best chosen ion in order to 
determine the best subset of ions, seven ions were predicted as key ions within the m: z 
range of 3,000 Da – 19,000 Da and chosen for further analysis. This reduction is necessary 
in order to find any potential biomarkers. However, when calculating the mean error for all 
the seven ions, for each sub-set of ions the mean error drops, and at one point (18,896 Da) 
the error change becomes insignificant indicating that, beyond this point there were no 
significant predictive ions present. Hence, the seven most predictive ions (3,081 Da, 5,709 
Da, 5,893 Da, 7,694 Da, 9,580 Da, 15,308 Da and 18,896 Da) were chosen to recreate the 
model (Figure 3.24 and 3.25). 
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Figure 3.24: Stepwise approach of choosing the most significant sub-set of ions, which can be 
used to predict MRSA and MSSA. After the seventh ion 18,896 Da, mean error variation becomes 
insignificant and chosen as the best sub-set of ions for predicting MRSA and MSSA. 
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Figure 3.25: Seven key mass ions chosen for the prediction of MRSA and MSSA showing the 
capability of predicting with the increasing of the intensity. In ions 3081 Da (a), 5893 Da (c) and 
9580 Da (e), predictive performance decreases with the increasing intensity while 5709 Da (b), 
7694 Da (d), 15308 Da (f) and 18896 Da (g) ions performance increase with the intensity. 
 
 
 
 141
From the population distribution curve of MRSA and MSSA, most of the MRSA isolates 
were correctly classified as MRSA and only two MSSA isolates were incorrectly predicted 
by the key ions (Figure 3.27). When the isolates reached closer to the predictive value of 1, 
most of the MRSA isolates were predicted 100 % as MRSA indicating that the seven ions 
chosen for the prediction are characteristic to MRSA. The same pattern could be seen for 
the MSSA isolates and the misclassified isolates in the middle, which probably represent 
strains that are in the process of gaining antibiotic resistance. 
 
The Receiver operating curve (ROC) from this seven ion input model showed an overall 
area under the curve (AUC) value of 0.9147, indicating that the seven ions chosen for the 
prediction of MRSA and MSSA in combination have high sensitivity and specificity (91%) 
(Figure 3.26).  However, a new blind dataset could be used to validate the model further. 
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Figure 3.26: Receiver operating curves (ROC) and Area under the curve (AUC) values for the first 
50 ANN sub-models (a). Mean AUC of all 50 sub-models (b) indicates a high sensitivity and 
specificity (91%). 
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     Figure 3.27: Population distribution of MRSA and MSSA. The red colour bars indicate MRSA while the blue colour bars indicate MSSA strains. 
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3.7 SDS-PAGE analysis of MRSA and MSSA 
 
 
From the two extraction methods investigated, results from the boiling method gave a very 
poor protein concentration and was not suitable for further analysis. The protein extracts 
prepared using lysostaphin gave a higher protein concentration suitable for 1D gel 
electrophoresis and was chosen for further studies. 
 
A pilot study with a total of 8 MRSA and MSSA isolates including type/reference isolates 
were run using precast NuPAGE® gels to visualise any differences between strains (Figure 
3.28). Most of the proteins were conserved within the molecular weight range of 39 - 64 
kDa and 19 - 28 kDa. Although the proteins are conserved within that region, one of the 
MSSA isolates (5) showed a different profile to the MRSA strain. These gel-to-gel 
comparison of the isolates showed that there are differences between MRSA and MSSA 
and further MS/MS studies on these isolates could help to identify unique proteins. 
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Figure 3.28: Comparison of MRSA and MSSA using NuPAGE® Bis-Tris precast polyacrylamide 
Gels: 
 
RM=Rainbow marker, 1=MRSA 88, 2=MRSA 25E, 3=MRSA MW2, 4=MRSA COL, 5=MSSA 
53Y, 6=MSSA O2B, 7=MSSA NCTC 8325, 8=MSSA 476, SM=See blue Marker. Total protein 
concentration was 1µg/µl and 10 µl was loaded on each well.  Protein bands could be observed  in 
the molecular weight range of 39 - 64 kDa and 19 - 28 kDa. 
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3.8 SELDI-TOF-MS and SDS-PAGE analysis of C. difficile 
 
3.8.1 Selection of a protein extraction method for C. difficile 
 
With the protein extraction method described above, (2.2.1), C. difficile yielded a protein 
concentration of ~ 5.0-10.0 µg/µl. The protein concentrations did not improve with the 
addition of lysozyme and was omitted in future work. Since no further optimisation was 
required for the extraction method, using this protocol SELDI-TOF-MS analysis was 
carried out on three different ProteinChip® arrays. 
 
A total of 114 (n = 114) isolates were run on SELDI and 28 (n= 28) isolates were analysed 
using SDS-PAGE gels. 
 
3.8.2 Different ProteinChip® arrays used in the study for SELDI analysis 
 
The weak cationic exchange (CM10), Hydrophobic (H50) and Strong Anionic Exchange 
(SAX) were used to analyse the C. difficile extracts. Both weak cationic exchange and 
hydrophobic chips produced six peaks while the Strong Anionic Exchange ProteinChip® 
array detected about 21 peaks. Since the profiles obtained using the Strong Anionic 
Exchange ProteinChip® array (SAX/Q10) showed a larger number of peaks with higher 
intensity, the Q10 array was chosen for further studies (Figure 3.29).  
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Figure 3.29: Comparison of H50, CM10 and SAX/Q10 ProteinChips® mass spectral profiles 
of Clostridium difficile (MPRL 47). The protein concentration of 300 mg/ml was applied to 
each spot. SAX/Q10 array showed more resolved peaks with less noise compared to the other 
two surfaces. 
 
 
 
Characteristic peaks/mass ions were obtained for all cell extracts but different peaks were 
observed for some isolates indicating that changes have occurred among isolates over the 
years (Figure 3.30 and 3.31). 
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Figure 3.30: Comparison of three C. difficile isolates T, B1 and L against the reference C. difficile 
strain NCTC 13366. Common mass ions (Blue arrows) were present among the four isolates but 
there is clear evidence of intraspecies diversity. For example, additional strain specific mass ions 
were present in T and L strains (Red arrows). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 148
  
MPRL 49 
MPRL 52 
MPRL 48 
MPRL 54 
MPRL 53 
MPRL 51 
MPRL 87 
MPRL 50 
MPRL 47 
NCTC 027 
L (2006) 
B1 (1970s) 
T (1980s)  
NCTC 630 
In
te
ns
ity
 
 
 m/z value
 
 
Figure 3.31: A cross section of SELDI-TOF-MS profiles of 14 isolates of C. difficile using 
SAX/Q10 ProteinChip® arrays, including the test isolates T, B1 and L. Common mass ions (red 
arrows) could be seen among all the strains while strain specific peaks were also detected (blue 
arrows).  
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3.8.3 One dimensional gel analysis of C. difficile 
 
To visualise protein patterns between isolates, the 28 isolates were run on 1D gel 
(NuPAGE®) having previously adjusted all extracts to the same protein concentration. 
Although the profiles were similar, most of the proteins were conserved in the ~ 38 - 49 
kDa region while few showed bands in the molecular weight range of 6 kDa and 17 kDa 
(Figure 3.32). The reference isolates L, T and B1 were also similar to the rest of the 
isolates. 
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Figure 3.32: Comparison of the SDS-PAGE profiles of 18 C. difficile isolates. Top gel: 1-10: 
NCTC 13287, NCTC 630, NCTC 027, NCTC 106, MPRL 47, MPRL 48, MPRL 49, MPRL 50, 
MPRL 51 and MPRL 52 respectively. Second gel: 11-18: MPRL 616, MPRL 1037, T, L, B1, 
MPRL 613, MPRL 2783 and MPRL 808 respectively. SM= See blue Marker. Overall the band 
patterns were homogenous with the exception, several unique bands were present in the profiles of 
MPRL 613 (16) and B1 (15) observed in the low molecular weight area ~ 6 kDa - 17 kDa. 
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3.9 VNTR analysis of C. difficile 
 
3.9.1 VNTR copy number calculation 
 
A total number of 47 loci were tested for this study. Ten of these were published earlier 
(van den Berg et al., 2007 and Marsh et al., 2006). Tandem Repeats Finder software was 
used to identify the repeat elements using the sequenced genome of C. difficile 630 strain 
as reference. Primers for the 37 loci were designed using Primer3 programme by selecting 
suitable primers from the conserved regions flanking the repeats at the 5’ and 3’ end. 
 
To calculate the copy number of a particular locus, the total number of nucleotides in the 
flanking regions were deducted from the size of the amplified product and divided by the 
repeat size (the number of bases present in that particular repeat). The copy number was 
calculated manually as shown below (Figure 3.33). For each isolate, this number was 
imported into BioNumerics software for comparison and was used to detect the variability 
within the same ribotype as well as the variability among the different ribotypes. 
 
                         5’               
                                          Z                          Repeats                                      3’ 
 Y                       AT AT AT AT AT
             
                                                                                                                     
  RP 
  FP 
 
                                                                               
                                                                        X 
                          
                 Forward primer: FP 
                 Reverse primer: RP 
                 Product size:  X 
                 Flanking regions: Z and Y 
                 Copy number       =         (X) – (Z+Y) 
                                                           Repeat size 
 
Figure 3.33: Formula used to calculate the copy number of a particular locus. The amplified 
product size is indicated as X and the flanking regions are labelled as Z and Y while the forward 
and reverse primers were labelled as FP and RP respectively.   
 
 
 
 
 152
3.9.2 VNTR analysis 
 
A total of 92 C. difficile isolates were analysed for this study and 47 VNTR loci were 
selected as described in methods (section 2.8.2 and 2.8.3).  DNA was extracted for each 
isolate using the MagNa Pure LC Robot. Multiplex PCRs were carried out for each isolate. 
Null results (i.e. absence of amplified product) in isolates were confirmed by carrying out 
reactions with only one primer pair in the PCR. 
 
Of the 47 loci, seven loci (CD16, 17, 26, 29, 31, 44 and 47) failed to give an amplification 
product from any isolate in the set. Hence, these loci were excluded from analysis. Also 
primer CD9, which was previously published, was unable to amplify repeats from any 
isolate. The remaining 39 primer pairs, including the published primers, successfully 
amplified the repeats for most of the C. difficile isolates (Tables 3.4, 3.5 and 3.6). For few 
isolates, although the primers were able to amplify and generate an amplicon, the size was 
identical to the sum of the two flanking regions. This indicated the absence of repeats in 
that isolate i.e. copy number was ‘0’. In some isolates, no product was amplified. These 
results were referred to as ‘null set’ (Tables 3.4, 3.5 and 3.6). The copy number for each 
isolate was calculated manually as described above. 
 
 
3.9.3 Cluster analysis using BioNumerics 
 
In order to understand and differentiate the strains of different ribotypes using the VNTR 
data, the bioinformatics tool, BioNumerics version 5.1 (Applied Maths, Belgium) was 
used. The copy numbers obtained for each isolate for different loci were imported into the 
BioNumerics database. Isolates that gave ‘null’ results i.e. no amplification product were 
entered as ‘99’ into the database as BioNumerics does not accept alphabets to be entered 
into its database. Also the copy numbers were rounded to the nearest integer when entering 
into the database e.g. 3.3 = 3 and 3.6 = 4. Cluster analysis was performed using the 
Unweighted Pair Group Method with Arithmetic Mean (UPGMA) algorithm for all the 
isolates. Parameters such as similarity coefficient, Dice, was used for the cluster analysis 
which statistically compare the similarity or diversity of two sample sets. 
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The stability tests performed on VNTR loci concluded that isolates with summed tandem 
repeat differences of ≤ 2 are genetically related (Marsh et al., 2006) but differences of one 
repeat unit between isolates should not be interpreted as separate subtypes (van den Berg et 
al., 2007). Another study using epidemiological data analysis of C. difficile isolates 
concluded that a difference of up to two repeat units (i.e. > 71% similarity) indicates 
closely related strains (Fawley et al., 2008). This indicates that even though there are one 
or two copy number differences within a locus among the isolates, they could be referred 
to as closely related isolates. 
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VNTR Locus Location Size (bp)  Copy no. range 027 
CD 1 755721-755950 6 12-36 
CD 2 3688632-3688751 7 11-46 
CD 3 3239736-3239835 6 14-50 
CD 4 167124-167172 7 9-12 
CD 5 1954913-1954939 3 5 
CD 6 664660-664705 8 6-17 
CD 7 4116072-4116109 9 2 
CD 8 692929-693015 8 3-14 
CD10 677132-677386 17 0-18 
CD11† 2168250-2168268 9 1 
CD12† 804519-804537 9 2 
CD13† 301056-301074 3 5 
CD14 788448-788465 9 Null 
CD15† 800026-800043 9 2 
CD18† 3014724-3014741 9 2 
CD19† 2167938-2167955 9 2 
CD20 2169070-2169086 7 2* 
CD21† 2169418-2169435 9 2 
CD22†β 804623-804645 3 1 
CD23† 804652-804699 18 0 
CD24 478055-478070 7 2* 
CD25† β 543601-543619 9 2 
CD 27 3246180-3246195 6 2* 
CD 28† β 3246752-3246770 9 2 
CD 30† β 794475-794493 7 2 
CD 32† β 252622-252644 6 3 
CD 33† 800719-800741 2 10 
CD 34† β 799700-799717 6 6 
CD 35† β 797131-797146 7 1 
CD 36† β 881618-881637 10 2 
CD 37† β 881702-881718 8 1 
CD 38† β 883903-883918 6 2 
CD 39† β 884179-884194 6 2 
CD 40† β 884601-884612 3 4 
CD 41 β 886202-886220 9 2* 
CD 42 β 923152-923190 20 19* 
CD 43 623650-623691 21 20-21* 
CD 45 3319803-3320164 45 0-4* 
CD 46† 3753183-3753574 45 6 
 
Table 3.4: Summary of the VNTR copy numbers for ribotype 027 isolates for 39 loci exhibited by 
majority of isolates. Locus CD23 was observed with a copy number of ‘0’. For loci CD12, 14 and 
46 (shown in red) a few isolates also produced copy numbers of Null, 2 and Null respectively. 
 
* indicates majority of the isolates produce the same copy number and only a few isolates exhibit 
one or two different copy numbers. 
† indicates stable loci (22 loci) with identical copy numbers for most of the isolates. 
β indicates the loci (14 loci) excluded from the first cluster analysis. 
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3.9.4 Cluster analysis of ribotype 027 isolates 
 
Fourteen of the 39 loci exhibited identical copy numbers for all 45 ribotype 027 isolates.  
A further 22 loci showed identical copy numbers for most of the ribotype 027 isolates 
(Table 3.4). Another seven loci exhibited least diversity (viz CD20, 24, 27, 41, 42, 43 and 
CD45) where only few isolates showed variable copy numbers compared to the rest of the 
ribotype 027 isolates. For the locus CD23, the copy number of the repeats was calculated 
as zero while the other ribotype strains showed a copy number of one, indicating CD23 as 
a marker for ribotype 027 to differentiate from strains of other ribotypes. The copy number 
for the locus CD14 was detected with a ‘null’ result for most of the isolates while only 
three isolates gave a copy number of two (Table 3.4). Hence this locus would also be a 
possible marker to differentiate ribotype 027 isolates. For loci, CD12 and CD46 the 
majority of the isolates gave copy numbers of two and six respectively, while few isolates 
were detected with null result. In general, for most of the loci, the presence of null results 
could be observed throughout ribotype 027 isolates. The null results were verified by 
repeating the VNTR PCR using single primer pair. 
 
The most diverse VNTR loci with differential copy numbers for most of the isolates were 
CD1, 2, 3, 4, 6, 8, and, 10 (Table 3.4). These loci were identified earlier by Marsh and Van 
den Berg (van den Berg et al., 2007 and Marsh et al., 2006). According to Van den Berg’s 
study, 3 of the 10 loci produced identical copy numbers for all ribotype 027 isolates; these 
loci were CD4 (copy number-10), CD5 (copy number- 4) and CD7 (copy number- 2). 
However in this study, only one locus, CD7 exhibited the same copy number (2) for all the 
027 isolates. Also the locus CD5 exhibited an identical copy number (5) for all the isolates 
but different from the published copy number (4). The third locus, CD4, showed variable 
copy numbers in this study (9-12).  
 
When performing cluster analysis, 14 loci which exhibited identical copy numbers for all 
the ribotype 027 isolates or loci which showed variable copy numbers in only one or two 
isolates were excluded from analysis (Figure 3.34). Also an arbitrary value of 90 % was 
considered to detect the similarity between the isolates. Eight clusters were detected among 
the isolates showing ≥ 90 % similarity within the isolates (A-H) (Figure 3.34). Also copy 
number differences were observed for isolates within each group to compare the stability 
test results by Marsh and van den Berg. 
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Comparing the copy number variability of isolates within each group, group A, consisted 
of two isolates which varied in the copy number of locus CD23; isolate G67 had ‘0’ and 
G77 null copy number. Group B consisted of nine isolates, and seven of these isolates 
showed 100 % similarity to each other. The other 2 isolates i.e. G71 and G32 showed 
different copy numbers in loci CD27 (1) and CD23 (null) while the rest of the seven 
isolates showed copy numbers of two (2) and zero (0) for CD27 and CD23 respectively.  In 
group C, out of the two isolates, G19 and G20, copy numbers varied in CD30 (null) and 
CD43 (20). In group D, isolate G31 showed different copy numbers in loci CD13 (null), 
CD27 (1) and CD33 (10) while isolate G35 showed copy numbers of five, two and ‘null’ 
for respective loci.  Group E consisted of four isolates, and two of these exhibited 100 % 
similarity. The remaining two isolates, G09 and G41 showed different copy numbers in 
loci CD23 (1), CD14 (2) and CD46 (6) respectively. Four isolates were clustered together 
in group F and all these isolates showed 100 % similarity to each other. Group G consisted 
of two isolates including the sequenced strain 630, NCTC 13366, and G45. These two 
isolates showed different copy numbers in loci CD24 (1) and CD15 (null) respectively. 
Also both the isolates showed two different copy numbers in loci CD46 (null and 6 
respectively). In the last group H, three isolates were detected with variable copy numbers 
in three loci. These were CD14 (null), CD23 (null) and CD24 (1). 
 
Considering this variation in the copy numbers within the loci of each group, most of the 
variability observed was either with one or two copy number differences. Also in some 
cases, within a group, isolates either showed copy numbers of ‘null’ or ‘0’ and ‘null’ or ‘6’ 
for a particular loci, e.g. group G and B. This was because either there was no product 
amplified or the repeats were absent. Hence, all these isolates within each group could be 
considered as genetically related although there were one or two copy number variances.  
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Figure 3.34: Cluster analysis of 45 ribotype 027 isolates, excluding the 14 loci (see Table 3.4) with 
identical copy numbers for most of the isolates (Table 3.4). Eight groups (highlighted A-H) were 
detected within ≥ 90 % similarity.  
 
 
 
Further analysis was performed on the set of 39 VNTR loci which were identified in this 
study, excluding the previously published VNTR loci i.e. CD1-10 (van den Berg and 
Marsh) and the 14 common loci. This was to determine the discriminatory power of the 
‘new’ VNTR loci designed for this study.  
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Similar to previous cluster analysis, arbitrary value of ≥ 90 % was considered to look at the 
similarity of the isolates. As a result, seven groups (A-G) were identified among the 
isolates (Figure 3.35). Group A consisted of 12 isolates with 100 % similarity to each 
other. Group B with two isolates showing different copy numbers in loci CD20 (null) and 
CD43 (21) was detected. In group C, two isolates with different copy numbers in three 
different loci could be observed. Group D contained four isolates and three of these 
showed 100 % similarity to each other. The remaining isolate differed in copy numbers in 
loci CD24 (1) and CD46 (6) compared to the others. In group E, 4 isolates showed 100 % 
similarity to each other while one isolate differed in locus CD12 (null) to the others. Group 
F contained the recently sequenced reference strain 630, NCTC 13366, which showed 100 
% similarity to isolate G41. Another strain isolated from the Stoke Mandeville outbreak 
(A027), clustered separately and showed 69 % similarity to NCTC 13366. The last group, 
G, was detected with two isolates differing in loci CD46 (6 and null). Interestingly, isolate 
G49 clustered separately from the rest of the isolates in both cluster analysis showing a 
lower similarity percentage, 47 %, to the rest of the ribotype 027 isolates. This isolate was 
later identified as non-027 isolate from fluorescent ribotyping at HPA, London.  
 
Comparing the two separate cluster analysis performed for ribotype 027 isolates, the ‘new’ 
primers were able to differentiate most of the ribotype 027 isolates, indicating these loci 
could be used as markers to differentiate among the ribotype 027 isolates. In particular, 
loci CD14 and 23 could be used as markers to differentiate ribotype 027 isolates from rest 
of the ribotypes. 
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Figure 3.35: Cluster analysis of 45 ribotype 027 isolates, only with the primers designed for this 
study (i.e. excluding the published loci CD1-10 and 14 loci with identical copy number for all 
isolates).  Seven groups (highlighted A-G) were identified with isolates showing ≥ 90 % similarity. 
Isolate G49 clustered separately, exhibiting only 47 % similarity to other ribotype 027 isolates and 
was later identified as a non-027 isolate. 
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VNTR Locus Location Size (bp) Copy no. range 
CD 1 755721-755950 6 14-37 
CD 2 3688632-3688751 7 7-27 
CD 3 3239736-3239835 6 9-39 
CD 4 167124-167172 7 3-10 
CD 5 1954913-1954939 3 5-6 
CD 6 664660-664705 8 4-16 
CD 7β† 4116072-4116109 9 2 
CD 8 692929-693015 8 3-16 
CD10 677132-677386 17 1-18 
CD11 β† 2168250-2168268 9 Null 
CD12 β 804519-804537 9 Null* 
CD13 301056-301074 3 5* 
CD14 β 788448-788465 9 2* 
CD15 β 800026-800043 9 2* 
CD18 3014724-3014741 9 1* 
CD19 2167938-2167955 9 Null* 
CD20 β 2169070-2169086 7 Null* 
CD21 β 2169418-2169435 9 Null* 
CD22 β† 804623-804645 3 7 
CD23 β† 804652-804699 18 1 
CD24 β 478055-478070 7 2* 
CD25 543601-543619 9 Null* 
CD 27 3246180-3246195 6 2* 
CD 28 3246752-3246770 9 Null-2 
CD 30 β† 794475-794493 7 2 
CD 32 β† 252622-252644 6 3 
CD 33 β† 800719-800741 2 10 
CD 34 β† 799700-799717 6 6 
CD 35 β† 797131-797146 7 1 
CD 36 β† 881618-881637 10 2 
CD 37 β† 881702-881718 8 1 
CD 38 β† 883903-883918 6 2 
CD 39 β 884179-884194 6 2* 
CD 40 β 884601-884612 3 4* 
CD 41 β 886202-886220 9 2* 
CD 42 β 923152-923190 20 19* 
CD 43 623650-623691 21 10-21 
CD 45 3319803-3320164 45 4-6 
CD 46 β 3753183-3753574 45 6* 
   
Table 3.5:  Summary of the VNTR copy numbers for 25 ribotype 001 isolates for 39 loci.  
Loci highlighted in red were observed with ‘null’ results for most of the isolates. 
 
* Indicates majority of the isolates produce the same copy number and only a few isolates exhibit 
one or two different copy numbers  
† Indicates stable loci with identical copy numbers for majority of the isolates. 
β Loci (23 loci) excluded from the first cluster analysis. 
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3.9.5 Cluster analysis of ribotype 001 isolates 
 
Among the 25 ribotype 001 isolates, 12 loci with identical copy numbers were observed 
within the 39 loci (Table 3.5). One of these 12 loci exhibited ‘null’ results for all 25 
ribotype 001 isolates (CD11). Also for another six loci, null results were detected for 90 - 
100 % of the isolates (Table 3.5). Ten loci (CD11, 12, 14, 18, 19, 20, 21, 22, 23 and 25) 
exhibited differential copy numbers for ribotype 001 and ribotype 027 isolates (Table 3.4 
and 3.5), Additionally for a further 11 loci, most of the isolates were detected with an 
identical copy number while one or two isolates either showed a different copy number 
with one or two repeats difference or a null result (Table 3.5).  
 
VNTR loci CD1-8 and 10 exhibited diverse copy numbers within ribotype 001 isolates and 
these loci were earlier published by Marsh and van den Berg (Table 3.5). According to the 
study by Van den Berg, for loci CD4, 5, 6 and 7 copy numbers of 5-7, 5, 6-8 and 2 was 
reported respectively. However in this study, only locus CD7 showed an identical copy 
number of 2 for all the ribotype 001 isolates and locus CD5 isolates had copy numbers of 
5-6.  
 
When performing cluster analysis, 23 loci that exhibited identical copy numbers for all the 
isolates or loci that showed variable copy numbers in only one or two isolates (Table 3.5 
and Figure 3.36), were excluded from the analysis. Similarly, an arbitrary value of ≥ 90 % 
similarity detected three clusters (A-C) among the 25 isolates. Group A consisted of two 
isolates exhibiting variable copy numbers within published loci CD1-10. Group B 
consisted of four isolates; of these three showed 100 % similarity to each other while one 
isolate, MPRL 587, showed a 92 % similarity to the other three. This isolate varied in copy 
numbers to the rest in loci CD18 (copy number-1) and CD43 (copy number-21). The last 
group C contained four isolates showing 100 % similarity to each other. 
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Figure 3.36: Cluster analysis of 25 ribotype 001 isolates, excluding the 23 loci with identical copy 
numbers for most of the isolates (Table 3.5). Three groups (highlighted A-C) were detected with ≥ 
90 % similarity. 
 
 
Cluster analysis was repeated with only the ‘new’ loci from the previous cluster analysis in 
order to detect the discriminatory power of the ‘new’ loci (Figure 3.37). An arbitrary cut-
off of ≥ 90 % was set to look at the similarities among the isolates and four groups were 
detected (A-D). Group A consisted of three isolates; two of these isolates showed 100 % 
similarity to each other and one isolate showed a similarity of 90 % to the other two.  This 
isolate (MPRL 684) showed a different copy number for loci CD18 (null) and CD45 (5) 
while the other two showed copy numbers one and four respectively. Groups B and D 
contained 4 and 7 isolates respectively and showed 100 % similarity to each other within 
the group. Group C consisted of two isolates and both showed different copy numbers in 
loci CD18 (null-1) and CD43 (20-21) and exhibited 90 % similarity to each other. 
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From the two separate cluster analysis performed for ribotype 001 isolates, the ‘new’ 
primers were able to differentiate most of the ribotype 001 isolates. This indicates that 
these loci could be used as markers to differentiate among the ribotype 001 isolates.  
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Figure 3.37: Cluster analysis of ribotype 001 isolates with the VNTR loci designed for this study 
(i.e. excluding loci CD1-10 and loci with identical copy number for all isolates). At the arbitrary 
cut-off level of ≥ 90 % similarity, four groups (highlighted A-D) were detected among the 25 
isolates. 
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 VNTR Locus Location Size (bp) Copy no. range 
CD 1 755721-755950 6 1-47 
CD 2 3688632-3688751 7 8-28 
CD 3 3239736-3239835 6 18-47 
CD 4 167124-167172 7 2-10 
CD 5 1954913-1954939 3 4-8 
CD 6 664660-664705 8 1-15 
CD 7 4116072-4116109 9 1-4 
CD 8 692929-693015 8 1-28 
CD10 677132-677386 17 2-24 
CD11 2168250-2168268 9 Null -1 
CD12 804519-804537 9 Null -2 
CD13 301056-301074 3 Null -5 
CD14 788448-788465 9 Null -2 
CD15 800026-800043 9 Null - 2 
CD18 3014724-3014741 9 1* 
CD19 2167938-2167955 9 Null -2 
CD20 2169070-2169086 7 Null -1-2 
CD21 2169418-2169435 9 Null -2 
CD22 804623-804645 3 7* 
CD23 804652-804699 18 1* 
CD24β 478055-478070 7 2 
CD25 543601-543619 9 Null -2 
CD 27 3246180-3246195 6 Null -1-2 
CD 28 3246752-3246770 9 Null -2 
CD 30 794475-794493 7 Null -2 
CD 32 β 252622-252644 6 3 
CD 33 800719-800741 2 10* 
CD 34 799700-799717 6 6* 
CD 35 β 797131-797146 7 1* 
CD 36 β 881618-881637 10 2 
CD 37 β 881702-881718 8 1 
CD 38 β 883903-883918 6 2 
CD 39 884179-884194 6 2* 
CD 40 884601-884612 3 4* 
CD 41 β 886202-886220 9 2* 
CD 42 923152-923190 20 9-19* 
CD 43 623650-623691 21 10-21* 
CD 45 3319803-3320164 45 0-5* 
CD 46 3753183-3753574 45 5-7* 
Table 3.6:  Summary of the VNTR repeats for 22 different ribotype isolates for 39 loci.  
Loci highlighted in red showed copy numbers of 1, 7 and 1 for majority of the isolates compared to 
ribotype 027 and 001 respectively. 
 
* Indicates, majority of the isolates produce the same copy number and only a few isolates exhibit 
one or two different copy numbers. 
β Loci (7 loci) excluded from the first cluster analysis. 
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3.9.6 Cluster analysis of non-ribotype 027 and 001 isolates 
 
Among the 22 non-ribotype 027 and 001 isolates, variable copy numbers were detected for 
majority of the 39 loci, Null results could be seen for nearly 90 % of the isolates in 12 
different loci (Table 3.6). Stable copy numbers were detected for 6 loci (CD24, 32, 36, 37, 
38 and 41) with one locus, CD41 showing a variable copy number for only one isolate 
(Table 3.5). In loci CD18, 22 and 23, copy numbers of one, seven and one were detected 
for majority of the isolates respectively and these loci could be potential markers to 
differentiate from the ribotype 027 and 001 isolates. Loci CD1-10 showed variable copy 
numbers for most non-ribotype 027 and 001 isolates.  
 
Cluster analysis was performed for the 22 non-ribotype 027 and 001 isolates by excluding 
seven loci with the same copy numbers or loci, which showed variable copy numbers in 
only one or two isolates (Figure 3.38). An arbitrary value of ≥ 90 % similarity was 
considered to detect clusters among the isolates. The different ribotype isolates clustered 
separately from each other showing high variability within the isolates. A single cluster 
was detected with five isolates. Two isolates showed 100 % similarity to each other and 
these two isolates belonged to the same ribotype i.e. 012. The other three isolates showed 
different copy numbers and showed different similarities to each other (Figure 3.38). From 
these three isolates, one of the isolate (MPRL 557) belonged to ribotype 002 and the other 
two ribotypes are unknown. 
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Figure 3.38: Cluster analysis of 22 different ribotype isolates, excluding the 7 loci with identical 
copy numbers for majority of the isolates (Table 3.6). One group (highlighted) was detected with ≥ 
90 % similarity. 
 
 
 
Cluster analysis was repeated by excluding the published loci and seven loci with identical 
copy numbers for most of the isolates, in order to detect if the loci identified for this study 
were able to differentiate the isolates. Within the ≥ 90 % similarity range, two different 
clusters were detected (A and B) (Figure 3.39). Cluster A consisted of two isolates MPRL 
602 and MPRL 841, showing 91 % similarity to each other. Cluster B was detected with 5 
isolates; of these three isolates showed 100 % similarity to each other. Interestingly, out of 
the three isolates, two were ribotype 012 and the other isolate was ribotype 002. The other 
two isolates, MPRL 202 and MPRL 595 showed 93 % and 90 % similarities with the other 
3 isolates respectively. 
 
Similar to other ribotypes isolates, the ‘new’ primers were able to differentiate most of the 
non-ribotype 027 and 001 isolates.  
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B
Figure 3.39: Cluster analysis of 22 different ribotype isolate, only with the primers designed for 
this study (i.e. excluding the published loci and loci with identical copy number for all isolates). 
Two groups (highlighted A and B) were detected showing ≥ 90 % similarity to each other. 
 
 
 
Overall comparison of all ribotype groups and loci 
 
Cluster analysis results from the three ribotype groups were closely compared in order to 
identify specific loci to differentiate the three groups. Hence, the discriminatory power of 
the newly designed primers and the published loci i.e. CD1-10 were also assessed. 
 
Cluster analysis was performed again for all ribotype isolates by using the new loci in 
order to detect the discriminatory power of these loci. Interestingly, two main clusters 
could be detected and majority of the isolates from the three groups clustered within these 
two clusters separately from each other (Figure 3.40).  
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Figure 3.40: Cluster analysis of all three ribotype groups (92 isolates) using the new loci. Majority 
of the isolates clustered within the particular group. Red: ribotype 027, Blue: ribotype 001, Black: 
other ribotypes. 
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Further, analysis of results from the previous clusters and careful observation of the copy 
numbers obtained for each locus by majority of isolates in each ribotype group revealed 
that loci CD11, 12, 14, 18, 19, 20, 21, 22, 23 and 25 showed different copy numbers in 
each ribotype group (Table 3.7).  Hence, these ten loci could be used as possible markers 
to differentiate the 027 and 001 ribotype groups from other ribotype groups.  
 
 
  Loci Ribotype 027 copy 
number 
Ribotype 001 copy 
number 
Other Ribotypes 
copy number 
CD11 1 Null 1 
CD12 2 Null 2 
CD14 Null 2 2 
CD18 2 1 1 
CD19 2 Null 2 
CD20 2 Null 2 
CD21 2 Null 2 
CD22 1 7 7 
CD23 0 1 1 
CD25 2 Null 2 
Table 3.7:   Different copy numbers detected within majority of ribotype 027, 001 and other 
ribotype isolates in new loci. 
 
 
Using these 10 loci, the cluster analysis was performed again in order to detect if these 
specific loci were able to differentiate the three ribotype groups (Figure 3.41). 
Interestingly, again majority of the isolates from the three ribotype groups were clustered 
separately from each other. 
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Figure 3.41: Cluster analysis of all three ribotype groups (92 isolates) using the new 10 specific 
loci. Majority of the isolates clustered within the particular groups. Red: ribotype 027, Blue: 
ribotype 001, Black: other ribotypes. 
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4. Discussion 
 
Accurate and definitive microorganism identification and detection is vital for disease 
diagnosis, treatment, infection control and outbreak investigation. Traditionally, bacterial 
identification has been based upon phenotypic characteristics, Grams stain, culture 
morphology, biochemical tests and more recently long chain fatty acid analysis. The 
importance of these tests is that it is able to yield more direct functional information of 
metabolic activities taking place in the cells for development, growth and survival. At 
present, most routine laboratories mainly rely on phenotypic based methods for the 
identification of bacterial pathogens (Iorio et al., 2007). However, because of the 
limitations of these methods, genotypic techniques have also been introduced over the 
years to characterise bacteria. With the wide spread use of PCR, 16S rRNA gene 
sequencing has become the most commonly used, accurate and reliable molecular based 
method for the identification of clinically important microorganisms. Also, it is one of the 
main tools used to detect taxonomic relationships among the bacteria (Clarridge 2004; 
Bergey’s manual 2009). However, as in other methods, it has its limitations and drawbacks 
(Woo et al., 2008).  
 
Over the years, with developments in the field of proteomics, mass spectrometry has 
become one of the major tools in microbiology due to its high sensitivity, detection limits 
and numerous applications (Graves and Haystead 2002; Cañas et al., 2006). Even to date, 
cellular fatty acid profiling by gas chromatography MS (GC-MS), which was introduced in 
early days of MS, remains an important tool for taxonomy and classification (Fox 2006). 
However, with the development of soft ionisation techniques, MALDI and ESI in 1980s by 
Karas and Hillenkamp and Fenn respectively led to the analysis of large molecules such as 
proteins comprising several hundred thousand daltons (Tanaka et al., 1988; Karas 1988). 
The main differences in terms of methods were that, the sample can be directly spotted to a 
target plate for MALDI analysis while with ESI; samples are sprayed in to the MS. One of 
the main advantages of MALDI over ESI is that it is more tolerant to sample contaminants 
like buffers and salts when they are present in low concentrations (Cañas et al., 2006).  
 
In the field of microbial identification, MALDI has become more popular due to the direct 
analysis of intact cells which made the method much simpler, thus reducing the sample 
preparation time, as compared to other analytical methods (Claydon et al., 1996; Edwards-
Jones et al., 2000; Jarman et al., 1999). This method enabled the detection of mostly 
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surface-associated proteins which are of major importance, as the surface of a cell is the 
main site of host-pathogen interactions. The MS fingerprints generated from these analyses 
were shown to be reproducible and specific for several bacterial species (Claydon et al., 
1996; Shah et al., 2000). Hence this method began developing as a fingerprinting tool to 
characterise biomarkers from microorganisms by assembling databases of mass spectral 
fingerprints containing reference and type strains (Keys et al., 2004). This enabled rapid 
high-throughput detection of microorganisms and the potential for use, especially in 
routine diagnostic laboratories was evident. To date a major problem faced in routine 
diagnostic labs is the lack of rapid techniques to identify microorganisms in time to 
influence patient treatment. Although there are many rapid automated or semi-automated 
diagnostic systems available for bacterial identification, each method has its limitations. 
Hence the aim of this study was to use MS and other proteomic techniques to characterise 
the nosocomial pathogens, Staphylococcus aureus and Clostridium  difficile. 
 
With the rising number of MRSA and C. difficile associated infections globally due to 
rapidly evolving strains, the need to detect these organisms at the earliest stages of 
infection is even more important to prevent further spread. To date the identification of S. 
aureus is routinely achieved using phenotypically based techniques (Kloos and Wolfshohl 
1982; Iorio et al., 2007 and Delmas et al., 2008). More recently, genotypic methods such 
as spa typing (Swenson et al., 2001) for the detection of the mecA gene has become the 
most popular method for the detection and typing of S. aureus (MRSA).  
 
In the case of C. difficile, it is mainly detected in the clinical laboratories by culture and by 
toxin detection. The cycloserine-cefoxitin-fructose agar, a selective media introduced by 
Lance George (George et al., 1979; Delmee 2001; O’Connor et al., 2001) in the 1970s is 
still used for presumptive identification of C. difficile. Immunoassay (EIA) has been used 
widely for the detection of toxin A and B as a screening test for C. difficile-associated 
diarrhoea (CDAD) while tissue culture which detects toxin A and B remains the gold 
standard for the detection of pathogenic C. difficile due to its sensitivity and specificity 
(Delmee 2001; Snell et al., 2004; Russmann et al., 2007). There are also various 
commercial kits for the detection of CDAD with different sensitivities and specificities 
(Reyes et al., 2007 and Brazier 1998). An additional detection method which involves the 
use of the common antibody to the enzyme, GDH present in all strains of C. difficile, is 
used by some laboratories (Wilkins and Lyerly 2003). 
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With the increasing number of samples which need to be identified correctly, rapid, high-
throughput techniques have become necessary in diagnostic laboratories. Such laboratories 
are now turning towards the emerging technologies to resolve these issues. 
 
MALDI-TOF-MS analysis of S. aureus and C. difficile 
 
This part of the study explored the use MALDI-TOF-MS as a tool for the characterisation 
of bacteria. The performance of an existing database (containing profiles of more than 
5000 isolates) and a search engine to match the spectra of clinical isolates to the profiles of 
type strains and laboratory reference strains was investigated. Furthermore, the relative 
similarity of the MALDI fingerprints amongst all S. aureus isolates and other closely 
related Staphylococcus spp were also tested.  For the study, 95 clinical isolates 
presumptively identified as S. aureus collected from The Royal London Hospital were 
confirmed as S. aureus using conventional biochemical tests by the Staphylococcus 
Reference Laboratory at HPA. 
 
The profiles generated by MALDI were mainly from surface-associated molecules, which 
in turn could be affected by environmental pressure. Hence, parameters such as variation in 
culture media, pH, growth time and incubation temperature were re-examined briefly, 
although these were standardised prior to assembling the database (Shah et al., 2000, 
2002). Although the MS of the MSA medium showed greater peak density compared to 
CBA within the mass range of 500- 3000 Da, CBA was chosen for the study because the 
mass ion density was still significant for cells grown on this medium. This is in agreement 
with the study of Walker et al. (2002) who showed that for S. aureus the reproducibility 
and a higher number of mass spectral ions could be obtained using CBA. Thus, CBA was 
also used as the standard medium for assembling the database (Figure 3.1).  Similarly, the 
spectra from different incubation periods showed that with increasing incubation time, the 
quality of the spectra decreased. Since the spectra from 24 h incubation times showed the 
largest density of peaks, the study was carried out using cells grown on CBA for 24 h; a 
factor that will be also beneficial for clinical laboratories due to the reduced turn-around 
times. 
 
The first phase of the study  revealed that with the exception of three isolates (HPA 80, 
HPA 547 and HPA 549), all 92 isolates matched to spectra in the database and were 
correctly identified by the software. However, almost all of the 95 isolates showed similar 
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profiles with several consensus mass ions in the range of ~ 800 - 3500 Da and could be 
regarded as specific surface biomarkers for the genus Staphylococcus. Within the same 
mass range, Edward-Jones et al. (2000) and Du et al. (2002) also reported the presence of 
specific biomarkers for S. aureus and MRSA. Subsequently, Bernado et al. (2002) also 
reported the presence of specific markers in this mass range although that study was not 
based on intact bacterial cells and therefore highlights the reproducibility of the 
methodology. For some of the clinical isolates, unusual peaks were detected in the mass 
range of ~2000 - 3400 Da which were absent from reference/type strains indicating 
possible phenotypic differences. From the parallel study done with the 2006 database at 
MMU to validate the methodology, contamination of these samples were again highlighted 
by their incorrect identification, RMS and probability values. Consequently these were 
purified by sub-culture, re-run and the results were concordant with other isolates (Table 
3.1). The presence of occasional contaminants in a sample that leads to altered RMS and 
probability values emphasises the high sensitivity of the technology which allowed for 
detection of mass ions from the contaminants even before they were visually detected on 
the agar plates and suggest that in the future the analysis of mixed samples may be 
possible.  
 
The second phase of the study contained 39 clinical isolates from a collection of 
temporally, geographically and genotypically diverse strains of S. aureus including MSSAs 
along with representatives of epidemic HA-MRSA (EMRSA-15, -16 and -17), CA-MRSA 
(so-called USA300, South West pacific and European clones) and two ‘aberrant’ strains 
(one coagulase-negative S. aureus and one small colony variant). Their successful 
identification to the species level by MALDI-TOF-MS gives further support to this 
approach. However despite good representation of MRSA strains analysed in the present 
study (~ 44 %), there were no consistent mass ions that distinguished between MRSA 
strains from other S. aureus strains that were reported by Edwards-Jones et al. (2000) and 
must cast doubt on the validity of this approach for antibiotic resistant profiling.  
 
Overall the results of this part of the study demonstrated clearly that isolates of S. aureus 
may be identified by MALDI-TOF-MS with a high degree of confidence (97.76 %) in a 
clinical laboratory using an established database. However, reliance on a few 
distinguishing biomarker peaks to differentiate populations of S. aureus into biological 
types nearly always begin deviating as more wild-type isolates are studied,  therefore the 
entire mass spectrum should be taken into consideration when devising a classification 
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scheme. In a similar attempt to identify coagulase-negative staphylococci (CNS) using a 
database containing 23 reference strains, Carbonelle et al. (2007) showed clear separation 
of coagulase-negative staphylococci from other closely related taxa. A recent study by 
Dupont et al. (2009) also demonstrated the robustness and high sensitivity of microbial 
identification using the same database used by Carbonelle for his study, by MALDI 
technology for clinical CNS isolates. But in his study, he compared MALDI with two 
automated systems, BD Phoenix and VITEK-2, phenotype based techniques for 
comparison. Excluding the species that were not present in the database, they were able to 
achieve a correct identification for all isolates with a percentage of 97.4 %, 79 % and 78.6 
% for MALDI, Phoenix and VITEK-2 system respectively. The previous studies carried 
out for the identification of S. aureus based on phenotypic properties using various 
commercial kits, such as API Staph-Ident kit, DMS Staph-Trac kit, MicroScan Pos ID and 
commercial slide agglutination tests showed variable results.  Kloos and Wolfshohl (1982) 
was able to detect a 90 % similarity between conventional methods and the API Staph-
Ident kit while Overman and Overley (1990) reported between 75 – 100 % reproducibility 
of results using two versions of the Staph-Ident kit. By using DMS Staph-Trac kit, Giger et 
al. (1984) achieved 88 % correct identification for S. aureus. A recent study by Layer et al. 
(2006) compared three methods; BD Phoenix, VITEK 2 and API ID32 STAPH test, for the 
detection of Staphylococcal species from clinical samples. They demonstrated that for the 
identification of CNS in routine laboratories, both BD Phoenix and VITEK 2 systems are 
within highly acceptable limits, although API ID32 STAPH revealed more correct results 
compared to both automated systems.  
 
Several molecular methods have also been developed to distinguish S. aureus isolates. A 
study carried by Peacock et al. (2002) for S. aureus isolates in a renal unit demonstrated 
similar discriminatory capabilities of both MLST and PFGE typing methods. They 
concluded that due to the time, cost, and expertise required to perform MLST, PFGE will 
remain the typing system of choice for outbreak investigations (Weller 2000), with MLST 
being reserved for long-term epidemiological and population genetic studies.  A similar 
study carried out by Melles et al. (2007) compared three methods, MLST, PFGE and 
AFLP, in order to type S. aureus isolates. They demonstrated that although there were 
discrepancies between the results of the three typing methods, all three showed similar 
results. They also highlighted the drawbacks of these methods such as the lack of 
reproducibility of the fragment patterns and the difficulty of the data exchange between the 
laboratories.  
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The present study assessed the potential of MALDI-TOF-MS of intact S. aureus cells as a 
diagnostic tool in the clinical laboratory and evaluated the performance of an existing 
database developed for microbial identification (Keys et al., 2004). The method described 
over the years and used here (Keys et al., 2004; Shah et al., 2008) was aimed at rapid 
characterisation of microorganisms to the species level and was intentionally devised to 
facilitate application in a high throughput clinical laboratory. To date, MALDI-TOF-MS of 
intact cells has been used widely to characterise bacteria. Such an application necessitates 
development of a microbial database in which MS spectra are attained under highly 
controlled experimental parameters using type and reference strains from an accredited 
culture collection such as NCTC. The database used in the present study currently holds 
MALDI-TOF MS profiles of more than 5000 bacterial strains. Here, the performance of 
this database and the MicrobeLynx™ search engine to match the spectra of clinical isolates 
(which may differ) to the profiles of NCTC strains was tested for the first time.  
 
A major aim of this study was to collect field isolates of S. aureus from a clinical 
laboratory and, with minimal culturing time, to adapt to the laboratory conditions, 
challenge the database and the search engine to match their mass spectral profiles to 
reference spectra of S. aureus. All but four of the 134 clinical isolates presumptively 
identified as S. aureus were correctly identified using MALDI-TOF-MS. Four aberrant 
isolates gave discrepant results, but were later confirmed as S. aureus by 16S rRNA 
analysis. Notably, they were shown to have low level contamination which clearly affected 
the quality of their mass spectra. 
 
Spectral patterns of closely related species of S. aureus such as S. epidermidis, S. 
haemolyticus and S. saprophyticus showed a high degree of similarity across the genus and 
there were several genus-specific biomarkers. It was possible to ascertain the intraspecies 
phenotypic diversity among clinical isolates of S. aureus and their similarity to 
type/reference strains by comparative analysis of MALDI spectra. However, the overall 
similarity in the profiles (as illustrated by the RMS value) rather than specific mass ions 
were used for identification of strains. Despite the observed differences, there were enough 
stable characteristics in the profiles of S. aureus to achieve correct identification of isolates 
(Rajakaruna et al., 2009). 
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A similar approach was carried out for the identification of C. difficile using the existing 
database. However, the three C. difficile isolates (L, B1 and T; see Material and Methods) 
tested using the CBA culture media, were unable to achieve correct identification using the 
MicrobeLynx™ software. This may have been due to the limited number of C. difficile 
spectra present in the database. When the growth medium was changed from CBA to FAA, 
the identification improved but only to the genus level in a few cases. This might be 
because the FAA medium was more suitable than CBA for the growth and the isolates may 
have expressed more characteristic mass ions on FAA. When comparing the profiles of the 
predicted isolates by the software (Figure 3.5), similar mass ions were seen for all the 
entries (1450 Da and 2600 Da) indicating that those predicted species maybe closely 
related including C. difficile. This may have been the reason the software was unable to 
differentiate between the three C. difficile isolates. Hence, in an attempt to identify C. 
difficile using MALDI, another database (SARAMIS™) was used for further analysis. 
 
 
Spectral ARchive And Microbial Identifications System (SARAMIS™) 
 
The SARAMIS™ database contains more than 100,000 spectral entries representing more 
than 1,200 species and 220 genera. Microbial identification is achieved through the so 
called SuperSpectra™, generated for each taxon i.e. genus, species and strain biomarkers. 
These specific SuperSpectra™ or biomarkers which are representative of respective groups 
of microorganisms are then used for automated identification of unknown isolates. 
Although the SuperSpectra™ tool is used to identify an unknown, a reference database is 
generated by continuously adding new spectra for each new species. To date more than 
2,400 SuperSpectra™ are available for automatic microbial identification. Also with the 
software installed in MS e.g. AXIMA MALDI-TOF-MS (Shimadzu, UK), it takes less than 
10 sec per 500 laser shots and analysis is rapid and convenient. 
 
To obtain a SuperSpectrum™, the raw mass spectra from 15-20 strains of a species are 
collected from different environments, laboratories grown on different culture media etc., 
and processed to yield peak lists and clustered to obtain the predominant mass ions of a 
specific species (Figure 4.1). This consensus spectrum is calculated for the mass signals 
that have been recorded at the frequency of 50-100 % excluding unspecific signals. Hence 
the consensus spectra contain peaks that are specific for higher taxonomic units such as 
genera or families in order to facilitate final identification to the species level. When the 
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SuperSpectra™ are calculated, each non-specific signal is identified by comparing with the 
reference database. For species identification, these spectra are given a low weighting. In 
cases where numerous isolates of a single species are analysed, cluster analysis tends to 
reveal sub-specific units and multiple SuperSpectra™ are calculated for that particular 
species.  
 
 
 
 
3000 mass m/z 15000
82
56
87
09
94
63
10
22
9
10
80
9
73
62
79
02
71
11
61
38
56
91
54
08
33
95
41
22
47
30
species
specificity:
genus
family
Klebsiella
pneumoniae
Klebsiella
oxytoca
Enterobacter
aerogenes
30 40
Percent matching masses
50 60 70 80 90
*
*
*
a
b
c
 
 
 
Figure 4.1: Dendrogram of mass spectral fingerprints of ten isolates each of three closely related 
species within the diverse family Enterobacteriaceae (a), illustration of a SARAMIS 
SuperSpectrum for Klebsiella oxytoca with taxonomic specificities of mass signals indicated by 
their height (b), and a mass spectrum of a clinical isolate of K. oxytoca with mass signals matching 
to the SuperSpectrum™ indicated by dotted lines (c). Asterisks (*) indicate DSM reference isolates 
of respective species.  
 
 
When a mass spectral fingerprint is matched to the SuperSpectra™ in the database, 
weighting values for each matching signals are summed up. As a result those 
SuperSpectra™ for which the highest specific concordance was established are listed. 
These sums of the mass signal values are then translated into a confidence value for 
identification and also indicated by a colour coded system by the software as shown here 
for C. difficile (Table 4.1). 
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 Colour code Confidence value 
Green 90-100 % (automatic identification) 
Yellow < 80 % (manual identification) 
Grey Spectra not acquired 
Red Mixed culture/poor sample preparation 
      (a) 
 
      (b) 
Table 4.1: (a) Confidence values of identification by the SARAMIS™ software. (b) Example of an 
output result by the software for C. difficile isolates.  
 
Compared to the previous Waters® method, the main difference of this method was the 
change of matrix solution from 5-chloro-2-mercaptobenzothiazole (CMBT) and alpha-
cyano-4-hydroxy-cinnamic acid (CHCA) to 2, 5-dihydroxybenzoic acid (DHB) in the 
presence of trifluoro acetic acid (TFA) and acetonitrile (ACN). Several studies have shown 
that experimental factors such as sample preparation, type of matrix, matrix solvent, 
instrument quality etc. significantly influence the MALDI profiles and the spectral quality 
(Williams et al., 2003, Shah et al., 2000, Wang et al., 1998). Hence, the effect of the ‘new’ 
matrix solution, DHB, on intact cells of C. difficile was investigated (Section 2.3.4). In 
brief, cells were held at different time intervals in DHB and its ultra-structure was 
examined by transmission electron microscopy. Disruption of the capsule and external 
polymeric material around the cells were clearly evident. However, the cell appeared to 
stay intact on the MALDI target plate (Figure 3.9). This is surprising as TFA and ACN are 
highly polar solvents and would readily cause lysis of cells in free solution (Williams et 
al., 2003). A similar observation was also reported by Pennanec et al. (2010) for 
Legionella, when the cells were introduced to 2.5 % of TFA. He observed the cells were no 
longer viable with addition of 2.5 % TFA in the presence of ACN and the observed peaks 
correspond to membrane and internal proteins.  
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In the present study, the images obtained from the target plates before and after the 
MALDI analysis revealed a uniform layer of cells which clumped to leave areas of the 
target plate clear (Figure 3.10 a). Closer inspection of these areas before analysis showed 
that the cells were arranged in parallel rows, indicating that the matrix has held the cells in 
a ‘frozen’ state. This may have been brought about by the rapid evaporation and 
crystallisation following addition of the matrix to the cells. The images obtained after the 
MALDI analysis revealed that the cells are less uniform and showed a metallic sheen 
indicating the disruption of the surface polymers. A similar observation was reported by 
Welham et al. (1998) for E. coli cells prior to MALDI analysis, where the cells remained 
intact after the addition of the matrix, 2, 4-hydroxyphenylazobenzoic acid (HABA), which 
contained 0.1 % TFA as a solvent. In their study, images obtained after the MALDI 
analysis showed cells that were completely intact, indicating the observed ions may arise 
from the cell wall. This difference may have been due to the two different matrices; DHB 
and HABA and the concentration of the TFA present in the matrix solvent. Although 
Welham et al. (1998) showed by using a matrix solvent containing 0.1 % TFA did not 
affect the bacterial cell wall, in the present study, 0.3 % TFA caused disruption of the 
surface polymers which were visible from the electron micrographs. The spectral profiles 
obtained using the SARAMIS™ method must therefore arise from intra cellular proteins. 
 
Although the SARAMIS™ method was standardised, parameters such as growth time and 
incubation times were re-examined briefly for C. difficile. The spectra obtained from the 
three test media: CBA, FAA and NA, for 24- 48 h showed similar reproducible spectra, 
despite the variation in the composition of the medium. However, the spectral qualities 
from the 24 h cultures grown on CBA were superior. Hence, this time period was selected 
for subsequent analyses. In the first phase, 53 isolates were analysed in duplicate and 
except for two isolates, all were identified as C. difficile with 80-100 % confidence values. 
Significant peaks were detected for most of the C. difficile isolates within the mass range 
of 4200- 4300 Da, 5400 Da, 6300 Da, 6640 Da and 6720 Da. The two isolates incorrectly 
identified as S. warnerai and Propionibacterium acnes were due to the presence of mixed 
cultures, highlighting the sensitivity of the system.  In the second phase, 63 isolates were 
tested and all were correctly identified by the database. Cluster analysis was performed 
based on the percentage matching identical masses of the spectra and available C. difficile 
profiles in the database. All isolates showed a high degree of similarity and therefore 
recovered in a single cluster. Also the MS data from the first set of data obtained using 24 
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h incubation clustered closely while the incorrectly identified isolates were recovered in a 
cluster distinct from the rest of the isolates. 
 
In addition, the SARAMIS™ database identified 14 closely related clostridial species 
correctly with a confidence value of more than 65 %. Although the confidence values were 
lower than the C. difficile identification scores for some of these species, the SARAMIS™ 
identification correlated with that of comparative 16S rRNA sequencing. Cluster analysis 
of these different species against C. difficile consequently resulted in their separation into 
different phena with < 30 % similarity of mass ions (Figure 3.17). Overall, the results from 
this study using the SARAMIS™ database showed ~ 98 % correct identification for C. 
difficile isolates. A similar study done by Grosse-Herrenthey et al. (2008) used MALDI-
TOF-MS for the detection of 31 different Clostridium species. The authors reported the 
successful identification of Clostridium species within minutes using MALDI-TOF-MS 
combined with a database and bioinformatics software tool. The results of this study also 
correlated with the 16S rRNA sequencing data and traditional diagnostic techniques for all 
the species. Thus, when compared to large number of methods described earlier for the 
detection of C. difficile, MALDI-TOF-MS provides a rapid and reliable identification  with 
minimal sample preparation and its high accuracy is likely to contribute markedly as a 
primary diagnostic tool in the near future. 
 
From the first attempt to identify bacteria using intact cells (Claydon et al., 1996; 
Krishnamurthy and Ross 1996 and Holland et al., 1996), MALDI-MS has rapidly grown 
over the years as an identification tool. With the introduction of the ICM technique, the 
need for a mass spectral fingerprint library of bacterial species in order to detect unknown 
isolates was essential. Standardised experimental parameters were considered a crucial 
factor in order to achieve comparable reliable identification (Shah et al., 2000, 2002). 
However, over the years as it evolved as a rapid, inexpensive and accurate method for 
bacterial identification, the methodology, software and databases have improved so 
significantly that many clinical laboratories are now employing it as their primary test in 
hospitals (see review, Emonet et al.,  submitted for publication, 2010).  
 
To date, apart from the C. difficile and S. aureus identification, MALDI has been widely 
used for the detection of other microorganisms. A database similar to AagnosTec 
developed by Bruker Daltonik GmbH, Germany (BioTyper) has also been used widely for 
the identification of microorganisms. A recent study by Seng et al. (2009) analysed more 
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than 1000 clinical isolates by MALDI-TOF-MS using Bruker BioTyper database in 
parallel with conventional phenotypic identification techniques. They reported a 95.4 % 
correct identification of bacterial isolates, 84.1 % for species and few isolates up to the 
genus level (11.3 %) by MALDI. In their study, up to 2.8 % isolates were not identified by 
the MALDI, due to the lack of accurate reference spectra for particular species. Hence, it 
was pointed out the critical requirement is the development of an accurate database for 
bacterial identification. Another study by Eigner et al. (2009) evaluated the performance of 
MALDI for the identification of various clinical isolates in a routine microbiology setting. 
They tested more than 1100 clinical isolates and 108 reference strains and compared it with 
phenotypic identification systems and 16S rRNA analysis. Overall results for all the 
isolates by MALDI were 93.5 % and 95.2 % for reference and clinical isolates 
respectively. They also reported the accuracy of identification for Enterobacteriaceae, 
non-fermenting gram-negative rods, Staphylococcus, Enterococcus and Streptococcus with 
MALDI as 95.5 %, 79.7 %, 99.5 %, 100 % and 93.7 %, respectively where most of these 
species are sent for identification in the routine clinical laboratories. A subsequent study by 
Bizzini et al. (2010) also reported MALDI as a fast and reliable technique to use in clinical 
laboratories, in which they were able to identify more than 1200 isolates to the species 
level (93.2 %) by MALDI-TOF-MS. 
 
Similarly, MALDI has been used for the detection of many other pathogens e.g. food and 
water contaminant pathogens, fungal, yeast and many more. Some of these included the 
identification of Legionella species in water samples (Pennanec et al., 2010), bacterial 
species associated with food contaminants (Mazzeo et al., 2006), classification and 
identification of Salmonella and Vibrio species (Dieckmann et al., 2008 and 2009). Also 
the identification of other pathogens such as Burkhoderia cepacia complex (Vanlaere et 
al., 2008), fungi (Erhard et al., 2008) and yeast identification (Marklein et al., 2009) by 
MALDI have also been reported recently. Another recent development of MALDI-MS is 
the identification of bacteria directly from positive blood cultures/bottles in clinical 
laboratories (La Scola and Raoult 2010; Maier et al., 2010). Currently the identification of 
microorganisms growing in blood cultures takes up to two days due to the sub-cultivation 
and biochemical identification. However with introduction of new sample preparation 
methods described by La Scola and Raoult (2010), Maier et al. (2010), MALDI has proved 
as a rapid and accurate alternative to classical method of identification of blood cultures in 
clinical laboratories. 
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SELDI-TOF-MS and SDS-PAGE analysis of S. aureus and C. difficile 
 
The main goal in proteomics is to resolve, separate, visualise and identify the proteins from 
complex mixtures. To date, the predominant technology for protein separation and 
isolation is polyacrylamide gel electrophoresis and it still remains one of the most effective 
ways to resolve a complex mixture of proteins. For many proteomic applications, SDS-
PAGE is the method of choice to resolve protein mixtures and can be used to resolve 
proteins with molecular masses of 10 -300 kDa (Graves and Haystead 2002). Surface 
Enhanced Laser Desorption/Ionisation (SELDI) ProteinChip® technology has the ability to 
generate rapid protein expression profiles from a variety of biological samples and allow 
the rapid characterisation of the microbes (Schmid et al., 2005). Unlike the inert MALDI 
target surfaces, the SELDI protein chip surfaces are uniquely designed to retain proteins of 
interest from complex mixtures according to their specific properties (Seibert et al., 2004). 
It has been shown that unlike MALDI, SELDI enables visualisation of spectral profiles 
containing peptides/proteins in the mass range of 10-150 kDa (Shah et al., 2002), thus, it 
may be used to detect specific biomarkers. However, when compared to SDS-PAGE, the 
sensitivity of SELDI-MS remains higher as lower molecular weight proteins can be 
resolved by SELDI-MS than SDS-PAGE (Figure 4.2). Hence, another aim of this study 
was to identify biomarker proteins or peptides that may be characteristic for MRSA, 
MSSA and C. difficile using SELDI-TOF-MS and SDS-PAGE. 
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Figure 4.2: Comparison of bacterial cell extracts separated by SDS-PAGE and SELDI-MS. 
Several peptides/proteins not seen by SDS-PAGE (lower molecular weight) are resolved by 
SELDI-MS (Taken from Encyclopaedia of Rapid Microbiological Methods. 3: Figure 1). 
 
 
For this part of the study, 50 MRSA and 49 MSSA isolates were analysed on different 
ProteinChip® arrays. Although a previous study (Innes, PhD thesis, 2008) suggested that 
SELDI has the potential to differentiate MRSA and MSSA, a limited number of isolates 
were tested. In order to reduce the variation of results, some parameters in a method 
needed to be fully optimised (Cordingley et al., 2003). For this purpose, the same protein 
extraction method used in previous studies and other methods were tested using different 
concentrations of lysostaphin, various pH range and different ProteinChips® in order to 
obtain the optimal cytosolic protein yield for SELDI analysis.  
 
By virtue of its complex cell wall, S. aureus is difficult to lyse, however, lysostaphin, an 
antibacterial enzyme is capable of specifically cleaving the cross-linking pentaglycine 
bridges of the peptidoglycan of staphylococci (Schindler and Schuhardt 1964). It has also 
been shown by Wu et al. (2003) that lysostaphin not only kills S. aureus in biofilms but 
also disrupts the extracellular matrix of S. aureus biofilms in vitro on plastic and glass 
surfaces at concentrations as low as 1 µg/ml. Hence, the use of lysostaphin in this protein 
extraction method ensures the detection of intracellular cytosolic proteins of S. aureus 
(MRSA/MSSA).  
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Efficient breakage of cells to release cytosolic proteins is one of the very important steps in 
proteomic analysis. Here, the total protein content was compared by two different 
extraction methods: the French Pressure Cell using water and lysis solution (containing 
detergents and chaotropic agents) and the Mickle beating of the cells in the presence of 
lysis solution and water. In this study, the standard lysis solution containing urea and 
CHAPS was used as it was shown to be compatible with different ProteinChips® for 
SELDI analysis (Cordingley et al., 2003). Commonly used detergents such as SDS was 
shown to be unsuitable as it causes ion suppression (Barzaghi et al., 2004). The extracts 
from the French Pressure Cell showed more protein bands on the 1D-gel than the extracts 
from the Mickle disintegration (Figure 3.20). The total protein content and the profiles on 
the SELDI also showed different results (Figure 3.19). Although the French Pressure Cell 
yielded a higher protein concentration (~ 30 µg/µl) and showed a higher number of peaks 
with a higher intensity in water extracts, Mickle beating combined with freeze-thawing 
with 30 µl lysostaphin produced an adequate amount (~ 10-15 µg/µl) of protein necessary 
for SELDI analysis and was the method of choice. 
 
SELDI-TOF-MS and ProteinChip® arrays used in this study allowed rapid, high-
throughput analysis of both large and small biomolecules with good reproducibility. 
Although the resulting spectra of MRSA and MSSA showed characteristic peaks specific 
to each strain, due to the vast amount of complex, noisy data generated by SELDI 
(approximately 13,000 data points per sample in the 3-30 kDa mass range), robust 
computer algorithms are vital to screen for potential biomarkers and remains a major 
challenge in bioinformatics (Ball et al., 2002). To overcome this problem, the SELDI-
TOF-MS data was analysed using a model based on Artificial Neural Network.  
 
Artificial Neural Networks (ANNs) are a form of Artificial Intelligence (AI) capable of 
modelling for complex systems and fast emerging as one of the most popular tools for 
complex data analysis. It is a mathematical/ computational model based on biological 
neural networks that organizes and process information (Lancashire et al., 2005). ANNs 
gathers knowledge by detecting patterns and relationships in data and learn through 
experience, not from programming. An ANN is formed from hundreds of single units, 
artificial neuron or processing elements (PE), connected with coefficients (weights), which 
constitute the neural structure and are organised in layers which resembles the biological 
neural network and therefore have many advantages (Kustrin and Beresford 2000). Firstly, 
they are essentially non-linear so that they are able to process data containing complex 
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interactions that are difficult to interpret. In addition, they are capable of generalisation, so 
they can interpret information which is different to that of the training data, thus 
representing a “real-world” solution to a given problem. A third advantage, which greatly 
helps proteomic data, is that they are fault tolerant, i.e. they have the ability of handling 
noisy or fussy information, while also being able to tolerate data which are incomplete or 
contain missing values. Like all other approaches, ANNs also have their limitations. The 
one major limitation of ANNs is that they do not explain how they reach a conclusion and 
often referred to as “black boxes” (Lancashire et al., 2005). Also training of ANN can be 
time consuming depending on the complexity of the data. Furthermore, the quality of the 
input data also plays a major role in the quality of the output by the model. 
 
There are many different network structures and different learning algorithms are applied 
ANNs (Abdi 2003). The most commonly used type of ANNs is the multi-layer perception 
(MLP) and back propagation (BP) algorithm because of its flexibility, adaptability and 
wide application capabilities (Wei et al., 1998; Desilva et al., 1994). In MLP, ANNs are 
organised into several layers, an input layer, one or more hidden layers and an output layer 
(Figure 4.3), with each layer having a number of neurons/ processing elements (Lancashire 
et al., 2009). The input layer interacts with the external environment to receive the input 
data and output neurons provide ANNs response to the input data while hidden neurons 
communicate only with other neurons (Kustrin and Beresford 2000). 
 
 
 
    Figure 4.3: Architecture of a typical multi-layered perception ANN (Lancashire et al., 2009) 
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During the development of the ANN model the data set was split into three sub sets; 
training data, test data and validation data. The ANN model was trained with the training 
data and continually optimised against the test data. The validation data was used to assess 
the ANN model on unseen data when the model was developed (Lancashire et al., 2005). 
Once an ANN model is built for a particular application, it should be trained since ANNs 
gather its knowledge through a learning process. There are two major learning algorithms 
used in ANNs; supervised and unsupervised. Supervised learning involves providing the 
network with a set of cases that have values for the input as well as the known desired 
outputs (Lancashire et al., 2009). In unsupervised learning, input information is only used 
for the training purpose, as the network itself governs how it groups the cases based on the 
input data. ANNs learn through special training algorithms such as BP algorithms 
(Lancashire et al., 2005). It contains two main steps, a forward step which involves 
generating a solution to the problem and the back propagation of the error to modify the 
weights in order to reach a minimum error. However, if a network is left to train for too 
long, it will over train and will lose the ability to generalise (Kustrin and Beresford 2000). 
When the ANN produced the desired output after training, the weighted links between the 
units are saved. These weights are then used as analytical tools to predict results for a new 
set of input data. 
 
For this study, in order to determine whether ANNs have the capability to identify specific 
biomarker ions, analysis was carried out using a stepwise approach in order to rank the 
ions based on the ability to predict as MRSA and MSSA. Hence unimportant and noisy 
values were removed and remaining single ions (3000-30,000 Da) were fed into the ANN 
model. From the first set of inputs, ion 3081 Da was chosen as the best predictive ion 
because of it’s lower mean error and compared to the rest of the ions and the process was 
repeated until the most important sub set of ions were achieved which was between 3000- 
19,000 m/z  values. After choosing the seven most predictive ions (3081, 5709, 5893, 7694, 
9580, 15308 and 18896 Da), each ion was reanalysed for predictive performance using 50 
ANN models.  
 
The predictive performance of the model based on the seven most distinct ions in the 
population distribution curve revealed that all of the MRSA isolates (except one) were 
correctly assigned by these ions while only two MSSA isolates were misclassified as 
MRSA (Figure 3.27). This may have been due to the loss of its resistance to methicillin or 
they maybe in the process of acquiring antibiotic resistance for example by acquiring 
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SCCmec type I, II and IV (Enright et al., 2002) (Figure 1.2.). Apart from these 
inconsistencies, the results indicate that these seven ions could be possible biomarkers for 
MRSA as indicated by the error bars. The area under the curve value obtained from 
receiver operating curve (0.9147) also indicated that this model have a high sensitivity and 
specificity (91%). However, the model could be validated using a blind data set for further 
confirmation.  
 
There are numerous applications of the ANNs technique in the field of bioscience, some of 
which have been applied to a number of human pathogens. A study carried out by Yang et 
al. (2009) for S. aureus and non-S. aureus isolates using SELDI-MS coupled with ANNs 
analysis, reported a sensitivity of 98.4 % and specificity of 98.6 % based on six protein 
peaks detected by the ANN model.  Another study by Schmid et al. (2005) used to identify 
and characterise Neisseria gonorrhoeae and closely related species and achieved a 
sensitivity of 95.7 % and specificity of 97.1 % using ANNs. A recent study by Xiao et al. 
(2009) demonstrated the successful identification of Klebsiella pneumoniae with an 
accuracy of 96.9 % using ANNs. ANNs have also been used successfully for analysis of 
MADI-MS data for the separation of strains of Bacillus anthracis vegetative cells, 
mixtures of cells and spores (Lasch et al., 2009).  
 
SDS-PAGE was also used in this study with the aim of detecting specific biomarkers 
between MRSA and MSSA. When selecting a protein extraction method suitable for SDS-
PAGE analysis, a boiling method (section 2.7.1 b) used with SDS was unable to produce 
adequate protein content, however, the addition of number of detergents and lysostaphin 
improved the yield.  The NuPAGE gels of S. aureus showed similar protein bands in the 
molecular weight range of 75 kDa, 50 kDa 30 kDa and 15 kDa for both MRSA and MSSA 
while one of the MSSA band patterns (Figure 3.28) showed several unique peptide/protein 
bands. In order to detect the presence of specific proteins/peptides in MRSA (MW2) and 
MSSA (476), some of these specific bands were analysed by digesting with trypsin 
followed by MS/MS analysis. The MS/MS analysis was carried out on LTQ-Orbitrap MS 
and the peptides were analysed using a Mascot search (Matrix science Ltd.). The 
corresponding proteins were viewed using Scaffold 3 proteomic software. With reference 
to isolates MW2 (MRSA) and 476 (MSSA), 26 and 19 unique proteins were identified 
respectively indicating the differences between MRSA and MSSA isolates (Appendix VI). 
However, further studies involving more strains are necessary to confirm the presence of 
these proteins. A similar study by Silva Santos et al. (2009) also demonstrated the presence 
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of species-specific whole-cell protein profiles for 139 isolates and concluded that SDS-
PAGE was useful for identifying clinically prevalent staphylococci species. 
 
In an attempt to detect intracellular biomarkers and the investigate intraspecies diversity of 
C. difficile, a similar approach was carried out using SELDI and SDS-PAGE. A total of 
114 isolates were analysed using SELDI and 28 by SDS-PAGE. The same protein 
extraction method was carried out as for S. aureus excluding lysozyme (Section 2.6.1). The 
protein extracts were analysed using three different ProteinChips® to select a suitable 
array. Since the profiles obtained using the Strong Anionic Exchange ProteinChip® array 
(SAX/Q10) showed a larger number of peaks with higher intensity, the Q10 array was 
chosen for further studies. The Q10 array contains positively charged, quaternary 
ammonium groups that interact with negative charges on the surface of target proteins.  
 
The SELDI profiles of these isolates showed the presence of characteristic peaks/ 
biomarkers (~ 9500 and 13000 Da) while some of the isolates showed additional peaks (~ 
3000-4500 and 14500 Da) on the MS profiles (Figure 3.31). This clearly shows the 
intraspecies diversity within C. difficile. Specifically comparing the SELDI-MS profiles of 
the three strains from 1970s- 2006 (T, B1 and L), additional peaks could be detected for 
strain T (1970s) and L (2006) in the mass range of ~ 3000-4500 Da, indicating changes 
may have occurred over the years (Figure 3.31). Interestingly the strain L, from the recent 
outbreak indicated additional peaks, which may correspond to its higher virulence. Further 
studies on these additional peaks may provide insight into its pathogenesis and SELDI-MS 
could also be used as a preliminary screening tool to detect the variability of the isolates. 
  
The SDS-PAGE carried for these strains also showed very similar protein band profiles. 
However, most of the proteins were conserved within the range of 6 kDa and 14-17 kDa 
and ~38- 49 kDa region, several of which may be of S-layer proteins (Figure 3.32). S-layer 
proteins of C. difficile are thought to be one of the main virulence factors and believed to 
play a significant role in host-pathogen interactions (McCoubrey and Poxton 2001; Wright 
et al., 2005). McCoubrey and Poxton (2001) also suggested the detection of S-layer 
proteins as a useful marker for phenotyping of C. difficile in epidemiological studies. 
 
The results of this study  and the vast number of recent publications (Seng et al., 2009; 
Eigner et al., 2009; Pennanec et al., 2010; La Scola and Raoult 2010) now demonstrating 
the application of MALDI-TOF-MS within research and clinical laboratories indicate that 
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the technique is best used at the species level as demonstrated here. In microbiology 
laboratories, while it is necessary to first rapidly identify a pathogen to the species level, 
for tracing the path of a strain, for example during disease outbreak, high resolution typing 
methods are required. Because of the limitation of MALDI-TOF-MS to reach this level of 
resolution at the present time, a newly developing approach, VNTR was undertaken using 
a diverse collection of C. difficile isolates.  
 
VNTR analysis of C. difficile 
 
Epidemiological investigations require rapid, reliable and highly discriminatory 
genotyping methods to track transmission and identify the emergence of new variants of 
pathogenic species. Current genotyping methods for detection of C. difficile outbreaks and 
nosocomial transmission include PCR ribotyping, AP-PCR, AFLP, PFGE, MLST and 
REA (section 1.2.5). These methods are labour intensive, subjective or lack sufficient 
discriminatory power to differentiate between closely related isolates. Due to the 
drawbacks of these typing methods and in order to efficiently track and detect the 
transmission of C. difficile locally and globally, new genotyping methods are being 
investigated. This study focused on a genomic approach for characterising isolates of C. 
difficile with the emphasis being placed on two predominant ribotypes (027 and 001) of C. 
difficile. 
 
A total of 92 C. difficile isolates belonging to different ribotypes were analysed to detect 
novel loci to differentiate C. diffcile by using Variable Number Tandem Repeats (VNTR). 
A total of 47 loci were tested for tandem repeats, including 10 loci that were published 
(Marsh et al., 2006 and van den Berg et al., 2007) (Table 2.11). The remaining 37 loci 
were identified from the sequenced C. difficile 630 genome using the Tandem Repeat 
Finder programme. Of the 47 loci, 8 loci including a published locus (CD16, 17, 26, 29, 
31, 44, 47 and CD9) failed to give an amplification product from any isolate in the set and 
were excluded from analysis. The failure to amplify products may have been due to base 
pair mismatch at the 3’ end of the forward or the reverse primer. The other reason could be 
that these repeats maybe absent in the isolates selected for this study. However, due to lack 
of time and the cost of designing new primers, further analysis on these primers was not 
considered. Also, a recent study by Marsh et al. (2010) omitted the use of CD9 primer in 
their study, as this locus generated few alleles and contains 2 tandem-repeat loci that 
cannot be resolved by automated capillary electrophoresis. 
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For all 45 ribotype 027 isolates, 14 of the 37 newly identified loci produced identical copy 
numbers (Table 3.4) and were unsuitable to use as markers to differentiate isolates within 
ribotype 027. Two of the new loci, CD14 and CD23 were detected with copy numbers 
‘null’ and ‘0’ respectively for ribotype 027 isolates. The ribotype 001 isolates and the 
remaining ribotypes yielded copy numbers different from those exhibited by ribotype 027 
isolates. Hence, these two loci could be used as potential markers to differentiate ribotype 
027 isolates from the rest of the ribotypes. In order to detect the corresponding genes for 
these particular loci, the amplification product was searched using BLAST 
(http://blast.ncbi.nlm.nih.gov/). The BLAST results indicated that CD14 and CD23 
corresponds to toxin genes tcdB, which is responsible for the increased toxin production of 
toxin B in virulent 027 strains and tcdC, which is a putative regulatory factor of toxin A 
and B which leads to increased toxin production in ribotype 027 respectively (Stabler et 
al., 2009). This confirmed the copy number variance detected in loci CD14 where ‘null’ 
result correspond to the 18bp deletion in tcdB gene in ribotype 027 isolates compared to 
ribotype 001 where the copy number was 2.  
 
For cluster analysis, an arbitrary value of ≥ 90 % similarity was selected to detect the 
homogeneity among isolates. A study by Fawley et al. (2008) concluded that differences of 
> 71 % (up to 2 copy numbers) could be considered as closely related strains. In this study, 
cluster analysis of the ribotype 027 using the new loci revealed 7 groups containing 
isolates from the same outbreak with 100 % similarity. Interestingly among these isolates, 
one or two copy number differences could be observed up to two or more loci indicating 
the emergence of subtypes within a clone (Fawley et al., 2008). A similar study by Zaiss et 
al. (2009) also observed the differences of variable copy numbers at 4 or more loci in 
isolates even when the isolates were affiliated to identical sequence types or ribotypes. 
However, according to stability tests performed by Marsh and van den Berg (2006 and 
2007); a difference of one or two repeat units between strains should not be interpreted as 
separate types or subtypes. Hence, the isolates within each group could be considered as 
closely related isolates. For the published loci (CD4, CD5 and CD7) copy number 
variances were observed between this study and the study by Marsh and van den Berg 
(2006 and 2007). These differences could be due to sizing variation (up to three base pairs) 
observed in different electrophoresis instruments (Pasqualotto et al., 2007). Hence, this 
could have been one of the reasons for the copy number variances observed in these two 
loci. One of the outbreak isolates, G49 clustered separately from the rest of the outbreak 
isolates and exhibited higher dissimilarity (53 %) on cluster analysis. This isolate was later 
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confirmed as a non-027 isolate by florescent ribotyping at the HPA, London. This indicates 
the high resolution power of the newly designed VNTR loci for differentiating ribotype 
027 isolates from other ribotypes. 
 
For ribotype 001 isolates, 10 loci (CD11, 12, 14, 18, 19, 20, 21, 22, 23 and 25) showed 
different copy numbers from ribotype 027 isolates. Hence, these could be potential markers 
for differentiating ribotype 001 isolates from 027 isolates (Table 3.7). BLAST results 
indicated that loci CD11, 19, 20, and 21 corresponds to CTn (putative conjugative 
transposon DNA recombination protein), CD12 corresponds to tcdC (putative regulatory 
factor), CD18 corresponds to cdtB (ADP-ribosyltransferase-pseudo gene), CD22 and 
CD23 corresponds to tcdC (putative exported protein) and CD25 corresponds to DanR 
(putative antibiotic resistance ABC) in the C. difficile 630 genome. Similar to ribotype 027 
results, the copy numbers for loci CD4 and CD6 obtained here deferred to that reported by 
van den Berg. For loci CD5, this study showed copy numbers of 5 or 6 whereas van den 
Berg et al. (2007) obtained a copy number of five. An identical copy number was exhibited 
by loci CD7 in both studies. This single copy number variance may have been due to the 
size variation of the fragments during the electrophoresis as described earlier (Pasqualotto 
et al., 2007). Cluster analysis (Figure 3.36 and 3.37) using the new loci showed four 
groups each containing closely related isolates. However, cluster analysis using all 39 loci 
did not yield these groupings of closely related isolates. Within the four groups, more 
isolates showed 100 % similarity to each other although there were few copy number 
variances among the isolates as before. Except for two ribotype 001 isolates, G18 and G28, 
all the isolates were obtained from the Microbial Pathogencity Research Laboratory 
(MPRL), Edinburgh. Interestingly, the G28 isolate clustered with the MPRL isolates in 
group D (Figure 3.37). 
 
For the 22 different ribotype isolates (13 known and 9 unknown ribotypes), all 39 loci 
showed variable copy numbers (Table 3.6). However, for loci CD18, 22 and 23 stable copy 
numbers of one, seven and one were detected respectively, independent of the ribotype. 
For the same loci, ribotype 027 isolates showed copy numbers of two, one and zero while 
ribotype 001 isolates showed copy numbers one, seven and one respectively. Hence, these 
three loci could be used as potential markers to differentiate other ribotypes including 
ribotype 001 from ribotypes 027. From the first cluster analysis (Figure 3.38) within ≥ 90 
% similarity range, one group containing five isolates were observed. From this, two 
isolates belonged to ribotype 012 showed 100 % similarity to each other. However, from 
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the second cluster analysis performed by using the new VNTR loci, two groups were 
detected within the same similarity range (Figure 3.39). This indicates that the new loci 
have a higher discriminatory power to differentiate isolates of different ribotypes. 
Interestingly, in one group (B) (Figure 3.39), along with ribotype 012 isolates, a ribotype 
002 isolate showed 100 % similarity indicating that these isolates could be closely related. 
Zaiss et al. (2009) detected a similar observation where two isolates were assigned to two 
different ribotypes with a summed tandem repeat difference of four repeats between the 
isolates and showed 100 % similarity to each other.  
 
In order to assess the discriminatory power of the new loci, cluster analysis was performed 
for all different ribotype isolates. Interestingly, two main clusters were observed and the 
majority (90 %) of ribotype 027 isolates clustered into a single group and the second 
cluster contained the remaining isolates (Figure 3.40). Individual cluster analysis revealed 
10 specific loci that could be used as potential markers to differentiate each of the three 
ribotype groups; ribotype 027, 001 and other ribotype groups (Table 3.7). When cluster 
analysis was performed using these 10 specific loci (CD11, 12, 14, 18, 19, 20, 21, 22, 23 
and 25), the majority of isolates belonging to each of the three groups clustered separately 
from each other (Figure 3.41). This suggests that these 10 loci could be used as potential 
markers to differentiate ribotype 027, 001 and other ribotype isolates. However, there were 
outlier isolates within each group and these could be isolates that are closely related to 
other isolates. Alternatively, this problem can be resolved by the sequence analysis of the 
VNTR loci as sequence data provides accurate information at the DNA sequence level 
(Zaiss et al., 2009) and could be used to detect phylogenetic diversity of each isolate.  
 
The aim of this part of the study was to detect novel loci to differentiate within and 
between the prevalent ribotypes 027, 001 and other ribotypes. These loci could be used as 
potential markers to detect outbreak strains from circulating strains. According to the 
results of this study, it can be suggested that 10 new VNTR loci could be used to 
differentiate between isolates of different ribotypes belonging to 027, 001 and other 
ribotypes. This could potentially be used as a highly reproducible, high-throughput and 
discriminatory genotyping technique for the virulent ribotype 027 isolates and ribotype 001 
of C. difficile. A similar study by Killgore et al. (2008) compared the discriminatory power 
of seven DNA fingerprinting techniques for 42 C. difficile isolates collected from four 
different countries, including 22 ribotype 027 isolates. They reported that only four 
methods MLVA, REA, slpA sequence typing and PFGE were able to recognise the 
 195
subtypes, while REA and MLVA had sufficient power to distinguish strains within type 
027. Similar studies (Fawley et al., 2008, Marsh et al., 2006; van den Berg et al., 2007; 
Zaiss et al., 2009) have highlighted the discriminatory power of the VNTR/MLVA 
technique for different ribotypes of C. difficile isolates and its utility in understanding the 
nosocomial transmission and epidemiology of C. difficile within hospitals and institutions. 
One of the key advantages of this typing technique, as highlighted in many publications, is 
that this technique is easy to perform using multiplex PCR reactions and gives a real-time 
microbial fingerprinting method (Marsh et al., 2006; Lindstedt 2005; van Belkum et al., 
2008). A major drawback of this technique is that the design of the loci is based on the 
genome of a single strain. Hence, designing universal primers might not be possible. This 
may have also been one of the reasons for the failure of amplification of products of the 
seven new loci. In addition, one of the important factors is that this typing technique 
should be applied to outbreaks to ensure the stability and reproducibility of each locus. 
Thus, further studies using these 10 new markers for other ribotypes of C. difficile should 
also be performed on a larger set of isolates. This could prove to be useful in finding 
evolutionary trends in C. difficile. The data should also be compared with other established 
typing methods and the epidemiological data of isolates. 
  
As mass spectral techniques develop, it is likely that in the future MALDI-TOF-MS will 
also be used as a typing tool to support the above method. One such study by Hain (2010) 
was recently reported for Listeria monocytogenes. However at the present time, a genome 
(VNTR) – proteome (MALDI-TOF-MS) algorithm to identify and type a species 
represents a new approach that can be developed for any major pathogen. DNA-based 
methods are now well established, by contrast mass spectral approaches are relatively new. 
Notwithstanding this, it is evident that intact MALDI-TOF-MS has evolved as a rapid, 
high-throughput technique, which could be used as an alternative method in routine 
clinical laboratories. Rapid bacterial identification based on a standardised library of 
reference spectral profiles enables the accurate identification of bacteria up to species or 
even to sub-species level. Thus, evidence over the years has supported this view. However, 
the critical issue of the limited use of a database still restricts the broad application of this 
exciting technology.  
 
In the future, an online database, similar to Genbank will enable Users of any MALDI 
mass spectrometer to undertake comparative analysis using this database and so broaden 
the applications of this technology. For example, the Waters® MMU database used earlier 
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in this study (Rajakaruna et al., 2009) was restricted to Users who had acquired only 
Waters® instruments and the MicrobeLynxTM software while BioTyper is tied to Users 
with Bruker instruments. SARAMIS™ has more flexibility as it is a software company but 
it is necessary to obtain a licence for its use and to link it to a mass spectrometer. The 
development of an online database, analogous to that used for 16S rRNA, in which Users 
can freely access a database globally, will enable the technology to move to the forefront 
of the microbial identification and lead to a dramatic impact in diagnostic microbiology of 
human infections. 
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Appendix I 
 
Comparison of the two MALDI-MS studies of S. aureus done at HPA and MMU using database 
versions 2005 and 2006 respectively. 
 
 
Second run for incorrect 
samples ID by MMU at HPA
HPA 26 MRSA S.aureus S.aureus
HPA 30 MRSA S.aureus S.aureus
HPA 39 MRSA S.aureus S.aureus
HPA 40 MRSA S.aureus S.aureus
HPA 41 MRSA S.aureus S.aureus
HPA 75 MRSA S.aureus S.aureus
HPA 76 MRSA S.aureus S.aureus
HPA 77 MRSA S.aureus S.aureus
HPA 78 MRSA S.aureus S.aureus
HPA 79 MRSA S.aureus S.aureus
HPA 80 MRSA S. pyaogenus S.aureus S.aureus S.aureus
HPA 81 MRSA S.aureus S.aureus
HPA 82 MRSA S.aureus S.aureus
HPA 83 MRSA S.aureus S.aureus
HPA 84 MRSA S.aureus S.aureus
HPA 85 MRSA S.aureus S.aureus
HPA 86 MRSA S.aureus S.aureus
HPA 133 MRSA S.aureus S.aureus
HPA 134 MRSA S.aureus S.aureus
HPA 139 MRSA S.aureus S.aureus
HPA 140 MRSA S.aureus S.aureus
HPA 144 MRSA S.aureus S.aureus
HPA 160 MRSA S.aureus S.aureus
HPA 222 MRSA S.aureus S.aureus
HPA 229 MRSA S.aureus S.aureus
HPA 230 MRSA S.aureus S.aureus
HPA 233 S.aureus S.aureus S.aureus
HPA 239 S.aureus S.aureus S.aureus
HPA 242 MRSA S.aureus S.aureus
HPA 247 MRSA S.aureus S.aureus
HPA 248 S.aureus S.aureus Proteus mirabilis 1-8 S.aureus
HPA 249 S.aureus S.aureus S.aureus
HPA 250 S.aureus S.aureus S.aureus
HPA 256 S.aureus S.aureus S.aureus
HPA 257 S.aureus S.aureus S.aureus
HPA 258 MRSA S.aureus S.aureus
HPA 259 S.aureus S.aureus S.aureus
HPA 260 S.aureus S.aureus 1-S. warneri / S.aureus 2,3,4,6,7 S.aureus
HPA 261 MRSA S.aureus S.aureus
HPA 262 MRSA S.aureus S.aureus
HPA 273 S.aureus S.aureus S.aureus
HPA 279 S.aureus S.aureus S.aureus
HPA 280 S.aureus S.aureus S.aureus
HPA 281 S.aureus S.aureus S.aureus
HPA 284 S.aureus S.aureus S.aureus
HPA 285 S.aureus S.aureus S.aureus
HPA 287 S.aureus S.aureus S.aureus
16S IDHPA No. Hospital ID.
First Run ID 
by HPA MMU ID
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Second run for incorrect 
samples ID by MMU at HPA
HPA 293 S.aureus S.aureus S.aureus
HPA 294 S.aureus S.aureus S.aureus
HPA 299 S.aureus S.aureus Inconclusive S.aureus
HPA 318 S.aureus S.aureus S.aureus
HPA 319 S.aureus S.aureus S.aureus
HPA 322 S.aureus S.aureus S.aureus
HPA 323 S.aureus S.aureus S.aureus
HPA 324 S.aureus S.aureus S.aureus
HPA 334 S.aureus S.aureus S.aureus
HPA 339 S.aureus S.aureus S.aureus
HPA 344 S.aureus S.aureus S.aureus
HPA 345 S.aureus S.aureus S.aureus
HPA 346 MRSA S.aureus S.aureus
HPA 347 MRSA S.aureus S.aureus
HPA 348 S.aureus S.aureus S.aureus
HPA 353 MRSA S.aureus S.aureus
HPA 356 S.aureus S.aureus S.aureus
HPA 358 S.aureus S.aureus S.aureus
HPA 389 S.aureus S.aureus S.aureus
HPA 401 MRSA S.aureus S.aureus
HPA 404 S.aureus S.aureus S.aureus
HPA 405 S.aureus S.aureus S.aureus
HPA 408 MRSA S.aureus S.aureus
HPA 409 S.aureus S.aureus S.aureus
HPA 410 S.aureus S.aureus S.aureus
HPA 412 MRSA S.aureus S.aureus
HPA 441 S.aureus S.aureus S.aureus
HPA 442 S.aureus S.aureus S.aureus
HPA 443 S.aureus S.aureus S.aureus
HPA 444 MRSA S.aureus S.aureus
HPA 489 S.aureus S.aureus S.aureus
HPA 496 S.aureus S.aureus S.aureus
HPA 497 S.aureus S.aureus S.aureus
HPA 499 S.aureus S.aureus S.aureus
HPA 500 S.aureus S.aureus S.aureus
HPA 501 S.aureus S.aureus S.aureus
HPA 523 MRSA S.aureus S.aureus
HPA 524 MRSA S.aureus S.aureus
HPA 545 MRSA S.aureus S.aureus
HPA 546 S.aureus S.aureus S.aureus
HPA 547 S.aureus S.haemolyticus S.aureus S.aureus
HPA 549 S.aureus S.epidermidis Missing from the storage and couldn’t send S.aureus
HPA 550 S.aureus S.aureus S.aureus
HPA 556 S.aureus S.aureus S.aureus
HPA 563 S.aureus S.aureus S.aureus
HPA 569 S.aureus S.aureus Pseudomonas aeruginosa S.aureus
HPA 571 S.aureus S.aureus S.aureus
HPA 573 MRSA S.aureus S.aureus
16S IDHPA No. Hospital ID. MMU ID
First Run ID by 
HPA
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Appendix II 
 
MALDI-MS results of S. aureus isolates (n= 39) received from Staphylococcal Reference 
Laboratory.  
All isolates were identified as S. aureus by the software apart from the isolates labelled in red, were 
confirmed from the second run. 
 
Sample ID Source MALDI ID 
H072660527 Clinical isolate S. aureus 
H072580475 Clinical isolate S. aureus 
H071920422 Clinical isolate S. aureus 
H071200363 Clinical isolate S. aureus 
H072940574 Clinical isolate S. aureus 
H073020460 Clinical isolate S. aureus 
H072660333 Clinical isolate S. aureus 
H072800374 Clinical isolate S. aureus 
H072340414 Clinical isolate S. aureus 
H072640555 Clinical isolate S. aureus 
H072500404 Clinical isolate S. aureus 
H072240800 Clinical isolate S. aureus 
H072900348 Clinical isolate S. aureus 
H072580470 Clinical isolate S. aureus 
H064560442 Clinical isolate S. aureus 
H072860414 Clinical isolate S. aureus 
H041940150 Clinical isolate S. aureus 
H072680434 Clinical isolate S. aureus 
H072640554 Clinical isolate S. aureus 
H072280533 Clinical isolate S. aureus 
H072820462 Clinical isolate S. aureus 
H072860467 Clinical isolate S. aureus 
H072580469 Clinical isolate S. aureus 
H072820481 Clinical isolate S. aureus 
H072740472 Clinical isolate S. aureus 
H072240582 Clinical isolate S. aureus 
H072820446 Clinical isolate S. aureus 
H072720523 Clinical isolate S. aureus 
H072680446 Clinical isolate S. aureus 
H072660541 Clinical isolate S. aureus 
H072860465 Clinical isolate S. aureus 
H072720526 Clinical isolate S. aureus 
H072820480 Clinical isolate S. aureus 
RH070000211 Clinical isolate S. aureus 
RH070000253 Clinical isolate S. aureus 
H072920482 Clinical isolate S. aureus 
H072660333 Clinical isolate S. aureus 
H072820464 Clinical isolate S. aureus 
H071380629 Clinical isolate S. aureus 
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Appendix III 
 
SARAMIS™ identification of 42 (n= 42) isolates subcultured on CBA for 24 h analysed in 
duplicates. MPRL 4857 was identified as S. warneri due to the contamination of the sample. Isolate 
MPRL 307 was not identified from the 24 h culture as C. difficile. But, was confirmed from the 48 
h culture. 
 
 
Strain ID Culture media Incubation time SARAMIS ID Confidence level (%) 
96.4 
MPRL 002 CBA 24 h C. difficile 91.0 
99.9 
MPRL 059 CBA 24 h C. difficile 91.0 
96.4 
MPRL 1037 CBA 24 h C. difficile 81.0 
90.0 
MPRL 13366 CBA 24 h C. difficile 89.0 
89.0 
MPRL 199 CBA 24 h C. difficile 99.9 
99.9 
MPRL 223 CBA 24 h C. difficile 99.9 
95.0 
MPRL 2282 CBA 24 h C. difficile 95.0 
99.9 
MPRL 2783 CBA 24 h C. difficile 99.9 
99.9 
MPRL 279 CBA 24 h C. difficile 99.9 
96.4 
MPRL 282 CBA 24 h C. difficile 96.4 
99.9 
MPRL 296 CBA 24 h C. difficile 99.9 
No spectrum 
MPRL 307 CBA 24 h No ID No spectrum 
81.0 
MPRL 308 CBA 24 h C. difficile 96.4 
95.0 
MPRL 371 CBA 24 h C. difficile 89.0 
91.0 
MPRL 372 CBA 24 h C. difficile 96.4 
95.0 
MPRL 379 CBA 24 h C. difficile 95.0 
96.4 
MPRL 382 CBA 24 h C. difficile No spectrum 
89.0 
MPRL 396 CBA 24 h C. difficile 91.0 
81.0 
MPRL 402 CBA 24 h C. difficile 99.9 
95.0 
MPRL 405 CBA 24 h C. difficile 89.0 
89.0 
MPRL 406 CBA 24 h C. difficile 91.0 
90.0 
MPRL 407 CBA 24 h C. difficile 89.0 
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99.9 
MPRL 418 CBA 24 h C. difficile 95.0 
No spectrum 
MPRL 422 CBA 24 h C. difficile 91.0 
96.4 
MPRL 4846 CBA 24 h C. difficile 96.4 
99.9 
MPRL 4847 CBA 24 h C. difficile 95.0 
96.4 
MPRL 4848 CBA 24 h C. difficile 91.0 
89.0 
MPRL 4849 CBA 24 h C. difficile 89.0 
96.4 
MPRL 4850 CBA 24 h C. difficile No spectrum 
91.0 
MPRL 4851 CBA 24 h C. difficile 89.0 
99.9 
MPRL 4852 CBA 24 h C. difficile 99.9 
99.9 
MPRL 4853 CBA 24 h C. difficile 95.0 
96.4 
MPRL 4854 CBA 24 h C. difficile 89.0 
91.0 
MPRL 4856 CBA 24 h C. difficile 96.4 
MPRL 4857 CBA 24 h Staphylococcus warneri 
89.0 
MPRL 554 CBA 24 h C. difficile 91.0 
96.4 
MPRL 560 CBA 24 h C. difficile 91.0 
99.9 
MPRL 586 CBA 24 h C. difficile 95.0 
96.4 
MPRL 588 CBA 24 h C. difficile 89.0 
91.0 
MPRL 589 CBA 24 h C. difficile 96.4 
91.0 
MPRL 591 CBA 24 h C. difficile 99.9 
89.0 
MPRL 613 CBA 24 h C. difficile 91.0 
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SARAMIS™ identification of 43 (n= 43) isolates subcultured on CBA for 48 h analysed in 
duplicates. MPRL 13366 was identified as P. acnes on one read which could be due to the 
contamination of the sample. Isolate MPRL 307 was not identified from the 24 h culture as C. 
difficile was confirmed from the 48 h run. 
 
 
 
Strain ID 
Culture 
media Incubation time SARAMIS ID Confidence level (%) 
96.4 
MPRL 002 CBA 48 h C. difficile 99.9 
96.4 
MPRL 059 CBA 48 h C. difficile 99.9 
91.0 
MPRL 1037 CBA 48 h C. difficile 81.0 
P.acnes 90.0 
MPRL 13366 CBA 48 h C. difficile 91.0 
89.0 
MPRL 199 CBA 48 h C. difficile 91.0 
96.4 
MPRL 223 CBA 48 h C. difficile 96.4 
No spectrum 
MPRL 2282 CBA 48 h No ID No spectrum 
91.0 
MPRL 2783 CBA 48 h C. difficile No spectrum 
96.4 
MPRL 279 CBA 48 h C. difficile 89.0 
No spectrum 
MPRL 282 CBA 48 h No ID No spectrum 
96.4 
MPRL 296 CBA 48 h C. difficile 81.0 
No spectrum 
MPRL 307 CBA 48 h C. difficile 91.0 
96.4 
MPRL 308 CBA 48 h C. difficile 91.0 
86.0 
MPRL 371 CBA 48 h C. difficile 91.0 
96.4 
MPRL 372 CBA 48 h C. difficile 91.0 
96.4 
MPRL 379 CBA 48 h C. difficile 86.0 
81.0 
MPRL 382 CBA 48 h C. difficile 96.4 
99.9 
MPRL 396 CBA 48 h C. difficile 99.9 
No spectrum 
MPRL 402 CBA 48 h C. difficile 76.8 
71.0 
MPRL 405 CBA 48 h C. difficile No spectrum 
96.4 
MPRL 406 CBA 48 h C. difficile 99.9 
71.0 
MPRL 407 CBA 48 h C. difficile 81.0 
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96.4 
MPRL 418 CBA 48 h C. difficile 99.9 
65.0 
MPRL 422 CBA 48 h C. difficile No spectrum 
81.0 
MPRL 4846 CBA 48 h C. difficile 71.0 
99.9 
MPRL 4847 CBA 48 h C. difficile 96.4 
89.5 
MPRL 4848 CBA 48 h C. difficile 86.0 
91.0 
MPRL 4849 CBA 48 h C. difficile No spectrum 
76.8 
MPRL 4850 CBA 48 h C. difficile 81.0 
96.4 
MPRL 4851 CBA 48 h C. difficile 91.0 
95.0 
MPRL 4852 CBA 48 h C. difficile 99.9 
No spectrum 
MPRL 616 CBA 48 h C. difficile 81.0 
91.0 
MPRL 617 CBA 48 h C. difficile No spectrum 
99.9 
MPRL 629 CBA 48 h C. difficile 99.9 
99.9 
MPRL 665 CBA 48 h C. difficile 99.9 
99.9 
MPRL 678 CBA 48 h C. difficile 99.9 
91.0 
MPRL 687 CBA 48 h C. difficile No spectrum 
96.4 
MPRL 712 CBA 48 h C. difficile 89.0 
96.4 
MPRL 808 CBA 48 h C. difficile 99.9 
96.4 
T CBA 48 h C. difficile 91.0 
89.0 
027 (L) CBA 48 h C. difficile No spectrum 
No spectrum 
B1 CBA 48 h No ID No spectrum 
89.0 
MPRL 369 CBA 48 h C. difficile 81.0 
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SARAMIS™ identification of 10 (n= 10) isolates subcultured on FAA for 48 h and 9 (n= 9) isolates 
subcultured on NA for 48 h, analysed in duplicates. 
 
 
Strain ID Culture media Incubation time SARAMIS ID Confidence level (%) 
99.9 
MPRL 002 FAA 48 h C. difficile 99.9 
99.9 
MPRL 4849 FAA 48 h C. difficile 99.9 
99.9 
MPRL 296 FAA 48 h C. difficile 96.4 
96.4 
027 FAA 48 h C. difficile 91.0 
99.9 
MPRL 617 FAA 48 h C. difficile 99.9 
96.4 
B1 FAA 48 h C. difficile 91.0 
99.9 
MPRL 371 FAA 48 h C. difficile 96.4 
99.9 
MPRL 2783 FAA 48 h C. difficile 99.9 
No spectrum 
MPRL 1037 FAA 48 h C. difficile 91.0 
91.0 
MPRL 223 FAA 48 h C. difficile 81.0 
96.4 
027 NA 48 h C. difficile 99.9 
MPRL 4849 NA 48 h No ID No spectrum 
99.9 
MPRL 223 NA 48 h C. difficile 96.4 
99.9 
MPRL 296 NA 48 h C. difficile 99.9 
96.4 
MPRL 002 NA 48 h C. difficile 99.9 
MPRL 1037 NA 48 h No ID No spectrum 
99.9 
MPRL 2783 NA 48 h C. difficile 96.4 
96.4 
B1 NA 48 h C. difficile 91.0 
MPRL 617 NA 48 h No ID No spectrum 
 
 
 
 
 
 
 
 
 
Appendix IV 
 
 
 
List of the forward and the reverse primers used in the VNTR study of C. difficile for all 47 loci. 
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Locus Location Forward primer sequence (label 5’-3’) Reverse primer sequence (label 5’-3’) 
 
CD1 
 
755721-755950 
 
FAM-TTAATTGAGGGAGAATGTTAAA 
 
AAATACTTTTCCCACTTTCATAA 
CD2 3688632-3688751 FAM-CTTAATACTAAACTAACTCTAACCAGTAA TTATATTTTATGGGCATGTTAAA 
CD3 3239736-3239835 NED-GTTTAGAATCTACAGCATTATTTGA ATTGGAATTGAATGTAACAAAA 
CD4 167124-167172 VIC-TGGAGCTATGGAAATTGATAA CAAATACATCTTGCATTAATTCTT 
CD5 1954913-1954939 PET-TTTTTGAAACTGAACCAACATA ACAAAAGACTGTGCAAATATACTAA 
CD6 664660-664705 PET-TGTATGAAGCAAGCTTTTTATT AATCCAGCAATCTAATAATCCA 
CD7 4116072-4116109 NED-GTTTTGAGGAAACAAACCTATC GATGAGGAAATAGAAGAGTTCAA 
CD8 692929-693015 VIC-AATTTTAAGTTAACGTTTTTCTACAT AGCCATTTTTATCAATCCTTTCTAT 
CD9 771338-771422 FAM-GTAGAAGGGGCAAATAATGAG CCTTCTGGCTTCCTTGTAATA 
CD10 677132-677386 PET-GGTGCACATGCTGGTCCTG AACGCATTAAATTTCACTCCTCATAC 
CD11 2168250-2168268 FAM-AGACAATGCACATATTCAACTCAC GTAGTTTCATCAATTCTTACATCTAAT 
CD12 804519-804537 VIC-CTTATCATAATTTCCAGACACAG AAGTACAAAAAGGTAAAATTTGAAGG 
CD13 301056-301074 NED-GTTATCTTCTGGGGTTAGAATC TTGGTCTAAACCTTTTATTTGAGC 
CD14 788448-788465 PET-GACATGTTAGACGAAGAAGTTCAA TGATGCCTCCATATCACCAA 
CD15 800026-800043 VIC-AAATAAACTTATTATAGGCAATCAAACA ATTTTATCATCTAACTCACAAGTCAA 
CD16 484804-484820 NED-AAGAAGAATGTGTTTAATATTGAGAGC TCTTTTTAAGACTTACTGCATTCTTG 
CD17 3254341-3254357 FAM-CATTCCAAAAGTATCTTTAGTTGC GGTGATGGAGATTATGTTGATTTTT 
CD18 3014724-3014741 NED-GGTGAGACGAAGATTAAAATACC TTGTTCTAGTACCAAATAATCCGTTTT 
CD19 2167938-2167955 VIC-GCCGAATTAAGAATAAAGTTGGTG TTGGCAAAATATTTGTTGGATG 
CD20 2169070-2169086 NED-GTGGAAGATATTGAGGCTGA TCGGAAGTTCTGCTTCCTTT 
CD21 2169418-2169435 PET -AATGCAAATTTGGAAGAAATGA CCAGCATAATACCAGCCAAAA 
CD22 804623-804645 VIC-GCACCTCATCACCATCTTCA TCAAAATGAAAGACGACGAAAA 
CD23 804652-804699 NED-CCTTTCTTCTCCTCTTCTTCTT GGTCATTTCTAACCAAACATCAGT 
CD24 478055-478070 FAM-CCACAGATAAAAATAAGAGGAAT CTTGTCCTCTATCAAACCAAGCTAC 
CD25 543601-543619 NED-CTTTCTGATTTTTCTTTTGTGTG AGAACCCTACATAGGAACAACTTC 
CD26 3245854-3245874 PET-CATTTGCATCTGCTCTTTTTAT GGAAATAAGCTTGATACTACTCAAAAA 
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CD27 
 
 
 
 
 
 
 
 
3246180-3246195 
 
 
 
 
 
 
 
 
FAM-ATTTTTGCATTTGTCTCACTTC 
 
 
 
 
 
 
 
 
CAGAGAATGGAACTGAAGTAGCTG 
CD28 3246752-3246770 NED-TCCAGAACCCGTTAATGTATC TTACGAAAGAATTAGGAGGTAAGAA 
CD29 789540-789558 FAM-GTAGAGGAGACTTATCCTGGAA GTGCAAATCAATATGAAGTTAGAATAA 
CD30 794475-794493 VIC-GTATTATTTTGATCCTGATACAGCTC TTGCTACTTTTCTGATTCCTCCA 
CD31 3253605-3253625 VIC-GCAGTTTCTATTCTATCTTCTCCTG GCAAATGATACAATAGCTAGTCAAGA 
CD32 252622-252644 PET-CAATACTTTTAAGAAAAGGAATACAA TAGCTTTTTACCTTGTTGAACTATTTG 
CD33 800719-800741 FAM-GTTGGTAAAACTAATCTTGGATATG AAAATAAAGTCACTTCCTTCTGTAGAC 
CD34 799700-799717 FAM-CATTAAAACCAGTTTATGAAGACAC CTGAAAAATCTATTGTTTGATTGCCTA 
CD35 797131-797146 NED-AATTTTTAAACCAACACCTTAACC TATTAAAGTCTACCCCATTGTCTTC 
CD36 881618-881637 VIC-GAGCTGCTGCACTAGTAGG GCCTTTTCCATTGTTTCTGC 
CD37 881702-881718 NED-GGGCTTCCTAAAGAAACAG TCACAACTCCCCTACAAGCA 
CD38 883903-883918 FAM-GAAATGGCTCCTCCAAAAG CATGTCCGTACCTGCCATTA 
CD39 884179-884194 NED-TGAAATGGCTCCTCCAAAA GGAAAAATTTAGCCCCTGCT 
CD40 884601-884612 VIC-GGCAGGGGAACTTATCAAA TCTGCACCAAGCATAGAAGC 
CD41 886202-886220 FAM-ATGCTGATGCCAATGCTAA GTCATACCACCAGGGAATGC 
CD42 923152-923190 FAM-CTGAAACAGCACTTGACATTGAA CCCTTTTTATTCATAATAATCATTCC 
CD43 623650-623691 PET-AAGTGTGCTAAGTGTTGTTTTGC TGATATAAAAAGACAAAAAGGGCAAT 
CD44 771250-771319 NED-TCATTGAAGACAGAGATACAAAAA GAAGCCTTCTGGCTTCCTTGT 
CD45 3319803-3320164 PET-TTTCATAAAAGATTCCTTTCCTGT AAGAGCATATATGGGAGTTTCTGTT 
CD46 3753183-3753574 VIC-TCAGAAAATGCACCTTTAAATC CCATAATAAGATTGCAGAGGTATAAGA 
CD47 1099662-1099714 NED-GCAGGAACACCAATGGAGA CCACAACCACCGTAACCTTT 
 
Appendix V 
 
 
Single-plex VNTR-PCR and multiplex VNTR-PCR reactions carried out for all 47 loci in 
the following combinations. 
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Loci Single-plex/Multiplex 
CD1 
CD2 
CD3 
CD4 
CD5 
CD6 
CD7 
CD8 
CD9 
CD10 
CD11 
CD12 
CD13 
CD14 
CD15 
CD16 
CD17 
CD18 
 
 
 
 
 
 
 
Single-plex PCR reactions 
CD29 
CD19 
CD21 
CD35 
 
Multiplex 1 
CD28 
CD26 
CD22 
CD33 
 
Multiplex 2 
CD27 
CD20 
CD30 
 
Multiplex 3 
CD31 
CD34 
CD32 
CD23 
 
Multiplex 4 
CD24 
CD25 
 
Multiplex 5 
CD36 
CD39 
CD41 
 
Multiplex 6 
CD37 
CD38 
CD40 
 
Multiplex 7 
CD42 
CD43 
CD44 
 
Multiplex 8 
CD45 
CD46 
CD47 
 
Multiplex 9 
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Appendix VI  
 
Specific proteins detected for isolates MW2 (MRSA) and 476 (MSSA) 
 
 
Protein specific for MRSA Protein specific for MSSA 
hypothetical protein SAV2474       PREDICTED: similar to lambda-immunoglobulin [Equus caballus] 
30S ribosomal protein S9       F0F1 ATP synthase subunit alpha      
50S ribosomal protein L14       50S ribosomal protein L1      
50S ribosomal protein L6       major tail protein       
hypothetical protein SAV0378       hypothetical protein MW2433      
30S ribosomal protein S4       ABC transporter ATP-binding protein     
cytidylate kinase        triosephosphate isomerase      
NAD-specific glutamate dehydrogenase      putative heme peroxidase      
UDP-N-acetylmuramyl tripeptide synthetase-like     cell shape determinant mreC      
S-adenosylmethionine synthetase      PREDICTED: similar to IGL@ protein [Equus caballus]   
glutamate-1-semialdehyde aminotransferase     PREDICTED: similar to keratin 1 isoform 7 [Macaca mulatta]   
GTP-binding protein EngA       F0F1 ATP synthase subunit beta     
phosphoesterase        immunoglobulin gamma 7 heavy chain [Equus caballus]   
translation-associated GTPase       6-phosphogluconate dehydrogenase     
arginine deiminase        transcription elongation factor NusA      
autolysin, N-acetylmuramyl-L-alanine amidase and endo-b-N-acetylglucosaminidas PREDICTED: similar to Keratin, type I cytoskeletal 14    
RecName: Full=Serum albumin; AltName: Full=BSA     30S ribosomal protein S1      
RecName: Full=Chaperone protein dnaK; AltName: Full=Heat shock protein 70 immunoglobulin gamma 1 heavy chain constant region [Equus caballus] 
alpha 2 globin [Equus caballus]      F0F1 ATP synthase subunit alpha     
thimet oligopeptidase-like protein                
pyruvate oxidase                 
hypothetical protein MW0374                
aspartyl-tRNA synthetase                
1-pyrroline-5-carboxylate dehydrogenase              
DNA gyrase, B subunit                
ATP-dependent Clp protease, ATP-binding subunit ClpC                   
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